var title_f16_34_16928="Management plan by BMI";
var content_f16_34_16928=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 576px\">",
"   <div class=\"ttl\">",
"    Child weight assessment algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 556px; height: 512px; background-image: url(data:image/gif;base64,R0lGODlhLAIAAsQAAP///4CAgAAAAEBAQMDAwDAwMPDw8NDQ0ODg4KCgoFBQUGBgYLCwsCAgIHBwcJCQkBAQEAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAsAgACAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2RBAGhoqOkpaanqKmqq6ytrqoEnrKzSgEDr7i5uru8ube0wMFBobTEwsfIN8ayy8nOzyzNndLQ1dYA1JvZ19zH25nf3eLMAcXl4+jB4Zfr6e6V7fDn7/Sa8ZT39fqK+ZL9+wAJ/UNAgMABFgcMKDGQIAADGwdHNHwY41/Ai3/+2QqgYMGJAbEAOIi4AuSOBw8I//wiYXLFAQcDRtwioGCeC4sYc+rReK4AgQQDfiFosKBcAgQADigYQNHhAI9Di5JAsGCAgohApSZdStGEyqlEy1EdkMBEgqojBCj8CgOnzrd1eIpocICAQgUJDBRICQAkggIIDJgUUBavXr4jEBw80AAAAwUGEAgA8DdwyxIBPI44HKuBXbxeY4oI0OBs15s24aoGpPHWU8q2GpRrCfLBrY0AJmObHZLE2QGTFVCcbDvUShKMFbKMdUA0zdAjHKAsULZt6tXY92hcQADp0IfEaIPiXhCp7vC9RThYYL5vyMmZC3YvwZikzFhs2ZJge6CACAMQVHRddgTaIZcIBPgHgP9UTIkAEgENKHfQebOd1tdDkolUjgGTQSghcnR9RBEECgXwAHSUkZhUY9YV6CIeB4qwQAFWlcMAje4BkACNBTxEoWM4jsDYAA5MJhiRuu04QI8sNRCUaCPcGNONBSygXHQFQDDAQUpuKeCLYNLhVhLKDfXFmGGmuQWaRwxZgH1rDqjmnGWwyY+cdOYJhp2J8Knnn0v42QMDRNKgVEy2JJCeDAggVUKjKwgK6KRFSOqCbikMZcCVMdDFkAIACGZDAtX5VtZlmOFJ6apTbOOUAyIkcABftli51UqEXkVZQwOcSIAAAZRli64jkBZAd1VVJytiCCqgAH7AAnULAufk+tD/oacZME8ABhTkWFAPlRfWCZayau4O2wjwkAInDiAbAQ7YGBMECZ34WGQRQmhXA40KYNADoB5w2o7deWYAaO4emxi/Q/Vr0ALccQhkZEcBJlh6ITK2W3IICMvtXouOpuq5JNcip25ftQSBKJM14IBdAHQUimdsDRYrdXB+1VyzOZLwwDkm5iayCMF1VRxuIzzg0QIeIwABYuihUG7JVMuQLoIxteSvfKECTGKv8nUrms0IOiDbfjHll/WixhDzo9CXxVceCQZEGOFusOEYNbkjV+33MCer125IvYpwUEg+cfQfQWPHolZSChGKtggqBo1qUgp6+TZ8mtV1d1IlVKVZ/yiQShyehcX2/ffqPKS7pK0tHVxAAaAqMDusIvHIuIOxBFCAA1K+OTmQVSp0OTazn7N5qDP+oiSTyAngKOk8egwklCRMzfr2qaKAqTzchw/E1eyoLv75L2gfiPro/81+Rua3L7/U8ftT//z4Dz3L+/mby38f/+sfpQKonfsJsH0E3IkBD3i+BObBgQyc00Z6QcEKWvCCpzhOBDcIAFBg8IOoABYIR0iKkHHwhFz4HgpXyAkVsvCFl3AhDGcoCRnS8IaNsCEOd4gIHfLwh4PwIRCHuAcGCOCIR8QdEZfIBw4h0V9MjOIeCvBEKVoRRkjE3hW3CIdfHfFEXAwjHJAIJ/8xmhENChBAgM7IxjQ8QACgaqMcy3AAwszxjmOAgKPwyMcuLLCPgAykIAdJyEIa8pCIdBEJF8nIRlowkeIQoSMnSclKkkKIkBQGJq+xyUzSopPVAKUnPSHKZ5RylJs4ZTJUiUpMsPIYr2xlJWIZDFrKsob7sOUtIaHLWfRylznMJTCR8UtSDhOWwjxmLTPVG4IcYSQqgJRZSoWDl8xAmiUgFQyKqcxD6DAAUOwLN1VwPFPxbXgz0A8MtGmCZqjTBOPsJiG+iRaq6AZblKmKrgwgOorFCikF0Wau4NQrZ03vKWuJxVgUFoD1mMRY6ZHWORLwGAUgRVtWwV7HRABGoCH/tIMKrQpDHdq7d3lPnp9MQSiusoA6UsZifllMY9jlmLo0DhsQcABFIaMpljjAAErT0Lfw5pMFlcMWimkMwfbYwbuc6qdBjZeOtDgZBujxK1KVHDGKKhWkamypJ0WpLL55rKAI7WjOq8pkFiAcgN7UGDIjTXpM8pWVhQI+AejP0IzRIS3CJmE5qutatAiSoqCkHHYF58YURAy+dtCvJIinWAFB1hxxTj4IWE97dLQACBTkrecAW0E4RdeYbM1boWBLY5X32Ec1ADy8aS3KtGiiARyMO7mRT+/KulfWvrMEkp2sHyqblg5+rjkY6pB68uofvex2NHGMzHJaWzjQhQJA/wqRqmMTVALuGjWwMSmq5JCzl5hlDowHua6KtOtbBYVVuKlUqU2SxCMGDKlIyAvKXWhX1GU4QHfT/YrsaIe3HS3lqKztC1lI0LyagBdzHfGrHqf6H9sRmBgG/oVjFUzNyMK3hWZQDtOsIOIOX+rD8S3DjH53hRUrMQbBRXEeYhxDGWeCxpbAsY3poGPkhAJ1DmoBNGdQF4MIiSQHWMxoY1XGIfR4x3F4MjaYQgCtALcF5cTkUzgSxwGoCEAxSQBRCOIA6djKCFKGshuerLHNiARcRBOBtbyFDd69uUG/CtatLKQ1B0nlN3buoAD4hYQ0q5kNT26oCR5St/bciGIbNv8JoxnmrwNU5mIsSYmi3dMYn9wUXmbmlJMPTYlEXwdeXnZczLoSafzAxLNCAwBabbLl/yIFJBupWW9klQRDkzoNT05AHKMkPJvFLcEgudFByCa3+dxnue6pm9gCzQRf//oMTwZQSBDAAEU7V2iZMdwDYJUh93i7qI/zkOGmG7NT9UbXTrD2tcsgZaXQCCR6sQq6mUcjbjkJv9Gmke16x+LnnWZJS8LdZbAKAeFVe968TCbEg6kPeU88DBZfRMYv7oWNJ8LjHN8CyL0Zco1LvOQkrzjKP37ylc+z5S4XxMgNMfOYS6HmL7f5PC3J854zEuc6d4LPHSnJoZMw6HkCOtL/xaf0pXOv6U5nHdSj/repU71qVr96ybKu9VUZ8Ykv7joXnYhEE4rdilRE4tnPCM4jQnbtUvSiAMAI9zCSse5iTOMa8c7FNw6b71eso4kBH8UJE36Lfzy84hfP+MY7vmoeNLrkJ78Lsz/+TLehvOY3jwoNXl4MEIxE6D+vg9E/wvSkV0bikYH61Neg9YyAveuttnpv1H72JguI7HGfvturw/e8N8Lu+wT84BNh+IhAvvHlq/viLx9wzX9+nE4QtiC7YMgowKY5e5CQjwAB+5ThmgicOX6Fzq170s9CNkQYIhn+tpwSGbw0bAn+4mbP96jaiNlKFE7gPPZ4ypd+93cC/7ohOUnyFEgBUZlmUHJmFYcTUjOBDSQlaHrmFQqFIWXBTytxFB3kLAFgHoSiGUHxgdS3FLZCAAxQFSFBEwrgGQOYI5kRE/akP+gngFawfrECKpMhbN2iVD7BVEQCVB5xL5qyVbHQVQOQVJRRadQXE/9FVLEgVX5hMehWGGUBMTBjApYmax7hVY1xaUVVLNwBFCLDUi6FN+3kfDaILgMCLGYzITFDODZlAqUVM0UhV6GgV3izYT40GU+hFAYhGzHoHuNmZz/yDUBlO4jCWoXYM6NxG0ySWmb1NjW4hq3ShnQGN4TzWXSIH1mTEqMlib0VZ7GGAmQBPA/QGAkiH8vmQf+GOIoosBfT5ljGkH/VsoiWRYMvaImXSIBXVoh100Hu9WxfoTihQi3csl4IRoqPoyNw8gDFFhMAEhGtOF77todKxC2RpRBk6FjWmB7GEFTNQIm7yItRgIMexk+zQxFBQU11mDtLgow6QjsalmC+AyuGJyQsohX9sSSx9V8L4II/8hdb0mYS4SRosWEAGYaj4SS0UyLzpSMNUBppaI69uAQl5hJ/NwPKQWgqgBJUEIBrOHouxgIMYHku4JCDhxmi9gQiaYMvOQgxmX4zuT5qaJGvd5NTYE0IEXYygJKqh5PnqJP0QwRq0wK/xXwl8HY5UJPPJyhjoSwVdWvTglHauB//HogUy2IXG8GNAPWAEKUStkB3UWIVJ+kaYCRRTJYSI8hUYsErZBmUQumSxWcwCANVSxMxXaUZ40eFsZAwVXZUXTgbHgESS6UvjUYCj9YxiEloMIMw74KFnNIhBuOROOCUy+cnO9OBD2YMe7d3sqZwfxkSn/lYVOEfAXKUjrhqIwBv1AJYLUENfUVtcjmXTeAnR1mHG1aKaGgSfUaKT8MAwJM2znFTz4Y1vPMdeBOb1zGbq2kDmGl8glI5g9NamyYcnFmWIlBULYGdzxEzMdEf5eBd8CaGhqNr3sUgIbFpHlael0mUtokaO0AlsOOJL1WQTwInAOmCLdEcQRERQQUA/y7IYe7JbzNxUw0WW/dpH84Jf7QXn7cJnzTQkUwFQBIKoSqgfCopCNEZfB3KBx+KeyGqQBgaKDrZfTAgGC1ZA9qkfShQfzzAkyLxJSWaBIJiDDD6ESGRgq1jFCvJbj/wFbwinL1XozYaPzsFGR34UW3JgfiEDSFIGePCHhp4ZgiSglsSpcyzEmPxC96igT+llqsZUGXxpNbSgc8yGtQSGMMiGuDElOdkpEeQD4UCMEmBFEElmVNoGY5jhZwxAjRlX9mThAcAAVYIAEUlVVy1jNRRU4/pbtmTUxXDp4t5FAxDaAIwLVJFhkPqk0opp5USP32WiHoTWgQwa7G2NzLSVv/oRyGMEQpVoYerpYfjFxsKqj+zhp0cBTQngikqoh+emqEXCqqp8wJ9JovFaKrNtlmqGiudBY72eCw+URBzuIe8NX6vtZzQOhrk0R3HNjSYMls5Sayhaqyx8Bi5wY2IIprqBjo/0iCtCW3FmqrJSI3YJVTqdVE7IiO3iobtegDhlhR6qDkjIF5wGinDSq50em9cgpAySCPNEQsGR6/XUyz3xikbRgz9WABGQTsORgxSkoQJuprLYHDqqGHJQ4oQhhY0MKKuR6dASQ7kenyiGrOe4LKph7N3oLOfx7NxkbDE6rNiArSgKrRzYLSNh7RxoLSLx7Rv4LSHB7VtILWAR7X/a2C1eIe1aaC1cDdBnPe1YOt5M+sDkQe2FFR0ZssLNju2Oce2WOe2fsN1cDtWc0s1clu3IIa353K3entjfWsufPu3OSa4qxK4hDsJhnu4kZC4IVe2afu4kHu2kTu5lPsKa4sRaFu5kxsWmhu5I9i5oKsKYosdjGsFDuoIXFsFqVsHpVsFp9sIq3uRLtK6VPC6sUe0HIq7wEC7U2C7ixC7UgC8csC7UuC7d/IMwhtlm2C8xIe8uptSmsC8yfe88FMgX4dEwdoIdfREG+kITzRox9AATwSacEF2R3S5hyC+SBSXjpBGSMSXwLAA3EsgaXdElyC/dycJb4REP8oJCfBE/+z7FkXidpfwv0fEIpKwvUe0op4gGfmLHXIXwJDgwAIAv5EAAUc0jMGQdgicHQ9cCWnXv4uAv9nrCQNswasBHORLCQPMwI1gwEA2C18nwhjxRig8CUakwZHgwKYkPS4ieJnAISXcCEGSDEsCJvl4CfBaCdKBvEOsE9QLB1HMBoLqDAKjuFicxVq8xVy8BY4bupO7bWCseaXyxWOsee92xmpceU2ZeWtstisBIW/ccyw7ZXNMecfhtXe8x6Qwug/KCcaQlIigH8nbo/NaD3xSyEIQyAdLCIQ8xVu7LZD8u76nyNDXWo7wyJawDJbMBYk8yW7AyI+gyeCji+/wydNwDv+CfAikjA+SvA+oDMiq3MiD0MqTwMmg3LzvmcrImclQ0sm7bMruEMvaMMuj/Mu5XCevrA/EbA/G7MuHfMvLjMiVnMxX+8yNYMv2E82nXM28jMnZjMybPM300Mw6sGTdUqE5ABT2QRDU2ppZWBcAhVk9IMopgM7OxgPsPBWsCM8SMh+6pc6Gs2A3oM2iR87d3JQ3eUSgkmc+AE7gOL+5MXdLCCwTfURqaM/eA0cU+NDhNBoS/UUVXQ5PZBMQ3dEq4ND3LM480C3ilxTORhBK9s4t0G0kGH70jBwE/QO4DMve3ANlp9K2oasNgQAPQBAO4SwYVR0w8YfY8NFPzS32O9H/jTHAoQXVpYfNBHi+Qm2WsfKBRw0KFbXU6hEULfXUES3VunHAIoHRDgLVCAAcTPMrZbaBQYGd8uvH4GwpcjdoxsPRApqp4kTAidFk8pslUNR2bn3SKs3TCL0f1Rd+EeHSOJ2JK2DUefUfulVGMDEF+1wojq3QPiAAWfJaFl0kDpBGD6HC/gJODadGiI0UsuEAENAYJ10smVokyiO+ViW+V42+8gnOBFjaRlQOqK3a4oTBoADbsI3Bst1QtY3W2ZPbFp0bvF3b1Q0c6cEYpP0ybofBhREv4vsXg8aUBl3Qgk1Ff3lE3EbY4JQav7LTRKMW7/3U5NEocq0oAlDXN9nT/xt9RLDm2jJiv4qtQlmIHBCA3eHyRGmT3Rnnfx1EgoId2sHMA5n6v8CBWM3F0cChHCct2Iz9avAB1eDkJINmHlaR4PUtTsDdAhpNgGSRqRbdcKHC4c344YgCRaiGwdKN2yaOqSm+Mg7ONjpu0cX9V+JbENWNAudtA78iG1ry1i7TghO+4lNB2yvjKPLbALPDf07CLdz9O17kZXZkyMKcFpOh209NGGSHIBPOEjnFVKotGapI2u+c17OhLs7Szg4BExQxFmdd1EetI0vxU1NVONQinF7q2wUh4aIhLRL8x7W5A4INHBY94ZWOKTiO1kYkHFTU4yB9VJfOFPu94tr90P9aDU9Z49aYvuq47Tg5joJwdCMjntZRnRukHi9DjhlFPp7A4jTUIb9KripNXgO/oiUJvtpzh8Fv5KZLXgIMcUQH8UZURC86It77Ld0OfeRmjoZb7TuEVuJ7ob5uDllAkansqC4TLWhawh6IWt7ixOXg25qD5jsCYGkNFwAJntytDUdyddxzN+bgnQAYTBabDvCR3iIVTukNbtGqDU7toulQBOL97hDiC+r2nSB2JNhcadEaP+hmvsq4LmgOry4QL06vPvIQ/d4McPG3DdLcQUVlwfHa4vFUBPKhPuwU+CvPot08H8N7rYbxLWirziE+UeXPvhmkAQFWUkcx0ez7QfH/0OLrGf3YaO4uFg3xarS/5Z4CzcHR/6sl9nsARQEc/qHSEP7p9G4jwGLDtuAvHU45LLIptX1XIGHkFg3hm173byraC68DEy6/G6J3CifxsI7WejFoLk/iSLQyRPPLl45EVd/L3iMagh8qhP/WKS/1iT+RtT7dAK48kE/Skg8WcOTQDi2/r73eK9yaLL0Dv+IT8luYk2FpQ0/2FdzOW/4AZaJGKVjBdkgaWQ8sOt/YWc3NkbXWtU5FTtT1JUjaFNFtGA5cHeLgmr/2FAhOd/iBED7yaSGIwYL6eX8eE29a4E/DLv7TxUz5jFDsNNDXsIMpQ2/pb96BISNmamQr+q5G/7gDAkgjKIQQACYKsK37wnGwAnPMCgLxCE2tIw6AHADBKxBeidEiyUIwGAUBo6YIDASDFKmaZX1bpub0cBAUGATHIQxQCB6EEjxASNhPXFSWcQjoDG3V3dHcHL7YIC62KDI+QkZKTlJSKhJsVWpucna+YDYaeo6SljI6OsLk5AwIAToNCfysviwEGHzmpLEwjJDgAmRBBMsSu5iMQCTwTqEhuBksQPQgRE9D5KGoADBMP7wKAlgLYI+mbp6bqq+zs1xmtsfLI4K6i87j5yfSpOubbvvT18/SvYAGBa6od3ChJ4UDGUJEx69gxEoAK6p7KEkjxo4EWShcNMABojbL8v8laEUppRCL8Dh6jAkDFUWZNgPCfJTzJs9QIOEtCnDyBgI7+ggEQEAJqVKXPntOcrDFJMKnUK/i2xm0Jlao7yAJZfFgwMimRYziYaBAQcsECkYawGNEacoBD1hIHbCg5diyTIsykLoi2oAZsFIkBSwYkkOuXbWwwLOnqr2ulttpRZT5csWvjyAvEOAgABIxerI0mOID0JUGmMjpcCAazt0GARxA8BF6NJJXJrRMWzbFQWhDvlkFf9SYHdI5bEG+dYBL7gO60Q0YwKKgiuLCABL0SCoZYN277GhyTk9q8w326g96ZgQZzpXD28JMAZCbBfYswHLPANkaA0zzBglGHYf/AgMnjDFZIzpss6BjP1llCiCFQTDMggrIpgAx0yB1oGsFYFPGbwQKkIBsELTyxTayOUDbeRO9V6Mm7s00oY0QxbcIZNE0UwVIpxXzBWQtuBHeDAlsKIUsQObAQIJ7bHPRDwRUqQcjy60DjmxznBDACMT854M4JhRWXIR6HOmiHgBeOGOFO9KpmY6n3FknTgkBhQhocshm3mRhfEHbHK+1QAgegATQiywLABrHlCoY0MMaWroDoR5WHsJlRoG8ksUMNiQJD5qjYrkpm5m4iYKSYXVJo56zypCnnbTG1KOfWwRwDUmm8VHkk9JQAw2x2Big2pi9kkPSpHokMI2oLjyr/6OnFsbRzTA8lMDAAsawYGgJGSawQ7mquuraM7Jso6itkaCHq7w1vNtevfPGSuG85YIp5CjXlgLICA20JGYOHho7TQNBwNGDGujO0ga7eoxTTr6V4UsrjvtkHJGus4YW3j8v3XtKIB1btTHKuZbM8crw8fnyyHOud/LK8cpco8o05yzPxz07hTHQGck6NGc7C30MlsCUxPQkB/zawgEGQO1C1Zr0WcMAQzFC9Xdc26vvjlJ9p1I8ABvtCc5pd4U0vTGESfAibGgSEgBshGS3JMW04JY4kVQN089YkYcCOGeTzHbARSt+ldv9FMMAr0UhUNcKCSilnRAHvOVvI3odgP8JFuZhDkp2A7ylBFmXq6VAUymF9sLqCOQlZKNwLTBAEpXTe8BJRuQo9ih4YLIAMOW5k8Af4vR1FwK574WYtwNUEZp3koFz+nYzJ924RDyDtDQlU7tA9yheq5MA2Etd3AnkkXmoRVIE4KLAMro/4OEBDCBQQDW6l+9b+yOAawywsGBgaQujKdsn6nc/6TzgW2oxAAL4xoIFNMEAVTCgUlL0BtcdwAegmIEBIICL2wQvBVnjRBYW0KG7zSYOQ5iGLLLgANwgAAIF6NUwAMGiHPSvB1v4AjhIRBoBtORfifOe+xj3grglERLmA8NhKlGMqy1Cb4dwD99W2ERzFOQEDpD/G9+KMgDbIDABBVAeAMYyA++0wIRiYFUSdAcKOdrNjGgEICi2NwSXDQgCSSiGItjFKxQsYBkHBKQXsVaM/MAJMmhgwRm+VQQe2CILIUrClwBCRB2cIU2YasgSmfi97rkgcpNLTO6W4bsn3AVzKViLa8SRO1FUDgsnqd0eMHcSLBgvBdNLgpiM0gLCrOB5q/uOUnjHDdRVgZcqWMbl9NJMPNjlI2oLI5ZaUAwRVIFUSViDbQLQBCyZ5Y9zpCICQVGMkIDzbXwcohMs+DYpCAGAhFyBId8WQrXUSnieIJQsXrWMI10EELaYQVFApakVfDJVhTFMKdBmyo04MZXwE0RS/wpovxyK5Vu66181SlOaBYqBYAYUwgYXVkEChE6BCuLVAILgAzUSIJ0nRUFpbIFAFXKjABRcRksR8FIhyMItBiBgCgq4SHi1jFphfCJICnBBPsAUF5IjIDCiuDVK1gOAdtxCaSR3DKsCwKfzvBsKKsUxFCZrkBjrpyLOWEWMaXETmuSWgewgmSPpBwJRKMAZ0rCGPzg0VduLaGDL9YD1bcKiFwVLRr15GzJSMhNzeIMilYK/X+kuhDPI3TEyYYNAyhWo2AjQ2/5oN9GasxVoFSdQ/QgSqQhSnX8sARhiyk6MghFuVL1gAVCHVSkMgLDfKe4upEYW6oW1jgkEwAEKoP8A0rpgAcW9wk9Ntzp72iBZqCvNPnEAVEWoMWxALQVqtICLirkKHpxjRVB10VBiBkIYxgDHfB1W0VJOdhJre2I3zbteUGCiDVSsK5aQgKUo1mMG+PzpO7cAoW4Wcr1icDBMI4xVoAKQGflM7R9DPNbfQjW4AY5EItWbV0eiTLIrvhUqvTlc/ZzQPA34KgLNCgAklLAlEM4EYeFKXlyAIpvUbS270HpMCAi5hLhY4PZSUgNL/oEkcR0CMGTxAC2LkI4Cjir4ZvwCEWwxZuy1p7xkbOaA1tjANmZGAYLZRjP91AF1Lk11k2sIArBoh+LYbmlI4wDTKaAA1mUyGHhMSeb/okCNa9HGjkkLpMKIN9HELABJhqXoKkR3zCp+843UTOpPAPjUaS5zQF7cuMeR2cyDe7ObVS00t5FS1rFura2Bq+Fe19rWA+71nkZNbJ2YGtipngSW6Dc+p02xE+jLSmWPTW1jW5vGrp5xsP00A7lJItoh3sQVo+ajL8ZZEuoL9+ZSh6S5RREf03bBuucB62wjW6Cq7vYhVFkDyinTlb+LpVKcU0tknhmbuyQLqE/gS3foBcnD7OUpeV3xRwBQpRpFxLjRXRJzs3o9u8Z1gGdtZn7foBh+k58I6PfRYbRRpDn135Z3egyVyq2oRwXFAs2KBZsWAZQVfwgvayA5SyoT/46few7C2+nwVB6dP7dk5+1Ansutcc51s4x4MAqTOa5jSX28mwPXbSA56slpm/jGk75PjXK4XRapmYUOZwFwwM9SEbbY1ddpcZvaO45KFhnWbanLXNQhLMN+P06CT1uQP+pWweYjFbo3Ey8cTn6YCm8QVFPpZxsDRJC6Sgk9BunXc15BwAHlmsrovzWDEA417R5fu4sbefJl763A6qwHglu0YIg2uNlDtseE9UmhCxOTn3IufLpRq87Xz9YQamSj3ulJeAO/vpykNf6vQ226/BW3tasFRGu/n+hD5lAOmBn5rldscm7jPhL25JscA6BjHuvOx0CGMiVLy4Iia9mRgf+YebiC8nEZJwybiFGYPXjYJ4yRHXDYiF3f80Gg8C1g94kZKBTAAyzVIeFAsyUfhWxgB75NUYRf+yBg+5Vcstna26nCjUlBnQHDA+AZAOmZdiVBnwmaGARaWxHaph3aFhhAoi3a4Bna0FGEkaUWCckRSlGSVg1AkPUf920cEwrZBToA53mfhU0Hr4AWAZYfFzIQQymFW6EgOkzUqKjhGrJhG7rhG8JhHMrhHNJhHbIhHG3birkgROQhzIBPppFXZUgad7UAcimXDmbeC/oTpFFYctmZvqzVEujFFvRPKwyhonnIV0giaTEUc0GW2jWEHYriKJJiKZqiHTpBH07WHjL/hCoWW7pdBZtlDMnRHmPYHvyFnLBVG1bIIr7QYi1uyS3GwFLpniRUkTBGwrytAyuuYC4CIyg+Iz64YkrdhlBNQp/0YiTUAxbRAzLCADMGQycYVTtwIyOsG2HE26rBYjRCIzsizlJkwmhUDlLMEm+pAUiEU2ToxRV1zidMjxAo03MUU079EtcxyVpkjm3cVRbF32dUAnp9Yq6lGKT8Tb6tozteHEYuozf6X1rJAQRcgQgY1cL4Td3JwgRVUBHQXMdhAdUMQxBQ100hAQLw3EwFAwR9C06lk3I0ZCGiTlvsYxGchCwRhnSQXTDNTjcFXGS0zk5aDlMipDhoR5+cne2U/11HNZ5FWpxGihxXtsM0goRtaBcJttEK2J9+jKR5+ZGXTZTStRYAJUDu9JNqBV53bQFYig1HoGQDaJACUNBcAtAacYMZtF5aZZANeNQDgZ4liYED3eRishUDSQ1f8s7p0UuyqB9lOaNXphhnqgNeEgAStEQDvs0MfIN5hZjgnVNOSRUVEUcHHZiFgaBd/po29uQbLJRrrOV6hZaTMc/5tdbraRbCjFOf6NGH3RGSAUX6OcH4Cd6H5UU6usxWemZGVmcngCZQbCNaqYQILJIsLJBbcVX/+UQJBQN3NBmFKJkEIphv2mbI2UWzGUBq8uZ0tcAIjpBZ2oFmWR88NUA4If+nhQmUCcpms8nTQqojdV6nNi2oRBqjdr6EotHAddnYfBaGyjGX54hJclVBCI1EkWwNomEibXZdRN5ArQWAh4gD7bSVLFTXoNEPBJRhBXVhDfyKDdTfXazVhl0VbZbVcpZhDYEhbXWmgjZokR5pZHEkQ/yikuainiXX/1xouFhXWRVXTW0iJRbXHyiIoiFlcdbCdgUodVnX3qlkci3DJRbhhxVpk2qkm3olXhoEnMLjZpJaAiapVuZp0BAbOF4Unu4pjQVqnR6bn5oSoA4qnCXqgz4NyD1bO9SbFLXbLRoqEyHqorYmpr4no2pTtFmIrWQc+XSjnR6CpyqBiTJHDJT/IzTSKTu2Kka+mOQw3VSmgBMMRu4Y5VsgpdfJknM4wUFqXfkwnDtEXRHkjltqDdNNndPBSqfcJsYh6EXaIsbFgJwKqkZISaPkw9lJJ0aMhOyAHNl0paZOawzspQEskJUNnmD6wQEUZunNZ0651N3h5AscngcpXk8ZwuPtz+JF5uTBFEOS6g3YRVRqTTDZALA6jdHhDgAFpCso5DM9xzwajrH+JFBxDrI+ZLUlixZMgQoSBRokBU8AVvLITjYyKLkKbAxc17cBmnIy2oseE/h5IAKdZg3oKJgeg99RoMymwvRtjvZZH4h6UaXCRehZJqmQxOOlUuKBkA/AZAgtV06d/yugcZcsRG2Y6cfUcB7zGSkg/Eq/0g40FQUBMMAyKFP0lI2SCcVYPGJaaYEr4SqSBYDvHAbokcVdoCvowABg5M7+fKtYQFPyLI/8wBGsyOqYjKvKriwMxOfSVBijhQR+1qzuKAJthUTxLeF+dg85VeCDXWDjIs1aOeeBLh8FGlhcukgmtKyY2Kc6qW4/NcChLezGgg94yI8QlBA25I4JSEsO7VCGwFCMyJAuMIELqIYDAG+vWJUPjZIN4caPlYiM5oIWkEMDjMAywAgcVAFsFFTqyQhkLMgOKS62MW61elGK8kf/JIFZfVnQiQP1/mWNohACyaxK7Kg7BODmSllkSv8NFErhklHhqEqrSIAp8pnu9ZXXH72ma7GKHCyNQoDnAsCm+clRCpYZs+RAAvDA75jAr2ASFuhAJFmYEJbsNvBANCERIHgOdQkA0p0BSSzIN6xCqgTLZOiQOJDAEDjZj0jSIAiAZ6GsqJ0vAccAlPpPdV2XEO6YbDADWVROpWlpi2zaDubvoI3X5i7XpLmAIW4OIw6wsw5sDKzVepouQFWh8qFdSoamO6goBUnwecIvgv1ftGpmnHWVbFwoLACEQo1KBZVTWBzJCesBOLzC4QBLIqsATUYwkUzGIJewN2XCD4OLG7RjEX/jkjKR0YKpmmYiH1xpvC2wizYxiGovc9H/JDyQ8ofWlqI5KoMOhC4RQHEU1h2UgJYUlhqwgbuEQy8PCQqcQQk0QA/ZTBwJlhToh24iUS7ccLtQASDcBWChwSwXL6+cgKMsDiaLcaE+K3vZsc5U22uITH0xCKY4iTPAVy8T8uWMgHIhstQ0zFSoxvrcx8S0FRykHg6oMg39yo+gRvlesjavEzePsV5983tcKrm+qjtaK9tUqvcktKYuNDs29C2aqjwoY2Sgarka6bFFNKZOdDQ29BB3HAYvwqp2NKemdK999KKG9DOOdLE2HQBVXcLpUtYVnK7iwuwcLJLdwcMd5QnNFNrx6UvP4i52AtmwhOp0azMKdCaTm+X5/+sC6VMVKIAWOtUthJ67xpxhmp5N9orqgQJXh172xV5Rg2zatPQ1ssvIhgFT6OJTQ7Um7FP1XWDeZKAQ0qz41eVXgB5wMhQEZCZaPyOgju32HMDcSk/uCEnitjVNjoAdwPXeRk93rEBio84ySMbLGHUtjjQDRuBdQyg7aSAH5ucHGuhXUG4JkoYmD/RKxzUeZ0hsLW8O+1AWBPH4GsyVREvcFtH00iRypEgF7dACIMwQz0pn095nXyb/CXBqZWFHrpUA0O8X9t9XUPcYJoYO1003nxqedjAsaZ5sIBYn6QAcCPGVgMsrxDA3xMGa1G0PZOF0pDVPKPfaMbcNIGIjyv+gdINplp7p1BDhJ1MIgHcimnZ3QTv119qMIeuAgyPKfuUXIT0UlUCM5EyDe95MfXNmQ8sfrTz0q1VbLbtFMBMQMeNXiDTKsky4H4BDboBJ6KDLLKuB8Fpyx9w3vnk4JCD3ZYS44gDqOUdaO7tCYs1nD7B4+3oDf83zZCxyMyjXjR+1XKOatf0426z1oOZ4tu340Fy5WiO1ym65lbt243y50WR5oI45QbM5bHPD6x1xU1vNK4cjIqCj41IXndtbmCs0h8dpmStOsMXIHZT0TwVjyi0CRdbuXM7pLoLgTiLCOCYj6FIC3Rw0OFN5R/bps1oQLmSsjuZPsALTe9FqgRn/oKxGkQj4FOw0RT+dzi3UQGRMRzo5U6/+I9ulW5gYkzpG6iM8TwNsNBnX0ZRnetuRWrCR7ROolI7Wq2Wma80Ww0n6pQgwDWba8lKZST/5lDkhUAkdVJX/VEseAMxda01Y0FM+E9olZRIAaxligeqBu9n2ri1FXK17FjEJ5egkt59zZZcDTbD9dWqAnrmRbl3iEbSrZW4eBgDxVjDI3R3FEb3gAVsoEFn4VrgD31aU2YWlgAPBHu/Aq9JC5rOD+89J7VUPZqgZHwF5HqQjNL9rpL/3zNstlCFM92xG7uAJqXy6gFg5wcoLqHk5x3xu9kDTdMaXe7+NylmcUVIItq3q/ydtHnzJK59x8099LmCo1cmabzqZ56Kg2A9TPfcA9t+PthFJpOQfqe+K9nwSvK8BCf0ggJqK1lkblYbVWNWWhRe5J+hDlNF/snb4Xe6YRm5HDl5cCpLKy5XW0wnXA1sgn2LkS/7k0+HewcQC7NgOtjZxApUnk+kSi0MpGxgSpxMAAUlz9VMbWHy4oK0sJpqm1UDmt7Ci+j2PptV2u1X9Yi5ZtW+fkCa74EXd5n1pAD2K7Yjj21pRUP7yM3/zL4mCo4xWAKoFaZdxVaJgViKX0qYSu9uj5XOGtXYUvkGVSpcDG7+NIH+xNz7MY/odu/n5RAZjxrb6A2P6t//7e4Ikiv8/sdk/CADiSJbmiabqyrbuC8fyTLNBUOf6zo+3j+sJh8SiLWhMKpfMpnP5ix0MpikKgXARegMXY+CoRQHjp/msLKPX7Lb7nVK3HAcTHSAwJRKtRZ73t4LQYEBFMyY3QrBIkOWCFXM3sgdDqSJphPlyEKaSCAcaKjqa8zlywAeA8ACQkBUwoFDnSiAQkCqy2MqgoOBI8uAQmLuFwKDKd6AwcAygzCzy93AMK0sS0BDQuDCQmnDwsOWJZGp7Ix4XZPkygE6G1GIq0q5EH0PQNU66z9/vfw3vBAIIIh4sANDugQJnx9ohEECgDhCEDgwYLJHg4DAA+AA4KPAOQQEEBhz/jiy5Jc9HiwsPNBORoECjBgQMKOAzIJu7E4gCkhiWYMCAIF+gCQ2AQFcCXr4AGIDlANe8AL2o/EDALRXWbiK2Di1BoBdShI28OYK1YAqsAFQMcFtA5dnLeVvkAmAgjsAxux2f+ZT3L7DgwUUAA7gJoEGWdjG/0cVj4ge9jqcGUNkIeUBaBQQeDF3r+cZXATGpNJaoqMuBfGHJxiPncwREXTUPfyOEgM+CBTUlV7zoAEfQEl8VvktcEzFNm3xkAlgATyRJ5+0o03Nw0CV0MgcVsGJwQDpKEiZJMl5oW3z1LhCmsCphmLD8+fSPsMC3+jEBB9lcY5a8BWUiBFCAUALk/zNCNw4w8EAD3DGCQAC8LZKFAA0clAt/8HREWUf2rNBTCubgEGFOSEEQzoBBAMgRe1QI+BhkN+THkSysyQLScSME89h6j0FgCAAEiUDQAgowkEVoa5HX2WdfQYCFg0oO1VEDDtQGX2z1bclllzqu0ABXZFnxhX9BqugajD+Z8EABdQjFESEiHECAnM5ApkB2VJSZGpFWsfKhPmiiEMgg1JBIYBdRsNjRH2rak8c5rLUzKWVlREGPj/6tGQ1MC0BAgIQQMikqhe88gEOpjXTEEpBZeglrrPTF12CCehXopmsEdoLmZAiWgNkBDj6nDq7HxDRAAcfkYUABCzCAK2otiv8ArbNUBJrORIQqkiN0kBgQaSeMduEcn7betdAPrgbAyroPGOBqcCTwSV1EIDW7hZjKHNOaOMHVaYi01dlZxyCKxRkwhyI4B5CsDj/cT3wQFwabiCQsUKACSOHKh0gDHDCuMwX08itCBX58XLVw3VWAta2MrHEJHy1Ak2sKjOzcakKBJxTKiVr2crJz0YOssiLkOYmxHd1cAK/aTgx11GhILDUPITphSEZNGHJwl1RXDXbYMHwt9gxXN5FAmEAzEWYBUm1Jdtlyzz0o3UScbbd8cefNN9R7u2CFCW6hHCvefQf29+GKe5k4C5qMsAArZ5qBbSkVo+AOJCZoDtPbMcD/kkBdTufd+OKmz1c6UkgNrs4rXxw0yHZBLZBFbqE6s4zk3KjD1FMDvGcXGa+rcqGWMhjOaecnrPOlDAksVNK0h5d+evWIG+/CgRtvIS89pNnWbDjPG1AnRxBoPIh7ADjX/W8yGaCYeinxcVP4O4lx+QnDKNU7R8Vw85VrfKET3wiH79iCkKFESHpomVzYqGe9CO6jdH8Q1g24sanj0IMz86BTPng0p2xIqAu+osuUcPAHFvUAebJpGBgAYJwfOGc7PzmGdxCik+1I6Dm8Ade05GWuskFQgkQEBQVzIZNFvCklvcqXODQ1BgIkMSJpykc7VFWhJgqBhZ2aCKTecYAc/6nBUSQUx5CEpKM8dAQCNwgAZsA2xCLKkQ1HdEp75pRBFvEIftIrnzPgJZElSm9gAYOMBptBAM99Ln8mGIYKI6WNfIwxF2XsooyCoMYuzEYXc4vjHD/5hDqKLFk48J4W3dIyfiEoUS3BVSkDZMUtFG1ZaIKWokp2PEYCy4Vb4MU74EUFeXHKAYASx5FqlMZp/Q6PncQeKJ85Ck/yjYt46FkCJHOyOvwgJmIBVrJWZg+d+QyT07JJy9AjN2lCc51DUKfdqImCyq3gjet0JzvvaTl8RkaXLJCnCugJTXvqc6AvEGg6+UnQJBg0oQzliTOfCc+GWu2hEq2oDhYqNniSb/8EBpBIUhjRCIvuU6QkvRtFPwnPB0CEkrm4gTnuZ1GMlnSgMoUjQkeQDQypCaAxPelMf5othlIzjPBiafKAWlOg1tOncqQmMQ+jyl0qtXlTrSqImFpEajagQBeSXgunmlSrzjGsUeNiGEVQ1J1WlaxiJSJbJ8bFpx4NLxDoWR14WtG3ttV6a2mjX/8K2MAKdrCELaxhD4vYxAaQqnt1gV4ba7pQJXaylK2sZS+LWHQ8NqBYhaxnl/rZgnY2tKTN6mj3utnSqhZWqQVla1cL21mdtq2vja1tBVPbps72trzN6G6tmtveCjcUwXXrb4eLXIcVV4LLTa5zQ3lcsEb3udT/Rd10kXrd6mr3H83la3a3C15SdLd64w2vec323ZIW140CaK973wvf+Mp3vvStr33vi9/86ne//O2vf9ub3p4md73/LbCBD4zgBCt4wfANcF6NZ4BrPuAX5HEB8yqsgmdUIQwX3pq00PphEsD0NRO0xXlXaGLhmqIA2qhVIx2rJbw2IHAiVpSDU8CJDTMWlzAu8Y2p68YfC1VLAjLEF44pgOE5ZXddAaBwapeKPxxZWrW4xQFfZGNVZAUZBRlQCXIDkywspSrzyguSkrEMEuFEgddABizeYx/xpvjEF50zbz8BrysZuQAGAPP3EMM+HMzwldLLAy/6bCdVQOQAOjxI/0d+sBzEGBpKarJOvsJgnEmg5yZrVF9HdoOlTtWpJl27qo/pvIMgD9cUJYJAd+aSwgBYcIRn1SAsO5WnG9Tsq2ckyKNlfSOyQOcBqEpgFyztGkOOAEqDmJaVavPrFyM7ztG0M6rNZm3bxocmgYq1FBnhQS1SJg+/Y8SZ/hCITL6jQ4ryjE14A5ZYJnsjNyg2qxQCpGjvctqmlrOQnatqFWuJTmhVzA7vFGtAzgmYHsHBMYcjI/T0mVPH7FeW3SUyVtysCveqF7q+3ICDKWx9i1DU6CDDb0FV+98DznZsP4EABbTtGKgcDZrCSMqXdbNOmsnHHz6SLApX0K7T+oHKDP8BpVbw+GY3y1c2TYC0aTEtDB3xmLTUnex+r/zapXA5bMt7Bn+6gcAsR27Aewt2yo147GUvqNe5Ho+3qzbtiiM73A8h99LSfXptd2ze746Cs9/5oWuPAY95IqYc0JgEgwvxBPsed8jf+e+hBYwfeoBXmEBvB48TQeScwgaxv8rfgD8e5T8rj2BsxBUcqYMughc8aVAjFgJT4Fa8AQ53qI4kTG6F6zRDPNlpBsq3G1xFWAeT3r15TstoRgCGFzuK2r30Yzu9Z02hNXqX8iDlQYn8ILMS47jkYj2MNE508hMFBto/9EuA/cZXPgKcT9B8AM/6wWCR98XvJN5rv/1ITHr/1Od2kgdaJ7AalxFvWAESBHFCJ4QHpfEyjtEwNNIalVNBIoRBpmRrh/FE4SYyp4CBlWRpDhhrWad1oiB4BngDc+EGxjcvQhFiq4ETJ4cGL2QHh9dhW2R9kPUJP3MgJYAiDLAgijIhjYBFeNBVGdIfE8FuJthF36ZEeURo9qApAgKFVFRCZHGEJSh6DROAKOAH7uVTP8gOmfccAhAVI/AQLEZhuWBiZDh2inRN0XAjDuAAHFQYO9hYhoEZyyAyOAAwcxKICHcYenIXvxIFGGeBaHVHd6KBehQGfEQZ8JIFHdWIgmRpg3hXvcKCQbV1KJAAAjASd5EM3FARHPF83HAs/xYyFkGxTGSQAJ4BF3ViC+5gAA6gGa7XALbwC37AFYyGfxzxhvnAC8sUIfwyFsUGH6lwC7AYGiWgjOwCiwUhFA6QG8LBimLWXopkNXqIWg+FGReBHDBhLEFjNMziLLaUK9pydE6obDjHYlLoGqhkNAJiSwOAAPBIaMg2S4ZkdAUCgJ94AgqQZCQwECwGASDhRnXVXgggDHXFCWhIkKzQXgWwiwuQABBwIFJRAGzUkbmhkYSzPhZijQkZAAkpjCjUBQwgAAogDGGAkn7wLi3ZSD6nSRBwhwIAZ2d4AAcgABrRBX4QHDIxACohABApLC0zY0aQgtpGgOw0fSdQlO6gUv/HIAwgs1LCkBL5AAEi9IM/CC4ktBE+GQYsCSgbUWUwVJBXmZY/SJBU0JFnCC8FwpJ84F6aZJPV5BRwKIzEtFJu2ZLagBDolg8dNSMO1I1PCVGKyVmnBoZzFiEr5UahIpl/6XMi1Ixk+INFCRYmlpacKWImNplkMBvDOJjzkAehKAyh6AcvEoWaiZd0WAJbZZGyiUrt9QWEaZBt2E7eSFuMuZiOKRDtBR0s5pOc0QAEMZqjaSGNQJDaMIewOZjgQQJdGRYC8CZoaWLHWSe+Zpoq9Xw0CS40WZEnoJHY8ZUyIZMyA2CyGTn7oZOg2Zy8yZS+KVZ71zdReQJSVJGytIv/ubKclYmdbqGRbKSXeskAGrmTYWQhqQCaipBiaSOKrmeaHqGRCmAIE3kYOrk8EICTX+mhaLg5DSmbJ3mUYQCa7OV4eQicY9WiKPWi12Cf1sOX9dGULxejuiWcBFWjszKja5WjprWjAggiPypdAxakpJmkPGikSoWf05SkN4pWjDAEnccCHWWANAiVTYpdSDqkIpYN/EGfM9CFWbqfJVOmfMWlP/WkpBOlb0cZwtRAA5KLSkc7yHA7YSFz7sB6VPR6zcdlvpOG+LB80VdPazpTbfpOb2o8lIEYQNQF2MEQ8Ocg8oc+J8EwvcJ9jcB/JddwShcnpDYdKRJQiKpeSxpB//oJFnVlJUTSRnngKkfTgZQBQoGCDwqIRie0Rlg2SE60pah6OopKN6paY2SAHpvEROdCFpYSBNgShEP4IBTSKCyFbGlKXqZKUsLaTF/aJ4dRSsCDEKkADpFYqcSYD5l6NKoRj5rYEeVybPIGDYcKrKajrQfFrUbVLO7HNC3RMwxAj1ElAjODrjCEIbs2S30BM+/6GLYkr6umJZoDsVmwEzl4BgOkB29jsRjBB1a6BsQaGFmDIQ0lpav1CXzSC3OFEAzEmINQCCOlhoTgQCoEBx77D2kjFIipTyM7d1pSVOuTI+tCBjoRANiBLX7hP16GO8tkfIXQe0WxF2kWtNoQBP+6cCk6cXvi1gsBUgzHAGaKIA4rkrG5dK9EGhnYKlKm8DGMlha1lpoyUSL5OCzLpj5RkAfpYxHrU39hxD2yhht80B53GxONUIJlELiDkBx8ACCDECVJEakKCQ90Gw02tJOiNbZkK6PzujimwC4PsAfERk7Makki8GxWQU4g9IEhdEH4iCLiMLqFhiZl0BfBBiDRSJEIsRm6R06GpCY99oWCgyXkg7NFwDw5tglaylxmK2CY0wtYkCfigHWQy3j49hTkFEUIcoUFkyhOIb3j9roborBF90qLUkoJsCAupi3oZlSLNLZpSZqF107eCwO7m1XI+2AqsFULE7dqJEa5qwj/C9MZYfAQcbJwSWeJgfQtauS/lOEqOgS/QvIntlZrKNMmb1IyPBLAhvRUejE2jJoC+MBnCbQFyKd0AeS0ZEAMeIoDweMDu4EyrLIWbfHCTlENJTNmGOo/lDBlS6YZVkF7Jny0i4DDPTwYOqt32BN1GNRFQnFN/Hs0LUOuYJBCGcMyQpGPruQxbnMYTiw9DRILqdLA7cgiBBKPzjAsNMRRYSIMdOgyiEG5vRtvxBaL9LB+tXETwtJndokmlrox5qF7GHoAvhaUqXIQjfapEJcgmJYuODlmiGYT3wEOLUFLx3GSUXFoLDvE9CtR9ToYGxG3vCuQJoAPzcJn7TBrGFQi/9kwEKRagrTqJI/brJ7aa2hEJA7sVTECSUcDHdhAAEaCJBEoEYMbBLmmy5eMuXVXzLAyDKugvm5crAByvYZyHBECkKssSUVIYZjiqemmbHlARsThvDpSbotgGp8SIBrij148D+EgzsTssF7KzN1KFwrnDFLkeUhRibBKBdvRIQTTMGnVBRW3EABNcofozR+3KBKXFAEra3viIsSiI1SBVmP6zl93zMa8vr9CD/r4HBmzMcnCB1wcMwLSjz4wc9MiTnVw0iKTJ2j6dGMAdCPxMwagjnUA0ugcsLgi0Z98W3rVeLGCpezQxjoNNtY6rJgssk/5ecHrhfxAvNkT1Cho1P+kQNSdFNUJpbkDNDj/08MTBhPSsnvIZ6g5bDvwcBQkEcMkgIvx+nzABxZZOyARggW7EyDLsDJ6wQ3FgLhtlAU5bKdmWDdQXdFOWtUEVQ704wvCogoo7SDywnCyoX57az+VTAh6TH41Qcjz4hQH82dSobiKW03b49DhQbBkgI+IzSGJBCWSLdMYesEBCdiWawODTVPGU4KGlBGc2WxawymlXEnCTBO7m4jLBha4CCrnDAwrUrun+wMsAZCQO4nO4dth0Qx+zVgz+3bkw0n3QBxCwDk9sHgpewI/vQTinQaynbO0PSgqcad/cBPr+FXX6xrhXBPAzb/DAC2CVNuD8gP/3XwcBfAu+oZ1NCTf46Fs1PbamBOmHwwDJUPdmJMPFBtvLnAH2mymLNDgRtXU5R3YbmoxyQQNF8xzL2ZHgaQrCA3cnSDQPhCJzpHfp4syf8Bw8iIAppFlKNcFz+MDCM3Y1E2z0hMcY10jHIQXuUANMKEZFQSoIsYA3FAw3GAN2KANuiDCNfwK6HfCxsBltGALdqlkasgHdm0P1UAnW04GcD21X5uLUF4WMjwUL7LkYS7E1bfhi9rhkCssUIxTnRgIGm0PL824m1MgPUl0HJUxLP7XZNAy/MtNX2GzGOTcmvR0fl4SQ8HjHOzgnhcO89fZioHjtgEZlVy3nXoNlvHH/4lNxi9jhIK2txRhEQdRuH3yEbb2EFS02c1c2lICybN+VwpUgpLqEoX7aYJM2nALQ5BsenM+rNHVbA5jCBg5s5a+nznFZ7SK3EISJbg23TDUyl5INNzwvHybulVUy52SixykgcbdJ5B7GpZE4eoSJE0Yy+ruNitapMi+rTvg7A6DMU1jRNAOyjIhEaAryexCTl90hNrSDtiRRcwK3yW0uwrCIMNy7i0O4EqIQl9l3PszKducTBxhzp9j3vikyb510cXq4gUTco6gEjjgQ5rYzwTx4fqrIvKMiceWI8CQK3BiJl0EuzWeB2SiSYYQCAs8voKYI0vDL+lCTkB/7O1sdv/+HuHwLMZIEHWQMeluRI5Ccw0lfedpnEBLPErxmIVKTAKI7dC6wu8U7/NTDKBpvyNhEjPi1BDdELswmEwz3fQCpwPfPQ8tcHjeVblnMPJwE/L3VDpWqn0i7qKBbwaDb6OFD5VEtrWB2nt9KhYVomRlzSmzU4lvwcPW4OWg89b2vGVaRiU3HDp07eZM3uVTA/WwXbb2bq9n6hGOO9Ddw6nTMT+eDmrn1goYWj43BB7iNxd1MgVLqT2GyxwDrUOKLNoXAQv5CAHtR0evD/uX6/T6Y7vKEBEhSBa1mqw/IAd5gIcfw8tiNu9Rv99zciO1Jv5BwNxrX91N0OPCy40GiJj/PZ3JkF+AIACIIzAkDvM0AFEQ71ESQSAOBCCINMCTucyGSywgOIKjURsRBruajuWUNp+9ZeFhqPqivh84LB6Dv+QzOk0KCJbqt9h8dsTAiwfAAN+Tb/w/IB+bW2Ch4SFiYpgcyUNBzICTAUQdJAHDlAvQVY8DmM6Dp8EKDoBDwIEeJkkVwOMmAIRegJasaU2XXoJTlxVBgmIaY/DfoCHCwoBCDEJCwAAeAHIkYQ9CAIJB8lICQg/mgnTDQs3ugnfzDMCBAnTetkgCg4KCwXM0+wDDDrg4OTHAN8YCEixoENAwEQdWAPi3rsCAAjX8OCiwoAEOLzUQQKwjQoe2AgX2/wWAOMAAA4ivmECIuCQKgJQWdRVoh4tbgwHJOG3i8ezgj4RAxwwMhCDGQhYYR3nT5HCEgAHYNJ0KIgCYggQGsvyqR4AUBAXYGqTCQ3WiAwOOCDDlmM3PVQBZtz4oNfRg0bt69wYUukcPgAbegLZKA3gBML6B/Cru0eYQkQE6Wt04UMAKiSgLaeyEa8WPglIDDrQKNWJzgM5Hptx4IPUZlM92GxPLS/s2bjSM3+QskJjwlDQLRHrKDWc3X9t8HJwDQvnFFDlRWrwgYKnnRBx+ZLT6Qh1GkOepq3vTGMR4IuXo1+NGzv79UPd61cPRJ20ya7a2qmYWMamSVbIBYNooUv+I8JVC/ykUXn5fARaDefbBt9hjE1qYXDUXaohXhrnR98ZCAziAnxAAJFCTWD/AZJlLAXLiR0gjGbgDRAo81KIfz5mo0j7mpRTchsJUGCSRAMlXJJICddjekEk6GeSHT0p5xpFTWokZe1FeueVeWnJ5ZZVfOhkmXk2KeeZdXqI55pJrgtkmbWq6OSeFcNKJJJl3TphnQXLq+aduZgKaJJ+DGldoX4IaumigdjIKH6KPKhZpbYpKeukIfmJ6G6WbAtWpIpp6eqeoo3bpqKntodqlpakaWqqrn64aK4aQtkqrnrDiShBsNPj6K7DBCjssscUaeyyyySq7LLNS2TrrrmLH6hotMTMwey222Wq7LbfJzobetNQ+Ga645Zp7CLnnQnmruu26iy67706Zrrz1ykuvvevhmy+/4u7bL6fxAjzwvQIYfDDCCSu8MMMNO/wwxBFLPDHFFVt88cHQEryxvxh7/DHIIYs8MskJa8wxyimrvDLLLbv8MswxyzwzzTXbfDPOOeu8M889+/wz0EELPTTRRRt9NNJJK7000007/TTUUUs9NdVVW3011llrvTXXXXv9Ndhhiz022WWbfTbaaau9Ntttuw1oCAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This algorithm reflects the author's approach to management of childhood overweight and obesity in a primary care setting.",
"    <div class=\"footnotes\">",
"     ALT: alanine aminotransferase.",
"     <br>",
"      * May be performed by nurse.",
"      <br>",
"       &bull; Some providers also measure a fasting insulin level, for the purposes of counseling, rather than&nbsp;for screening.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. William Klish",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_34_16928=[""].join("\n");
var outline_f16_34_16928=null;
var title_f16_34_16929="Patient information: Leukoplakia (The Basics)";
var content_f16_34_16929=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83680\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/19/7477\">",
"         Leukoplakia",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/53/6994\">",
"         Patient information: Mouth sores (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Leukoplakia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/leukoplakia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H115678938\">",
"      <span class=\"h1\">",
"       What is leukoplakia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Leukoplakia is a condition that causes white or gray patches inside the mouth or on the tongue (",
"      <a class=\"graphic graphic_picture graphicRef62948 \" href=\"UTD.htm?7/19/7477\">",
"       picture 1",
"      </a>",
"      ). These patches can be thick. They usually develop slowly over time.",
"     </p>",
"     <p>",
"      Leukoplakia usually happens when something irritates the inside of the mouth, such as poorly fitting dentures or a rough spot on a tooth. Smoking and chewing tobacco are also common causes of leukoplakia. Leukoplakia can sometimes turn into mouth cancer after a few years, but this is uncommon.",
"     </p>",
"     <p>",
"      A type of leukoplakia called &ldquo;oral hairy leukoplakia&rdquo; sometimes happens in people with HIV infection. This type of leukoplakia is caused by a virus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H115678953\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have white or gray patches on your tongue or in your mouth that don&rsquo;t go away, see your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H115678968\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. The doctor or nurse will talk with you and do an exam. He or she might also do a test called a &ldquo;biopsy.&rdquo; For this test, the doctor will take a small sample of the gray or white patch. Then another doctor will look at the sample under a microscope.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H115678983\">",
"      <span class=\"h1\">",
"       How is leukoplakia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main treatment for leukoplakia is to avoid the things that cause it. If you smoke or use chewing tobacco, quit! If you have poorly fitting dentures or a rough place on a tooth that is rubbing against your cheek, ask your dentist to fix the problem.",
"     </p>",
"     <p>",
"      Many people don&rsquo;t need any other treatment for leukoplakia. But if your doctor or nurse thinks it might turn into mouth cancer, he or she might recommend surgery to remove the leukoplakia.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H115678998\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/53/6994?source=see_link\">",
"       Patient information: Mouth sores (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/34/16929?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83680 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-4BCC47CC64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_34_16929=[""].join("\n");
var outline_f16_34_16929=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115678938\">",
"      What is leukoplakia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115678953\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115678968\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115678983\">",
"      How is leukoplakia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115678998\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83680\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/19/7477\">",
"      Leukoplakia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/53/6994?source=related_link\">",
"      Patient information: Mouth sores (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_34_16930="Med bronchogen cyst CXR V";
var content_f16_34_16930=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right paratracheal bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows a mass in the right tracheobronchial angle that mimics an enlarged azygos vein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_34_16930=[""].join("\n");
var outline_f16_34_16930=null;
var title_f16_34_16931="Facial nerve danger zones";
var content_f16_34_16931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Danger zones for temporal, marginal mandibular, buccal, and zygomatic branches of the facial nerve. Danger zones for the great auricular and the spinal accessory nerves, and the parotid gland.",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Facial nerve danger zones. The frontal branch (F) of the facial nerve where it crosses the zygoma (area 4). The marginal mandibular (M) nerve where the superficial musculoaponeurotic system is thinned in the lower face (area 5). The parotid duct (PD) and the buccal (B) and zygomatic (Z) branches at the anterior border of the masseter muscle (area 6). The great auricular nerve (GAN) and the spinal accessory nerve (SAN) at Erb's point on the posterior margin of the sternocleidomastoid muscle (area 7). The parenchyma of the parotid gland (P) (area 8).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_34_16931=[""].join("\n");
var outline_f16_34_16931=null;
var title_f16_34_16932="Internal herniations";
var content_f16_34_16932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Internal hernias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 526px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Internal hernias have been described in up to 5 percent of patients undergoing laparoscopic bariatric surgery. Hernias through the transverse mesocolon are the most common and require operative treatment. The arrows show the common areas of herniation. To reduce the incidence of internal hernias, all areas of potential herniation should be closed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &copy; 2010 Cine-Med.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_34_16932=[""].join("\n");
var outline_f16_34_16932=null;
var title_f16_34_16933="Sodium nitrite: Drug information";
var content_f16_34_16933=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium nitrite: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/49/21267?source=see_link\">",
"    see \"Sodium nitrite: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F14600043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14600029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F14600325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cyanide poisoning:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Given in conjunction with sodium thiosulfate. Administer sodium nitrite first, followed immediately by the administration of sodium thiosulfate: 300 mg (10 mL of a 3% solution); may repeat at one-half the original dose if symptoms of cyanide toxicity return",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Alternatively,",
"     </i>",
"     in patients who are unable to tolerate significant methemoglobinemia (eg, patients with comorbidities that compromise oxygen delivery, such as heart disease, lung disease), dosing may be based on hemoglobin levels (when rapid bedside testing is available) to prevent fatal methemoglobinemia; see table (Berlin, 1970):",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hemoglobin Level (g/dL)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose of 3%",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Sodium Nitrite Solution",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (maximum dose: 10 mL)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.19 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.22 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.25 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.27 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.3 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.33 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         13",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.36 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         14",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.39 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Monitor the patient for 24-48 hours; if symptoms return, repeat sodium nitrite and sodium thiosulfate at one-half the original dose.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F14600324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     <b>",
"      Cyanide poisoning:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Given in conjunction with sodium thiosulfate. Administer sodium nitrite first, followed immediately by the administration of sodium thiosulfate: 6 mg/kg (0.2 mL/kg or 6-8 mL/m",
"     <sup>",
"      2",
"     </sup>",
"     of a 3% solution); maximum dose: 300 mg (10 mL of a 3% solution); may repeat at one-half the original dose if symptoms of cyanide toxicity return",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Alternatively",
"     </i>",
"     , in patients who are unable to tolerate significant methemoglobinemia (eg, patients with comorbidities that compromise oxygen delivery, such as heart disease, lung disease): Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Monitor the patient for 24-48 hours; if symptoms return, repeat sodium nitrite and sodium thiosulfate at one-half the original dose.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F14600326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14600327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; however, renal elimination of sodium nitrite is significant and risk of adverse effects may be increased in patients with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14600328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F247322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 30 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F14600028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14600329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer via slow I.V. injection (2.5-5 mL/minute) as soon as possible after diagnosis of acute, life-threatening cyanide poisoning; follow immediately with the administration of sodium thiosulfate. Decrease rate of infusion in the event of significant hypotension, nausea, or vomiting.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F14600059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Y-site administration: Incompatible:",
"     </b>",
"     Hydroxocobalamin",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F247324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute, life-threatening cyanide poisoning in combination with sodium thiosulfate",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F14600052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, cyanosis, flushing, hypotension, palpitations, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, coma, confusion, dizziness, fatigue, headache, lightheadedness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Methemoglobinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site tingling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Numbness, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, tachypnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14600047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F247318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension:",
"     <b>",
"      [U.S. Boxed Warning]: Sodium nitrite may cause severe hypotension resulting in diminished oxygen-carrying capacity; serious adverse effects may occur at doses less than twice the recommended therapeutic dose. Monitor for adequate perfusion and oxygenation; ensure patient is euvolemic. Use with caution in patients where the diagnosis of cyanide poisoning is uncertain, patients with pre-existing diminished oxygen or cardiovascular reserve (eg, smoke inhalation victims, anemia, substantial blood loss, and cardiac or respiratory compromise),",
"     </b>",
"     and in patients who may be susceptible to injury from vasodilation; the use of hydroxocobalamin is recommended in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Methemoglobinemia:",
"     <b>",
"      [U.S. Boxed Warning]: Sodium nitrite may cause methemoglobin formation resulting in diminished oxygen-carrying capacity; serious adverse effects may occur at doses less than twice the recommended therapeutic dose. Monitor for adequate perfusion and oxygenation. Use with caution in patients where the diagnosis of cyanide poisoning is uncertain, patients with pre-existing diminished oxygen or cardiovascular reserve (eg, smoke inhalation victims, anemia, substantial blood loss, and cardiac or respiratory compromise), and in patients at greater risk for developing methemoglobinemia (eg, congenital methemoglobin reductase deficiency);",
"     </b>",
"     the use of hydroxocobalamin is recommended in these patients. Use with caution with concomitant medications known to cause methemoglobinemia (eg, nitroglycerin).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anemia: Use with caution; patients with anemia will form more methemoglobin. Dosage reduction in proportion to oxygen-carrying capacity is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Patients with G6PD deficiency are at an increased risk for hemolytic crisis following sodium nitrite administration; monitor for an acute drop in hematocrit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antihypertensives: Concurrent use of antihypertensives or diuretics and sodium nitrite should be done with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phosphodiesterase-5 enzyme (PDE5) inhibitors: Concurrent use of PDE5 inhibitors and sodium nitrite should be done with caution due to the increase in vascular nitric oxide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Methemoglobin reductase, which is responsible for converting methemoglobin back to hemoglobin, has reduced activity in pediatric patients. In addition, infants and young children have some proportion of fetal hemoglobin which forms methemoglobin more readily than adult hemoglobin. Therefore, pediatric patients (eg, neonates and infants &lt;6 months of age) are more susceptible to excessive nitrite-induced methemoglobinemia. Hydroxocobalamin may be a more effective and rapid alternative",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Nitrites should be avoided due to fetal hemoglobin's susceptibility to oxidative stress.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Cyanide poisoning: Due to the risk for serious adverse effects, use with caution in patients where the diagnosis of cyanide poisoning is uncertain. However, if clinical suspicion of cyanide poisoning is high, treatment should not be delayed. Treatment of cyanide poisoning should include decontamination and supportive therapy. Consider consultation with a poison control center at 1-800-222-1222.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Initiation of treatment: Collection of pretreatment blood cyanide concentrations does not preclude administration and should not delay administration in the emergency management of highly suspected or confirmed cyanide toxicity. Pretreatment levels may be useful as postinfusion levels may be inaccurate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Return of symptoms: Patients receiving treatment for acute cyanide poisoning must be monitored for return of symptoms for 24-48 hours; repeat treatment should be administered if symptoms return.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smoke inhalation: Use nitrites cautiously in patients with cyanide poisoning related to smoke inhalation because methemoglobinemia and carboxyhemoglobinemia may worsen oxygen-carrying capacity.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F14600044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14600045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed following maternal exposure to high concentrations of sodium nitrite in drinking water. Teratogenic effects were not observed in animal reproduction studies of sodium nitrite. Embryotoxic and nonteratogenic effects were observed in animal reproduction studies of sodium nitrite. Methemoglobin reductase is lower in the fetus compared to adults and may result in adverse effects due to nitrite-induced prenatal hypoxia. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14600046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sodium Nitrite Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/mL (10 mL): $92.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F247320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for at least 24-48 hours after administration; blood pressure and heart rate during and after infusion; hemoglobin/hematocrit; co-oximetry; serum lactate levels; venous-arterial PO",
"     <sub>",
"      2",
"     </sub>",
"     gradient; serum methemoglobin and oxyhemoglobin. Pretreatment cyanide levels may be useful diagnostically.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14600060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium nitrite promotes the formation of methemoglobin which competes with cytochrome oxidase for the cyanide ion. Cyanide combines with methemoglobin to form cyanomethemoglobin, thereby freeing the cytochrome oxidase and allowing aerobic metabolism to continue.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Agency for Toxic Substances and Disease Registry (ATSDR), &ldquo;Medical Management Guidelines for Hydrogen Cyanide (HCN).&rdquo; Available at",
"      <a href=\"file://www.atsdr.cdc.gov/MHMI/mmg8.pdf\" target=\"_blank\">",
"       file://www.atsdr.cdc.gov/MHMI/mmg8.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/34/16933/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berlin CM, &ldquo;The Treatment of Cyanide Poisoning in Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1970, 46(5):793-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/34/16933/abstract-text/4320419/pubmed\" id=\"4320419\" target=\"_blank\">",
"        4320419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geller RJ, Barthold C, Saiers JA, et al, \"Pediatric Cyanide Poisoning: Causes, Manifestations, Management, and Unmet Needs,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 118(5):2146-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/34/16933/abstract-text/17079589/pubmed\" id=\"17079589\" target=\"_blank\">",
"        17079589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gracia R and Shepherd G, \"Cyanide Poisoning and Its Treatment,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(10):1358-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/34/16933/abstract-text/15628833/pubmed\" id=\"15628833\" target=\"_blank\">",
"        15628833",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hall AH, Dart R, and Bogdan G, &ldquo;Sodium Thiosulfate or Hydroxocobalamin For The Empiric Treatment of Cyanide Poisoning?&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2007, 49(6):806-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/34/16933/abstract-text/17098327/pubmed\" id=\"17098327\" target=\"_blank\">",
"        17098327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howland MA, &ldquo;Antidotes in Depth: Sodium and Amyl Nitrite,&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 9th ed, Nelson LS, Hoffman RS, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2011, 1519-22.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85782 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_34_16933=[""].join("\n");
var outline_f16_34_16933=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14600043\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14600029\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14600325\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14600324\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14600326\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14600327\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14600328\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247322\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14600028\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14600329\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14600059\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247324\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14600052\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14600047\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247318\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300060\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223008\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14600044\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14600045\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14600046\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570481\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247320\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14600060\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/85782\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/85782|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/49/21267?source=related_link\">",
"      Sodium nitrite: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_34_16934="Epidemiology and classification of diabetic neuropathy";
var content_f16_34_16934=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and classification of diabetic neuropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/34/16934/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/34/16934/contributors\">",
"     Eva L Feldman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/34/16934/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/34/16934/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/34/16934/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/34/16934/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/34/16934/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the peripheral and autonomic nervous systems is probably the most common complication of diabetes. Clinical diabetic neuropathy is categorized into distinct syndromes according to the neurologic distribution, although many overlap syndromes occur. In both type 1 and type 2 diabetes, the prevalence varies with both the severity and duration of hyperglycemia.",
"   </p>",
"   <p>",
"    This topic will review the epidemiology and classification of diabetic neuropathy. Other aspects of diabetic neuropathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41928?source=see_link\">",
"     \"Pathogenesis and prevention of diabetic polyneuropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diabetic polyneuropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8938?source=see_link\">",
"     \"Diabetic autonomic neuropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12986?source=see_link\">",
"     \"Treatment of diabetic neuropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic polyneuropathy is the most common neuropathy in the Western world [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/1\">",
"     1",
"    </a>",
"    ]. Clinical and subclinical neuropathy has been estimated to occur in 10 to 100 percent of diabetic patients, depending upon the diagnostic criteria and patient populations examined. Prevalence is a function of disease duration, and a reasonable figure, based upon several large studies, is that approximately 50 percent of patients with diabetes will eventually develop neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence and incidence of diabetic polyneuropathy can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a landmark study, over 4400 patient with diabetes were serially evaluated over 25 years [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]. Neuropathy was defined as decreased sensation in the feet and depressed or absent ankle reflexes. The onset of neuropathy correlated positively with the duration of diabetes and, by 25 years, 50 percent of patients had neuropathy.",
"     </li>",
"     <li>",
"      In a community-based study from northwest England of 15,692 patients with diabetes, the prevalence of clinical neuropathy, defined by the loss of pinprick, vibration, and temperature sensation, was 49 percent, while the prevalence of painful neuropathic symptoms was 34 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/7\">",
"       7",
"      </a>",
"      ]. The prevalence of painful neuropathy symptoms accompanied by clinical neuropathy was 21 percent. The risk of painful neuropathy was increased in patients with type 2 diabetes, women, and those of South Asian ethnicity.",
"     </li>",
"     <li>",
"      In a cross-sectional multicenter study of 6487 diabetic patients in the United Kingdom, the overall prevalence of diabetic neuropathy was 28.5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/8\">",
"       8",
"      </a>",
"      ]. There was a correlation with disease duration such that the prevalence reached 44 percent in patients between 70 and 79 years of age. Patients were diagnosed with neuropathy if they had decreased or absent vibration, pin-prick, and temperature sensation at the great toe with reduced or absent ankle jerks and, if the signs were mild symptoms, such as burning, numbness, tingling, cramping, or aching.",
"     </li>",
"     <li>",
"      Two reports evaluated the incidence of new cases of diabetic neuropathy. In one, 231 patients with type 2 diabetes but no peripheral neuropathy were followed for a mean of 4.7 years [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/9\">",
"       9",
"      </a>",
"      ]. The incidence of new cases of distal symmetric sensory neuropathy was 6.1 per 100 person-years. As expected, the occurrence of neuropathy was associated with the level of hemoglobin A1C (HbA1c). A similar rate of new cases was described in a series of patients with type 1 diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/10\">",
"       10",
"      </a>",
"      ]. The incidence was increased in patients with hypertension (relative risk 4.1).",
"     </li>",
"     <li>",
"      In the UKPDS trial, 3867 newly diagnosed patients with type 2 diabetes were randomly assigned to either intensive therapy (sulfonylurea or insulin) or conventional therapy (diet control) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/11\">",
"       11",
"      </a>",
"      ]. After ten years, absent ankle reflexes, as a sign of diabetic neuropathy, were noted in 35 and 37 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The high rate of diabetic neuropathy results in substantial morbidity, including recurrent lower extremity infections, ulcerations, and subsequent amputations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=see_link\">",
"     \"Management of diabetic foot lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diabetic patients with foot problems occupy more hospital beds than do those with all other diabetic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/3\">",
"     3",
"    </a>",
"    ]. The cumulative risk of lower extremity amputation in one report was 11 percent 25 years after diagnosis of diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic neuropathy is classified into distinct clinical syndromes. A characteristic set of symptoms and signs exist for each syndrome, depending on the component of the peripheral nervous system that is affected. The most frequently encountered neuropathies include (",
"    <a class=\"graphic graphic_table graphicRef59626 \" href=\"UTD.htm?7/11/7357\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distal symmetric polyneuropathy",
"     </li>",
"     <li>",
"      Autonomic neuropathy",
"     </li>",
"     <li>",
"      Thoracic and lumbar nerve root disease, causing polyradiculopathies",
"     </li>",
"     <li>",
"      Individual cranial and peripheral nerve involvement causing focal mononeuropathies, especially affecting the oculomotor nerve (cranial nerve III) and the median nerve",
"     </li>",
"     <li>",
"      Asymmetric involvement of multiple peripheral nerves, resulting in a mononeuropathy multiplex",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the Rochester diabetic study, for example, approximately 50 percent of patients had distal symmetric polyneuropathy; about 14 percent had symptoms and a few percent had difficulty walking. Other neuropathies included median mononeuropathies (25 percent), autonomic neuropathy (7 percent), and other neuropathies, including thoracic and lumbar polyradiculopathy and cranial mononeuropathies (3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Symmetric polyneuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal symmetric sensorimotor polyneuropathy is the most common type of diabetic neuropathy and is often considered synonymous with the term diabetic neuropathy. It is characterized by a progressive loss of distal sensation correlating with loss of sensory axons, followed, in severe cases, by motor weakness and motor axonal loss. Classic \"stocking-glove\" sensory loss is typical in this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diabetic polyneuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Autonomic neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic autonomic neuropathy is a common complication of diabetes. It is a diagnosis of exclusion and may be unnoticed because of multiorgan involvement and insidious onset. It can, however, cause severe dysfunction of a single organ. Among the problems that can occur are postural hypotension, gastroparesis, and enteropathy with constipation or diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8938?source=see_link\">",
"     \"Diabetic autonomic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Polyradiculopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term asymmetric proximal neuropathy was initially used to describe injury to proximal limb and nerve roots. Because of the pleiotropic presentation of this type of diabetic neuropathy, several other terms appeared in the literature, most prominently diabetic amyotrophy and diabetic thoracic polyradiculopathy. These forms of diabetic neuropathy are probably subtypes of diabetic polyradiculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diabetes frequently injures the nerve roots at one or more thoracic or high lumbar levels with subsequent axonal degeneration and frequent contralateral, cephalad, or caudal extension. The various subgroups of polyradiculopathy present as distinct syndromes but also share certain features in common. Affected patients are typically older, have coexisting peripheral polyneuropathy, and have weakness and atrophy in the distribution of one or more contiguous nerve roots with frequent territorial expansion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Diabetic amyotrophy (lumbar polyradiculopathy)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic amyotrophy is reviewed here briefly and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common type of diabetic polyradiculopathy is a syndrome frequently called diabetic amyotrophy. Diabetic amyotrophy is not a pure lumbosacral plexopathy because it also affects the lumbosacral nerve roots and peripheral nerves. The etiology is debated, and several pathophysiologic mechanisms (ischemic, metabolic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inflammatory) have been proposed as the cause. Of these, the most likely cause is ischemic injury from a nonsystemic microvasculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link&amp;anchor=H2#H2\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\", section on 'Background'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The traditional features of diabetic amyotrophy include the acute, asymmetric, focal onset of pain followed by weakness involving the proximal leg, with associated autonomic failure and weight loss. Progression occurs over months and is followed by partial recovery in most patients. The same process can occur in the contralateral leg, immediately following (within days) or much later than (months to years) the initial attack. The diagnosis of diabetic amyotrophy is mainly based upon the presence of suggestive clinical features in a patient with known or newly diagnosed diabetes mellitus. Appropriate laboratory investigations, particularly electrodiagnostic studies, and neuroimaging in select patients, are useful to exclude other peripheral and central nervous system etiologies as a cause of the neurologic symptoms and signs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link&amp;anchor=H3#H3\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link&amp;anchor=H6#H6\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No treatments are proven to be effective for diabetic amyotrophy. There is limited and conflicting data regarding the benefit of immunosuppressive therapies including oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , intravenous immune globulin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and plasma exchange. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link&amp;anchor=H11#H11\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Thoracic polyradiculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although less common than diabetic lumbar polyradiculopathy, thoracic polyradiculopathy can cause marked symptoms. Affected patients present with severe abdominal pain, sometimes in a band-like pattern, and frequently have undergone extensive gastrointestinal diagnostic studies in attempts to identify the etiology of their pain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thoracic and upper limb involvement has also been observed as part of the syndrome of diabetic amyotrophy in a minority of patients. Some have symptoms and signs suggesting a thoracic radiculopathy, a brachial plexopathy, or mononeuropathies of the ulnar and median nerves. Most upper limb symptoms occur in association with lumbosacral plexus involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link&amp;anchor=H4#H4\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\", section on 'Cervical and thoracic involvement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Diabetic neuropathic cachexia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another rare but identifiable syndrome is diffuse diabetic polyradiculopathy superimposed upon severe peripheral neuropathy. This syndrome is associated with unintended severe weight loss and depression and is known as diabetic neuropathic cachexia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. It most frequently occurs in men with type 2 diabetes on oral hypoglycemic agents who are middle-aged or older. Most patients improve spontaneously within 12 to 24 months, although some have residual neurologic deficits. There is no specific therapy, and management is supportive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mononeuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of mononeuropathy associated with diabetes: cranial and peripheral, as discussed in the sections that follow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cranial mononeuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cranial mononeuropathies occur in those nerves which supply the extraocular muscles, especially cranial nerves III (oculomotor), VI (abducens), and IV (trochlear). Patients with diabetic ophthalmoplegia typically present with unilateral pain, ptosis, and diplopia, with sparing of pupillary function [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Facial mononeuropathy (Bell's palsy) occurs more frequently in diabetic than in nondiabetic patients. This observation suggests that the disorder is due to diabetes in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Peripheral mononeuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common peripheral mononeuropathy in diabetic patients is median mononeuropathy at the wrist. While estimates vary, it is likely that at least one-quarter to one-third of patients develop either symptomatic or asymptomatic median mononeuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/1\">",
"     1",
"    </a>",
"    ]. Ulnar mononeuropathy, either at the elbow or, less commonly, at the wrist can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the lower extremities, peroneal mononeuropathies with compression at the fibula are a well recognized complication of diabetes. Common peroneal palsy, for example, can result in foot drop. It is probable, however, that isolated femoral mononeuropathies are rare in diabetes; many of these patients, after careful clinical and electrodiagnostic examinations, are found to have a high lumbar radiculopathy (diabetic amyotrophy). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Diabetic amyotrophy (lumbar polyradiculopathy)'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Mononeuropathy multiplex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple mononeuropathies in the same patient are known as mononeuropathy multiplex (or asymmetric polyneuropathy). The other major disorder that can produce this syndrome is vasculitis, which should also be considered in affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16934/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=see_link\">",
"     \"Clinical manifestations of vasculitic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20208?source=see_link\">",
"       \"Patient information: Nerve damage caused by diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/5/21587?source=see_link\">",
"       \"Patient information: Diabetic neuropathy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114010799\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetic polyneuropathy is the most common neuropathy in the Western world. Clinical and subclinical neuropathy has been estimated to occur in 10 to 100 percent of diabetic patients, depending upon the diagnostic criteria and patient populations examined. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diabetic neuropathy is classified into distinct clinical syndromes. A characteristic set of symptoms and signs exist for each syndrome, depending on the component of the peripheral nervous system that is affected. The most frequently encountered diabetic neuropathies include (",
"      <a class=\"graphic graphic_table graphicRef59626 \" href=\"UTD.htm?7/11/7357\">",
"       table 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Distal symmetric polyneuropathy (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Symmetric polyneuropathy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Autonomic neuropathy (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Autonomic neuropathy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Thoracic and lumbar nerve root disease, causing polyradiculopathies (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Polyradiculopathies'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Individual cranial and peripheral nerve involvement causing focal mononeuropathies, especially affecting the oculomotor nerve (cranial nerve III) and the median nerve (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Cranial mononeuropathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Peripheral mononeuropathy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Asymmetric involvement of multiple peripheral nerves, resulting in a mononeuropathy multiplex (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Mononeuropathy multiplex'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/1\">",
"      Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/2\">",
"      Dyck PJ, Litchy WJ, Lehman KA, et al. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology 1995; 45:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/3\">",
"      Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacol Ther 2008; 120:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/4\">",
"      Pirart J. [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (author's transl)]. Diabete Metab 1977; 3:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/5\">",
"      Pirart J. [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (2nd part) (author's transl)]. Diabete Metab 1977; 3:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/6\">",
"      Pirart J. [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author's transl)]. Diabete Metab 1977; 3:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/7\">",
"      Abbott CA, Malik RA, van Ross ER, et al. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011; 34:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/8\">",
"      Young MJ, Boulton AJ, MacLeod AF, et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/9\">",
"      Sands ML, Shetterly SM, Franklin GM, Hamman RF. Incidence of distal symmetric (sensory) neuropathy in NIDDM. The San Luis Valley Diabetes Study. Diabetes Care 1997; 20:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/10\">",
"      Forrest KY, Maser RE, Pambianco G, et al. Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes 1997; 46:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/11\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/12\">",
"      Humphrey LL, Palumbo PJ, Butters MA, et al. The contribution of non-insulin-dependent diabetes to lower-extremity amputation in the community. Arch Intern Med 1994; 154:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/13\">",
"      Bastron JA, Thomas JE. Diabetic polyradiculopathy: clinical and electromyographic findings in 105 patients. Mayo Clin Proc 1981; 56:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/14\">",
"      Kikta DG, Breuer AC, Wilbourn AJ. Thoracic root pain in diabetes: the spectrum of clinical and electromyographic findings. Ann Neurol 1982; 11:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/15\">",
"      Ellenberg M. Diabetic neuropathic cachexia. Diabetes 1974; 23:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/16\">",
"      Neal JM. Diabetic neuropathic cachexia: a rare manifestation of diabetic neuropathy. South Med J 2009; 102:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/17\">",
"      Brown MR, Dyck PJ, McClearn GE, et al. Central and peripheral nervous system complications. Diabetes 1982; 31:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/18\">",
"      Pecket P, Schattner A. Concurrent Bell's palsy and diabetes mellitus: a diabetic mononeuropathy? J Neurol Neurosurg Psychiatry 1982; 45:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16934/abstract/19\">",
"      Adour K, Wingerd J, Doty HE. Prevalence of concurrent diabetes mellitus and idiopathic facial paralysis (Bell's palsy). Diabetes 1975; 24:449.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5275 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-714CE7359B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_34_16934=[""].join("\n");
var outline_f16_34_16934=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H114010799\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Symmetric polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Autonomic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Polyradiculopathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Diabetic amyotrophy (lumbar polyradiculopathy)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Thoracic polyradiculopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Diabetic neuropathic cachexia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mononeuropathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cranial mononeuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Peripheral mononeuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Mononeuropathy multiplex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114010799\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5275\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5275|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/11/7357\" title=\"table 1\">",
"      Classification diabetic neuropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=related_link\">",
"      Clinical manifestations and diagnosis of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=related_link\">",
"      Clinical manifestations of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=related_link\">",
"      Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8938?source=related_link\">",
"      Diabetic autonomic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=related_link\">",
"      Management of diabetic foot lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41928?source=related_link\">",
"      Pathogenesis and prevention of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/5/21587?source=related_link\">",
"      Patient information: Diabetic neuropathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20208?source=related_link\">",
"      Patient information: Nerve damage caused by diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12986?source=related_link\">",
"      Treatment of diabetic neuropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_34_16935="Toxocariasis: visceral and ocular larva migrans";
var content_f16_34_16935=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Toxocariasis: visceral and ocular larva migrans",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/34/16935/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/34/16935/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/34/16935/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/34/16935/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/34/16935/contributors\">",
"     Edward T Ryan, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/34/16935/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/34/16935/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/34/16935/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxocariasis (also called visceral larva migrans [VLM]) refers to human infection caused by roundworms that are not natural human parasites. Toxocariasis occurs as a result of human infection with the larvae of the dog ascarid, Toxocara canis, or, less commonly, the cat ascarid, Toxocara cati. Another form of VLM is caused by human ingestion of eggs of the pig ascarid, Ascaris suum. Clinical presentations consist of VLM and ocular larva migrans (OLM); infection may also be subclinical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxocariasis occurs worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/1\">",
"     1",
"    </a>",
"    ]. Infection tends to occur more frequently in tropical regions than in temperate regions, and more frequently among rural populations than urban populations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/2\">",
"     2",
"    </a>",
"    ]. Toxocara larvae can develop at temperatures &lt;50 degrees Fahrenheit although efficiency decreases as the temperature increases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the seroprevalence of Toxocara has been estimated at 13.9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/1\">",
"     1",
"    </a>",
"    ]; rates are increased among individuals living in poverty and among certain minority groups (especially African Americans) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/3\">",
"     3",
"    </a>",
"    ]. Prevalence rates of 40 percent or more have been reported in Indonesia and Brazil [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24389847\">",
"    <span class=\"h2\">",
"     Life cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The life cycle of Toxocara canis occurs in dogs and the life cycle of Toxocara cati occurs in cats; the prevalence of Toxocara infection is highest among puppies and kittens. In North America, it is estimated that about 5 percent of dogs and puppies are infected [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Humans acquire the infection as accidental hosts (",
"    <a class=\"graphic graphic_figure graphicRef51830 \" href=\"UTD.htm?6/23/6520\">",
"     figure 1",
"    </a>",
"    ).&nbsp;Eggs are shed in the stool of the definitive host.&nbsp;In the environment, eggs embryonate and become infective after about three weeks. Soil contamination with infectious eggs occurs most readily in relatively warm climates, and these embryonated eggs can remain infective in the environment for several years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/6\">",
"     6",
"    </a>",
"    ]. Following ingestion of infective eggs by dogs or cats, the eggs hatch and larvae (0.5 mm in length) penetrate the gut wall.&nbsp;The larvae then migrate through the lungs, bronchial tree, and enter the esophagus; adult worms develop in the small intestine, where they lay eggs that are shed in the stool.",
"   </p>",
"   <p>",
"    In most older animals, larvae penetrate the gut wall and subsequently larvae encyst in tissues. Encysted larvae can reactivate in female dogs during late pregnancy and infect puppies via transplacental and transmammary routes; adult worms can subsequently become established in the small intestines of puppies.",
"   </p>",
"   <p>",
"    Toxocara can also be transmitted through ingestion of paratenic hosts (a host that is not required for the parasite life cycle, but nonetheless can serve to maintain the life cycle). Eggs ingested by small non-canine mammals (such as rabbits) can hatch and larvae can penetrate the gut wall with subsequent migration into various tissues where they encyst.&nbsp;The life cycle is completed when dogs eat larvae encysted in the tissues of these paratenic hosts and the larvae develop into egg-laying adult worms in the small intestine.",
"   </p>",
"   <p>",
"    Humans are accidental hosts who become infected by ingesting infective eggs in contaminated soil or encysted larvae in the tissues of infected paratenic hosts.&nbsp;Direct contact with infected puppies and kittens is not classically considered to be a risk factor for human infection since the eggs must embryonate before becoming infective, although sometimes pets carry embryonated eggs in their fur. Following ingestion, the eggs hatch and larvae penetrate the intestinal wall and are carried by the circulation to a variety of tissues (liver, heart, lungs, brain, muscle, eyes). The larvae do not undergo any further development in these sites, but the host inflammatory response against the migrating larvae can cause both mechanical and immunopathological damage to tissues, which leads to severe local reactions that are the basis of toxocariasis.&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24389861\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals who ingest embryonated eggs in the form of contaminated food or, more commonly, soil are at risk for developing infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/7\">",
"     7",
"    </a>",
"    ]. VLM is principally a disease of young children, especially those with exposure to playgrounds and sandboxes contaminated by dog or cat feces [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. Infection can also be acquired via ingestion of raw liver or other undercooked meat from an infected intermediate host (rabbit, chicken, cattle, or swine) containing encapsulated larvae [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of visceral larva migrans (VLM) are a consequence of both the damage caused by migrating larvae and the host eosinophilic granulomatous response. Migration of larvae can cause eosinophilic infiltration, granuloma formation, or eosinophilic abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are major categories of clinical manifestations: VLM and ocular larva migrans (OLM). These have also been reported to occur simultaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18545296\">",
"    <span class=\"h2\">",
"     Visceral larva migrans",
"    </span>",
"    &nbsp;&mdash;&nbsp;VLM occurs most commonly in young children and results in hepatitis and pneumonitis as the larvae migrate through the liver and lungs, respectively. Heavy infection may result in fever, anorexia, malaise, irritability, hepatomegaly, respiratory symptoms, pruritic urticaria-like cutaneous lesions and eosinophilia.",
"   </p>",
"   <p>",
"    Larvae frequently localize in the liver; hepatic manifestations may include hepatomegaly or nodular lesions. Pulmonary involvement may cause dyspnea, wheezing, and a chronic nonproductive cough in 20 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Rales are common on physical examination. The chest radiograph demonstrates abnormalities in &ge;40 percent of patients with symptomatic illness. Bilateral peribronchial infiltration is most common; parenchymal infiltrates can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Computed tomography (CT) may demonstrate multifocal subpleural nodules with halo or ground-glass opacities and ill-defined margins [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/15\">",
"     15",
"    </a>",
"    ]. Severe respiratory tract involvement is an uncommon complication of heavy infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Toxocariasis can be mistaken for metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]; the presence of eosinophilia and radiologic findings may be helpful differentiating features. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Larvae can also travel via the systemic circulation to muscles, the heart, the eye, or the central nervous system (CNS) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Manifestations of the CNS include eosinophilic meningo-encephalitis, space occupying lesions, myelitis, and cerebral vasculitis causing seizures. Manifestations of the peripheral nervous system include radiculitis, affection of cranial nerves, or musculoskeletal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/21\">",
"     21",
"    </a>",
"    ]. Death due to myocardial or CNS involvement has been described, but is rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18545304\">",
"    <span class=\"h2\">",
"     Ocular larva migrans",
"    </span>",
"    &nbsp;&mdash;&nbsp;OLM involvement may occur as the sole manifestation of VLM; it often presents in individuals without antecedent history of symptomatic VLM [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/22\">",
"     22",
"    </a>",
"    ]. OLM occurs most commonly among older children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/4\">",
"     4",
"    </a>",
"    ]. In one review of ocular toxocariasis in the United States, the median patient age was 8.5 years (range 1 to 60 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ocular lesion is due to larval localization in the eye and the granulomatous response around the larva. Common symptoms are unilateral visual impairment, causing failing vision and subsequent strabismus. The typical lesion is a whitish elevated granuloma. Occasionally, OLM may present as uveitis, papillitis, or endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/23\">",
"     23",
"    </a>",
"    ]. Ocular lesions may resemble retinoblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/24\">",
"     24",
"    </a>",
"    ]. The most serious consequence of infection is invasion of the retina with granuloma formation in the periphery or posterior pole, leading to dragging of the retina and eventual retinal detachment which can lead to blindness [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18545786\">",
"    <span class=\"h2\">",
"     Other presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxocara can also present with other manifestations. Mild infection may present with eosinophilia only. Other symptoms may include fever, headache, behavioral disturbances, anorexia, abdominal pain, rash, hepatomegaly, nausea, vomiting, as well as wheezing and pulmonary infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wheezing and pulmonary infiltrates, together with eosinophilia, are also the hallmark features of childhood asthma. It has been postulated that the presence of Toxocara larvae in lungs may be an underlying factor in the onset of allergic pulmonary disease, perhaps because of the host response to the parasite; a causal association remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/26\">",
"     26",
"    </a>",
"    ]. One study performed in the United States found a significant association between prior Toxocara infection and diminished pulmonary function (as measured by forced expiratory volume in one second [FEV(1)]) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/27\">",
"     27",
"    </a>",
"    ]. However, other studies have failed to demonstrate an association between Toxocara seropositivity and asthma; one study suggested that this association may be attributable to cross-reactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/28\">",
"     28",
"    </a>",
"    ]. There is also some evidence that treatment of chronic cough with both asthma therapy and anthelminthics may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24389956\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, visceral larva migrans (VLM) should be suspected in the setting of compatible clinical manifestations, together with leukocytosis, eosinophilia, and hypergammaglobulinemia (elevated serum levels of IgE, IgG, and IgE). Marked leukocytosis with eosinophilia occurs in more than 30 percent of cases, and elevated titers of anti-A or anti-B isohemagglutinins are commonly observed in about 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/10\">",
"     10",
"    </a>",
"    ]. An eosinophilic granulomatous hepatitis may develop leading to abnormalities in liver function tests, including elevated transaminases",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alkaline phosphatase.",
"   </p>",
"   <p>",
"    There is an enzyme-linked immunosorbent assay (ELISA) antibody assay which detects human IgG antibodies to Toxocara",
"    <span class=\"nowrap\">",
"     excretory/secretory",
"    </span>",
"    antigens; it is available from the United States Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The test can detect subclinical or mild infection, though it cannot differentiate between T. canis and T. cati infections. For VLM and some forms of covert toxocariasis, the sensitivity and specificity of the Toxocara EIA (titer 1:32) are estimated at 78 percent and 92 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/4,10,32,33\">",
"     4,10,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A positive ELISA result does not necessarily demonstrate the presence of active toxocara infection or prove that clinical symptoms are attributable to that toxocariasis; the result must be interpreted in the setting of compatible clinical symptoms and epidemiologic exposure. Cross-reactivity of the ELISA assay with other parasite antigens is common, and the test may remain positive for several years even following treatment. In some settings positive ELISA results can be confirmed by western blotting [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/34\">",
"     34",
"    </a>",
"    ]. Definitive diagnosis of VLM may also be established via detection of larvae in biopsy tissue, which will show Toxocara larvae within eosinophilic granulomatous lesions. However, biopsy is rarely indicated.",
"   </p>",
"   <p>",
"    The sensitivity of ELISA for ocular larva migrans (OLM) is considerably lower than for VLM; the diagnosis of OLM generally relies on the findings on ophthalmologic examination (",
"    <a class=\"graphic graphic_picture graphicRef50062 \" href=\"UTD.htm?41/28/42446\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/35\">",
"     35",
"    </a>",
"    ]. It is possible to compare the antibody levels between the serum and aqueous humour; if the (level of specific IgG in aqueous",
"    <span class=\"nowrap\">",
"     humour/level",
"    </span>",
"    of specific IgG in",
"    <span class=\"nowrap\">",
"     serum)/(total",
"    </span>",
"    IgG in aqueous",
"    <span class=\"nowrap\">",
"     humour/total",
"    </span>",
"    IgG in serum) is greater than 3.0, this can be considered diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polymerase chain reaction (PCR)-based methods for detecting Toxocara in clinical samples have been described, but are not commercially available [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stool examinations are not helpful since the parasite does not complete a full life cycle involving the human gastrointestinal tract.",
"   </p>",
"   <p>",
"    Pulmonary involvement may result in eosinophilia that is detectable in bronchoalveolar lavage (BAL) fluid. One case of marked pulmonary infiltration demonstrated 64 percent eosinophils in the BAL analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of CNS involvement, the cerebrospinal fluid may show eosinophils [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40632?source=see_link\">",
"     \"Eosinophilic meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24389963\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic and cerebral lesions may be observed with ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. In one review of radiographic changes associated with hepatic VLM, CT, and MRI show multiple, ill-defined lesions, usually measuring 1.0 to 1.5 cm in diameter, scattered throughout the liver parenchyma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/9\">",
"     9",
"    </a>",
"    ]. Lesions are usually oval but may be angular or trapezoid. The lesions differ from metastatic nodules in that they are usually uniform in size, non-spherical in shape, and are best seen on portal venous phase (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75616 \" href=\"UTD.htm?28/42/29351\">",
"     image 1",
"    </a>",
"    ). Pulmonary VLM appear on CT as multifocal subpleural nodules with halo or ground-glass opacities and ill-defined margins (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56060 \" href=\"UTD.htm?24/58/25510\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment approach is uncertain and controlled data are limited. In general, individuals with mild symptoms due to toxocariasis do not require anthelminthic therapy; symptoms are usually self-limited and resolve within a few weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/43\">",
"     43",
"    </a>",
"    ]. Eosinophilia may resolve much more slowly over many months, likely due to ongoing antigenic stimulation from dead larvae. In the setting of protracted symptoms the possibility of reinfection (such as from continued ingestion of contaminated soil) should be considered.",
"   </p>",
"   <p>",
"    For individuals with moderate to severe symptoms due to visceral larva migrans (VLM), it reasonable to offer treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    (400 mg orally twice daily for five days) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In cases of severe respiratory, myocardial, or central nervous system (CNS) involvement, concomitant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    is warranted.",
"   </p>",
"   <p>",
"    The optimal approach to treatment of ocular larva migrans (OLM) is uncertain; there are some reports of response to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    (adults: 800 mg orally twice daily for two weeks; children: 400 mg orally twice daily for two weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. This should be given with concomitant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for adults; 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for adults) tapered over a few months. In complicated cases, surgical intervention may be warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     Mebendazole",
"    </a>",
"    is an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    (100 to 200 mg orally twice daily for five days) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/49\">",
"     49",
"    </a>",
"    ], but albendazole is preferred, especially in OLM and neurologic disease, since it crosses the blood-brain barrier.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     Ivermectin",
"    </a>",
"    does not appear to be effective for toxocariasis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/50\">",
"     50",
"    </a>",
"    ]. Diethylcarbamazine (DEC) (3 to 4",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for 21 days, starting at 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for adults) has been found to be effective in a small number of cases but has greater side effects than albendazole so is rarely used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8277939\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Good hygiene practices, timely disposal of pet feces, and routine deworming of pets are important strategies for prevention of toxocariasis in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/3\">",
"     3",
"    </a>",
"    ]. Handwashing should be encouraged after contact with pets or areas at high risk for soil contamination, such as playgrounds and sandboxes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16935/abstract/3\">",
"     3",
"    </a>",
"    ]. Education regarding behaviors that increase risk for infection is also important, including geophagia and consumption of raw or undercooked meat (particularly liver).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24356127\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Toxocariasis (also called visceral larva migrans [VLM]) refers to human infection caused by helminths that are not natural human parasites. Toxocariasis occurs as a result of human infection with the larvae of the dog ascarid, Toxocara canis, or, less commonly, the cat ascarid, Toxocara cati. VLM is principally a disease of young children, especially those with exposure to playgrounds and sandboxes contaminated by dog or cat feces. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The life cycle of Toxocara canis occurs in dogs (",
"      <a class=\"graphic graphic_figure graphicRef51830 \" href=\"UTD.htm?6/23/6520\">",
"       figure 1",
"      </a>",
"      ). Puppies are a major source of environmental egg contamination. Humans are accidental hosts who become infected by ingesting eggs in contaminated soil or encysted larvae in the tissues of infected paratenic hosts.&nbsp;Ingested eggs mature into larvae which penetrate the intestinal wall and are carried by the circulation to a variety of tissues (liver, heart, lungs, brain, muscle, eyes). The larvae can cause severe local reactions at these sites. (See",
"      <a class=\"local\" href=\"#H24389847\">",
"       'Life cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Larvae frequently localize in the liver; hepatic manifestations may include hepatomegaly or nodular lesions. Mild infection may be asymptomatic and only suspected by the finding of elevated blood eosinophilia. Heavy infection may result in fever, anorexia, malaise, irritability, hepatomegaly, and pruritic urticaria-like cutaneous lesions. Ocular larva migrans (OLM) is due to larval localization in the eye and the granulomatous response around the larva. Common symptoms are unilateral visual impairment and subsequent strabismus; complete visual loss can occur. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VLM should be suspected in the setting of compatible clinical manifestations together with leukocytosis, eosinophilia, and hypergammaglobulinemia (elevated serum levels of IgE, IgG, and IgE). In the appropriate clinical scenario, the diagnosis can be confirmed by enzyme-linked immunosorbent assay (ELISA) antibody assay which detects human IgG antibodies to Toxocara",
"      <span class=\"nowrap\">",
"       excretory/secretory",
"      </span>",
"      antigens. (See",
"      <a class=\"local\" href=\"#H24389956\">",
"       'Laboratory tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, individuals with mild symptoms due to toxocariasis do not require anthelminthic therapy; symptoms are usually self-limited. For individuals with moderate to severe symptoms we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      (400 mg orally twice daily for five days) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In cases of severe respiratory, myocardial, or central nervous system involvement, we suggest concomitant treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (0.5-1.0",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Good hygiene practices, timely disposal of pet feces, and routine deworming of pets are important strategies for prevention of toxocariasis in humans. Handwashing should be encouraged after contact with pets or areas at high risk for soil contamination, such as playgrounds and sandboxes. (See",
"      <a class=\"local\" href=\"#H8277939\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/1\">",
"      Won KY, Kruszon-Moran D, Schantz PM, Jones JL. National seroprevalence and risk factors for Zoonotic Toxocara spp. infection. Am J Trop Med Hyg 2008; 79:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/2\">",
"      Azam D, Ukpai OM, Said A, et al. Temperature and the development and survival of infective Toxocara canis larvae. Parasitol Res 2012; 110:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/3\">",
"      Centers for Disease Control and Prevention (CDC). Ocular toxocariasis--United States, 2009-2010. MMWR Morb Mortal Wkly Rep 2011; 60:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/4\">",
"      Hotez PJ, Wilkins PP. Toxocariasis: America's most common neglected infection of poverty and a helminthiasis of global importance? PLoS Negl Trop Dis 2009; 3:e400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/5\">",
"      Mohamed AS, Moore GE, Glickman LT. Prevalence of intestinal nematode parasitism among pet dogs in the United States (2003-2006). J Am Vet Med Assoc 2009; 234:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/6\">",
"      Despommier D. Toxocariasis: clinical aspects, epidemiology, medical ecology, and molecular aspects. Clin Microbiol Rev 2003; 16:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/7\">",
"      Glickman LT, Cypess RH. Toxocara infection in animal hospital employees. Am J Public Health 1977; 67:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/8\">",
"      Mok CH. Visceral larva migrans. A discussion based on review of the literature. Clin Pediatr (Phila) 1968; 7:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/9\">",
"      Lim JH. Toxocariasis of the liver: visceral larva migrans. Abdom Imaging 2008; 33:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/10\">",
"      Rubinsky-Elefant G, Hirata CE, Yamamoto JH, Ferreira MU. Human toxocariasis: diagnosis, worldwide seroprevalences and clinical expression of the systemic and ocular forms. Ann Trop Med Parasitol 2010; 104:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/11\">",
"      Paul M, Stefaniak J, Twardosz-Pawlik H, Pecold K. The co-occurrence of Toxocara ocular and visceral larva migrans syndrome: a case series. Cases J 2009; 2:6881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/12\">",
"      Huntley CC, Costas MC, Lyerly A. Visceral larva migrans syndrome: clinical characteristics and immunologic studies in 51 patients. Pediatrics 1965; 36:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/13\">",
"      Snyder C. Visceral larva migrans &mdash; ten years' experience. Pediatrics 1961; 28:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/14\">",
"      SHRAND H. VISCERAL LARVA MIGRANS. TOXOCARA CANIS INFECTION. Lancet 1964; 1:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/15\">",
"      Sakai S, Shida Y, Takahashi N, et al. Pulmonary lesions associated with visceral larva migrans due to Ascaris suum or Toxocara canis: imaging of six cases. AJR Am J Roentgenol 2006; 186:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/16\">",
"      Beshear JR, Hendley JO. Severe pulmonary involvement in visceral larva migrans. Am J Dis Child 1973; 125:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/17\">",
"      Ota KV, Dimaras H, H&eacute;on E, et al. Toxocariasis mimicking liver, lung, and spinal cord metastases from retinoblastoma. Pediatr Infect Dis J 2009; 28:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/18\">",
"      Anderson A, Fordham LA, Bula ML, Blatt J. Visceral larval migrans masquerading as metastatic disease in a toddler with Wilms tumor. Pediatr Radiol 2006; 36:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/19\">",
"      Marx C, Lin J, Masruha MR, et al. Toxocariasis of the CNS simulating acute disseminated encephalomyelitis. Neurology 2007; 69:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/20\">",
"      Enko K, Tada T, Ohgo KO, et al. Fulminant eosinophilic myocarditis associated with visceral larva migrans caused by Toxocara canis infection. Circ J 2009; 73:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/21\">",
"      Jabbour RA, Kanj SS, Sawaya RA, et al. Toxocara canis myelitis: clinical features, magnetic resonance imaging (MRI) findings, and treatment outcome in 17 patients. Medicine (Baltimore) 2011; 90:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/22\">",
"      Good B, Holland CV, Taylor MR, et al. Ocular toxocariasis in schoolchildren. Clin Infect Dis 2004; 39:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/23\">",
"      Stewart JM, Cubillan LD, Cunningham ET Jr. Prevalence, clinical features, and causes of vision loss among patients with ocular toxocariasis. Retina 2005; 25:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/24\">",
"      Chuah CT, Lim MC, Seah LL, et al. Pseudoretinoblastoma in enucleated eyes of Asian patients. Singapore Med J 2006; 47:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/25\">",
"      Suh LH, Sweeney DA, Jun AS. A 33-year-old man with a white pupil. Clin Infect Dis 2006; 43:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/26\">",
"      Cooper PJ. Interactions between helminth parasites and allergy. Curr Opin Allergy Clin Immunol 2009; 9:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/27\">",
"      Walsh MG. Toxocara infection and diminished lung function in a nationally representative sample from the United States population. Int J Parasitol 2011; 41:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/28\">",
"      Mu&ntilde;oz-Guzm&aacute;n MA, del R&iacute;o-Navarro BE, Valdivia-Anda G, Alba-Hurtado F. The increase in seroprevalence to Toxocara canis in asthmatic children is related to cross-reaction with Ascaris suum antigens. Allergol Immunopathol (Madr) 2010; 38:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/29\">",
"      Bede O, Sz&eacute;n&aacute;si Z, Danka J, et al. Toxocariasis associated with chronic cough in childhood: a longitudinal study in Hungary. J Helminthol 2008; 82:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/30\">",
"      Cypess RH, Karol MH, Zidian JL, et al. Larva-specific antibodies in patients with visceral larva migrans. J Infect Dis 1977; 135:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/31\">",
"      Jones WE, Schantz PM, Foreman K, et al. Human toxocariasis in a rural community. Am J Dis Child 1980; 134:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/32\">",
"      Jones JL, Kruszon-Moran D, Won K, et al. Toxoplasma gondii and Toxocara spp. co-infection. Am J Trop Med Hyg 2008; 78:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/33\">",
"      Glickman L, Schantz P, Dombroske R, Cypess R. Evaluation of serodiagnostic tests for visceral larva migrans. Am J Trop Med Hyg 1978; 27:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/34\">",
"      Magnaval JF, Fabre R, Mauri&egrave;res P, et al. Application of the western blotting procedure for the immunodiagnosis of human toxocariasis. Parasitol Res 1991; 77:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/35\">",
"      Despommier D. Toxocariasis: clinical aspects, epidemiology, medical ecology, and molecular aspects. Clin Microbiol Rev 2003; 16:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/36\">",
"      de Visser L, Rothova A, de Boer JH, et al. Diagnosis of ocular toxocariasis by establishing intraocular antibody production. Am J Ophthalmol 2008; 145:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/37\">",
"      Fogt-Wyrwas R, Jarosz W, Mizgajska-Wiktor H. Utilizing a polymerase chain reaction method for the detection of Toxocara canis and T. cati eggs in soil. J Helminthol 2007; 81:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/38\">",
"      Roig J, Romeu J, Riera C, et al. Acute eosinophilic pneumonia due to toxocariasis with bronchoalveolar lavage findings. Chest 1992; 102:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/39\">",
"      Eberhardt O, Bialek R, N&auml;gele T, Dichgans J. Eosinophilic meningomyelitis in toxocariasis: case report and review of the literature. Clin Neurol Neurosurg 2005; 107:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/40\">",
"      Ishibashi H, Shimamura R, Hirata Y, et al. Hepatic granuloma in toxocaral infection: role of ultrasonography in hypereosinophilia. J Clin Ultrasound 1992; 20:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/41\">",
"      Jain R, Sawhney S, Bhargava DK, et al. Hepatic granulomas due to visceral larva migrans in adults: appearance on US and MRI. Abdom Imaging 1994; 19:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/42\">",
"      Zachariah SB, Zachariah B, Varghese R. Neuroimaging studies of cerebral \"visceral larva migrans\" syndrome. J Neuroimaging 1994; 4:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/43\">",
"      Schantz PM, Glickman LT. Toxocaral visceral larva migrans. N Engl J Med 1978; 298:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/44\">",
"      St&uuml;rchler D, Schubarth P, Gualzata M, et al. Thiabendazole vs. albendazole in treatment of toxocariasis: a clinical trial. Ann Trop Med Parasitol 1989; 83:473.",
"     </a>",
"    </li>",
"    <li>",
"     Drugs for parasitic infections, Med Letter Drugs Ther, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/46\">",
"      Barisani-Asenbauer T, Maca SM, Hauff W, et al. Treatment of ocular toxocariasis with albendazole. J Ocul Pharmacol Ther 2001; 17:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/47\">",
"      Small KW, McCuen BW 2nd, de Juan E Jr, Machemer R. Surgical management of retinal traction caused by toxocariasis. Am J Ophthalmol 1989; 108:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/48\">",
"      Giuliari GP, Ramirez G, Cortez RT. Surgical treatment of ocular toxocariasis: anatomic and functional results in 45 patients. Eur J Ophthalmol 2011; 21:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/49\">",
"      Magnaval JF. Comparative efficacy of diethylcarbamazine and mebendazole for the treatment of human toxocariasis. Parasitology 1995; 110 ( Pt 5):529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16935/abstract/50\">",
"      Magnaval JF. Apparent weak efficacy of ivermectin for treatment of human toxocariasis. Antimicrob Agents Chemother 1998; 42:2770.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5716 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-201.211.0.116-CD7FE02458-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_34_16935=[""].join("\n");
var outline_f16_34_16935=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24356127\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24389847\">",
"      Life cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24389861\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18545296\">",
"      Visceral larva migrans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18545304\">",
"      Ocular larva migrans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18545786\">",
"      Other presentations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24389956\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24389963\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8277939\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24356127\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5716\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5716|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/42/29351\" title=\"diagnostic image 1\">",
"      Hepatic toxocariasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/58/25510\" title=\"diagnostic image 2\">",
"      Toxocariasis - chest images",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5716|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/23/6520\" title=\"figure 1\">",
"      Toxocariasis life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5716|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/28/42446\" title=\"picture 1\">",
"      Ocular toxocariasis with peripheral granuloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40632?source=related_link\">",
"      Eosinophilic meningitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_34_16936="Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action";
var content_f16_34_16936=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/34/16936/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/34/16936/contributors\">",
"     David F Graft, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/34/16936/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/34/16936/contributors\">",
"     David B Golden, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/34/16936/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/34/16936/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/34/16936/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hymenoptera stings can result in life-threatening anaphylaxis, and the most severe reactions can be refractory to single or multiple doses of epinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Immunotherapy for venom allergy has been available for over 30 years and is highly effective. Unfortunately, many patients with sting-induced allergic reactions are not referred to an",
"    <span class=\"nowrap\">",
"     allergist/immunologist",
"    </span>",
"    for evaluation and are never offered this potentially life-saving therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The indications for treatment with venom immunotherapy (VIT), as well as patient selection, effectiveness, and mechanism of action will be reviewed here. Protocols and safety of VIT and the diagnosis of venom allergy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=see_link\">",
"     \"Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14824?source=see_link\">",
"     \"Diagnosis of Hymenoptera venom allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY OF SYSTEMIC ALLERGIC REACTIONS TO VENOM",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systemic allergic reaction to a sting involves signs and symptoms of IgE-mediated allergy distant from the site of the sting. In contrast, a local reaction consists of painful swelling and erythema limited to tissues contiguous with the site of the sting. Systemic allergic reactions may range from widespread hives and angioedema (ie, a cutaneous systemic reaction) to anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"UTD.htm?20/36/21068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An understanding of the natural history of venom allergy is critical to the determination of which patients should be treated with VIT. The natural history differs between adults and children (defined in studies as younger than 17 years of age), with adults being at greater overall risk for recurrent systemic reactions. The following generalizations can be made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In adult patients with past systemic reactions and evidence of venom specific IgE, the risk of a systemic reaction to a subsequent sting is approximately 30 to 60 percent if VIT is not administered [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/1,4,5\">",
"       1,4,5",
"      </a>",
"      ]. Patients with severe initial reactions have the highest risk of a recurrence. The variability in reaction rates may arise from differences in Hymenoptera species, the amount of venom delivered during a particular sting, whether the sting was sustained in-hospital or in the field, fluctuations in the patient's immunologic status, or other factors [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children who have had moderate or severe systemic reactions are at increased risk for systemic reactions during childhood and adulthood if not treated with VIT. However, this risk is lower than that in adults and has been estimated at approximately 30 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/7\">",
"       7",
"      </a>",
"      ]. Children with severe initial reactions have the highest risk of a recurrence.",
"     </li>",
"     <li>",
"      Children (under 17 years of age) with symptoms limited to the skin (eg, urticaria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angioedema, even if widespread) have about a 10 percent chance of a future systemic reaction, and most of these reactions will also be limited to the skin [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/8\">",
"       8",
"      </a>",
"      ]. The chance of a more serious reaction in the next 10 to 20 years is probably less than 5 percent, and in the largest series, no severe reactions were reported [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/7-9\">",
"       7-9",
"      </a>",
"      ]. Thus, these children are at low risk for subsequent sting-induced anaphylaxis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recurrent systemic reactions to venom tend to be similar in severity to the initial reaction in an individual patient [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/10\">",
"     10",
"    </a>",
"    ]. The chance of a patient experiencing a more severe reaction to a future sting by the same insect is small (&lt;10 percent) and declines only slightly over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS OF VIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venom immunotherapy (VIT) is the most effective form of immunotherapy currently in use. Protection from recurrent systemic allergic reactions appears to be established in most patients within a week of reaching maintenance doses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/11\">",
"     11",
"    </a>",
"    ], and may improve further with time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Reduced risk of recurrent reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;An adult's risk of a recurrent systemic reaction is approximately 30 to 60 percent in the absence of VIT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. After completing a course of VIT, the risk is reduced to 5 percent or lower [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/1,12-15\">",
"     1,12-15",
"    </a>",
"    ]. The few patients who do have recurrent systemic reactions tend to have much milder symptoms.",
"   </p>",
"   <p>",
"    The effectiveness of VIT in adults with past systemic reactions was demonstrated in several observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/12-14\">",
"     12-14",
"    </a>",
"    ] and a small number of randomized, controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. A systematic review included seven trials, but the reviewers combined patient groups that did not have equivalent types of reactions or natural histories [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/17\">",
"     17",
"    </a>",
"    ]. At the time of this writing, just two randomized controlled trials have directly addressed the question of how well VIT prevents recurrent systemic reactions in adults allergic to winged Hymenoptera species [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/1,16\">",
"     1,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the randomized trials mentioned above involved 60 adults with systemic reactions of similar severity, who were treated with either VIT (using a maintenance dose of 100 mcg of purified venom), immunotherapy with Hymenoptera whole body extract, or placebo injections for six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/1\">",
"     1",
"    </a>",
"    ]. In-hospital challenge stings resulted in systemic reactions in",
"    <span class=\"nowrap\">",
"     1/18",
"    </span>",
"    (6 percent) in the VIT group, compared to",
"    <span class=\"nowrap\">",
"     7/12",
"    </span>",
"    (58 percent) in the placebo group. The placebo-treated patients were then crossed-over to VIT, and at the conclusion of the study, only",
"    <span class=\"nowrap\">",
"     1/55",
"    </span>",
"    VIT-treated patients had a systemic reaction to challenge sting. The whole body extract contained minimal venom and proved no better than placebo; hence, this approach was subsequently abandoned.",
"   </p>",
"   <p>",
"    The most effective dose of venom for use in VIT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=see_link&amp;anchor=H8#H8\">",
"     \"Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring\", section on 'Dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effectiveness of VIT is also influenced by the duration of treatment. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13239?source=see_link\">",
"     \"Hymenoptera venom immunotherapy: Determining duration of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Honeybee versus vespid VIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Honeybee stings cause higher rates of recurrent systemic reactions compared to stings of vespids (ie, yellow jackets, hornets, and wasps) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/5\">",
"     5",
"    </a>",
"    ]. Unfortunately, honeybee VIT is less effective in preventing future systemic reactions than vespid VIT (eg, 77 percent versus 91 percent in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/18\">",
"     18",
"    </a>",
"    ], and the protection provided by honeybee VIT does not last as long as that from vespid VIT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;VIT improves quality of life by reducing anxiety and allowing patients to participate in the outdoor activities that they prefer [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In contrast, quality of life is not improved by avoidance and having self-administered epinephrine available [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INDICATIONS AND PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines have been published regarding the selection of patients for VIT, and the approach presented here is consistent with these guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. The European and North American guidelines are slightly different, and the latter is represented in this review. The indications for venom immunotherapy are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef72508 \" href=\"UTD.htm?0/25/412\">",
"     table 2",
"    </a>",
"    ). Venom immunotherapy is administered through a series of subcutaneous injections. Very few data are available on sublingual venom immunotherapy, and the technique is considered investigational [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The information in this review pertains only to subcutaneous injection immunotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Patients with past systemic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;An individual is a candidate for VIT if BOTH of the following are true:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a reliable history of a systemic allergic reaction to an insect sting AND",
"     </li>",
"     <li>",
"      The patient has either a positive venom skin test OR elevated serum levels of venom-specific IgE",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A positive venom skin test or the presence of venom-specific IgE in the absence of a history of a sting-induced systemic reaction is NOT an indication for therapy, since approximately one quarter of the general population is sensitized to venom (ie, has demonstrable venom-specific IgE) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/28\">",
"     28",
"    </a>",
"    ]. As with many other types of allergy, patients may be sensitized to an allergen without actually reacting to it upon exposure. Up to 50 percent of asymptomatic sensitized individuals will have negative tests if re-evaluated in two to five years.",
"   </p>",
"   <p>",
"    In contrast, a patient with a convincing history of a systemic sting reaction, but negative tests for venom-specific IgE, may in fact be at risk for future systemic reactions (mechanisms unclear); such patients require further evaluation. This diagnostic dilemma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14824?source=see_link\">",
"     \"Diagnosis of Hymenoptera venom allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thirty to 60 percent of untreated adults with a history of a systemic reaction and positive skin tests will react to a challenge sting [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. The risk is relatively greater for those with the following characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/4,8,18\">",
"     4,8,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe past reactions",
"     </li>",
"     <li>",
"      Allergy to honeybee venom rather than vespid (ie, yellow jacket, hornet, and wasp) venom (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Honeybee versus vespid VIT'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Reactions in the recent past, since the risk declines somewhat with time",
"     </li>",
"     <li>",
"      Elevated baseline tryptase (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=see_link&amp;anchor=H947131#H947131\">",
"       \"Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring\", section on 'Measurement of baseline tryptase'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these considerations, the North American guidelines suggest that VIT is appropriate for adults who experienced ANY degree of systemic reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/10,29\">",
"     10,29",
"    </a>",
"    ]. In the small percentage of adults with mild reactions (eg, generalized hives), the decision to pursue VIT would need to weigh the 10 percent chance of a more severe reaction against the inconvenience of treatment, but most clinicians favor VIT for these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/5,30\">",
"     5,30",
"    </a>",
"    ]. In contrast, VIT should be firmly advocated for individuals who had life-threatening anaphylaxis, and these patients should be advised that insect",
"    <span class=\"nowrap\">",
"     avoidance/access",
"    </span>",
"    to epinephrine is not considered an adequate alternative to VIT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/24,31\">",
"     24,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with moderate or severe systemic reactions to a Hymenoptera sting have an increased risk of systemic reactions during adulthood if not treated with VIT; the risk is estimated to be about 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/7\">",
"     7",
"    </a>",
"    ]. Therefore, these children should be treated with VIT.",
"   </p>",
"   <p>",
"    In contrast, children with past reactions limited to the skin (ie, generalized hives",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angioedema) are at low risk of developing a more severe reaction to subsequent stings, even if VIT is not administered [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/7\">",
"     7",
"    </a>",
"    ]. This was demonstrated in a study of 242 children (aged 2 to 17 years) who had experienced generalized cutaneous reactions to insect stings [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/8\">",
"     8",
"    </a>",
"    ]. All had positive skin tests to venom. VIT was administered to 68 children. About one-half of children were randomized to the treatment they received, while parent preference determined the treatment of the others. During four years of observation, there were 280 accidental stings in 122 of the children. In the children receiving VIT, 1.2 percent of the stings resulted in systemic symptoms, compared to 9.2 percent in the untreated group, but none of the stings caused more severe symptoms than the original event, and 16 of 18 reactions were milder. Thus, although VIT is effective in children with generalized cutaneous reactions, it does not appear to be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;VIT is particularly advantageous for individuals with the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occupations or leisure activities that involve significant time spent outdoors (eg, landscapers), in direct contact with Hymenoptera (eg, beekeepers and their family members [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/32\">",
"       32",
"      </a>",
"      ]), or in remote areas far from emergency medical services",
"     </li>",
"     <li>",
"      Those (either the patient or a family member) in whom the uncertain risk of anaphylaxis causes significant anxiety",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The few reports of VIT administration during pregnancy are reassuring [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/33\">",
"     33",
"    </a>",
"    ]. In one, 15 women had 22 pregnancies, resulting in 19 normal infants, one first-trimester miscarriage, one miscarriage secondary to placenta previa, and one child with multiple congenital abnormalities of unknown cause [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/33\">",
"     33",
"    </a>",
"    ]. The overall rate of pregnancy complications in this group was not higher than expected with pregnancy in the general population.",
"   </p>",
"   <p>",
"    VIT is not initiated, nor are doses increased during pregnancy, as is the practice with other forms of injection immunotherapy. However, women who are already receiving VIT when they become pregnant may continue treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3921273\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to discuss the risks of VIT with patients when obtaining informed consent. Approximately 3 to 12 percent of patients have treatment-induced systemic reactions, although the majority of these reactions are mild and easily treated. Adverse effects and safety are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=see_link&amp;anchor=H15#H15\">",
"     \"Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring\", section on 'Adverse effects and safety of VIT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913870\">",
"    <span class=\"h2\">",
"     Patients requiring ACE inhibitors or beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving ACE inhibitors are theoretically at increased risk during anaphylaxis, possibly due to the inhibition of angiotensin II during hypotension, or to accumulated bradykinin, a potent vasodilator. Patients receiving VIT and concomitant treatment with ACE inhibitors appear to be at risk for more severe anaphylaxis in response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. However, there does not appear to be a correlation between ACE inhibitor therapy and a higher overall",
"    <strong>",
"     incidence",
"    </strong>",
"    of anaphylaxis, either during VIT or during other types of immunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The 2011 practice parameters suggest that in patients with indications for both VIT and ACE inhibitor therapy, alternatives to ACE inhibitors be considered. If no equally effective alternative medication is available, the clinician should make an individualized decision about the use of ACE inhibitors, considering the risk and benefits for that patient, as well as the patient&rsquo;s preferences [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients taking beta-adrenergic blockers may not respond readily to treatment of an allergic reaction, since epinephrine may not have full access to beta receptors. Data are limited, but one study reported no severe reactions to VIT in 25 patients taking beta-blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/40\">",
"     40",
"    </a>",
"    ]. Other forms of allergen immunotherapy, such as that for respiratory allergies, are not usually administered to patients in whom beta blocker therapy is essential (eg, individuals with significant cardiovascular disease). However, recommendations for VIT in such patients are different because of the life-threatening nature of untreated Hymenoptera anaphylaxis, especially in a patient taking these medications. In summary, patients on VIT should discontinue beta blockers if possible, but if not, then VIT should proceed with caution [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another option is to hold the ACE inhibitor or beta blocker for 24 hours before each injection, although the effectiveness of this has not been specifically studied.",
"   </p>",
"   <p>",
"    Angiotensin receptor blockers (ARBs) have not been implicated in severe anaphylaxis in immunotherapy patients, although the data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Patients with large local reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with large local reactions are not usually candidates for VIT because the risk of anaphylaxis to future stings is low (5 to 10 percent). However, many patients will develop large local reactions if stung again [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Some individuals may be sufficiently debilitated, despite the use of post-sting pharmacotherapy, that they seek more effective treatment. This is particularly true of patients with occupations in which there is regular Hymenoptera exposure. Therefore, if a patient&rsquo;s quality of life is sufficiently reduced by these reactions, VIT should be offered.",
"   </p>",
"   <p>",
"    Acute treatment of large local reactions to Hymenoptera stings is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12313?source=see_link\">",
"     \"Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A preliminary nonrandomized study found that VIT reduced the severity and duration of recurrent large local reactions in patients with positive skin tests to venom [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/44\">",
"     44",
"    </a>",
"    ]. Nineteen patients with large local reactions were treated with VIT and compared to 10 untreated patients. Sting challenges were performed after 7 to 11 weeks of VIT, after which the untreated patients were crossed over to VIT for up to four years, with annual sting challenge. A response to VIT was defined as a reduction in size or duration of the local reactions by at least 50 percent. In the first season, a response was observed in 50 percent of the treated patients, compared with 20 percent of the untreated controls. After two to four years of VIT, 100 percent of the treated group had responded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of action of venom immunotherapy (VIT) is only partially understood. A systemic allergic reaction to venom requires sting-induced production of venom-specific IgE antibodies that subsequently bind to tissue mast cells and circulating basophils. A future sting may then result in cross-linking of these IgE molecules by venom proteins, triggering the activation and degranulation of mast cells and basophils and the release of mediators of anaphylaxis (histamine, leukotrienes, and others). Successful VIT is associated with several humoral and cellular changes that may interfere with this pathologic mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The production of venom-specific IgG - Venom-specific IgG typically increases, peaking at two to four months after starting VIT and then remaining fairly constant over five to six years of treatment. These IgG antibodies are referred to as \"blocking\" antibodies, because they are capable of blocking in vitro mediator release from allergen stimulated mast cells and basophils. The production of blocking antibodies has been considered the most likely therapeutic mechanism. One study demonstrated that honeybee-allergic patients could tolerate challenge stings after passive immunization with the gamma globulin fraction of pooled beekeeper's serum, which contained high titers of blocking antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/46\">",
"       46",
"      </a>",
"      ]. Another study found that the serum level of venom-specific IgG was inversely correlated with the likelihood of challenge sting-induced systemic reactions in patients on VIT [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/47\">",
"       47",
"      </a>",
"      ]. However, after four years of treatment, that correlation no longer held true, so other factors may be important in determining clinical benefit.",
"     </li>",
"     <li>",
"      Changes in T cell responses - VIT appears to shift the T-cell phenotype away from the Th2-type (producing interleukin (IL)-4 and IL-5) and towards the Th-1 type (interferon (IFN)-gamma) or a regulatory type of T response (IL-10 and the production of IgG4) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/48-51\">",
"       48-51",
"      </a>",
"      ]. Osteopontin, a biomarker for the Th-1 immune response, has been studied with gene array analyses as a possible means of assessing the Th-2 to Th-1 shift in VIT [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduction of venom-specific IgE - Venom-specific IgE rises initially, peaking at 8 to 12 weeks, then declines slowly over three to five years to pretreatment levels [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16936/abstract/10\">",
"       10",
"      </a>",
"      ]. This is believed to be an epiphenomenon of VIT, rather than a therapeutic mechanism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The immunologic changes that result from injection immunotherapy, of any type, are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27062?source=see_link\">",
"     \"Subcutaneous immunotherapy for allergic disease: Therapeutic mechanisms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/5/42066?source=see_link\">",
"       \"Patient information: Allergy shots (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venom immunotherapy (VIT) is widely available and highly effective, but many patients with past systemic reactions are not referred to an allergy specialist to determine if they are candidate for treatment. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If NOT treated with VIT, adults who have experienced systemic allergic reactions (ie, anaphylaxis) have a 30 to 60 percent chance of a systemic reaction with each future sting. The severity of the recurrent reactions is usually similar for a given individual. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Natural history of systemic allergic reactions to venom'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If NOT treated with VIT, children (aged less than 17 years) who have experienced systemic allergic reactions involving more than just the skin have about a 30 percent chance of similar reactions to future stings. In contrast, children whose initial reactions were limited to the skin",
"      <span class=\"nowrap\">",
"       (urticaria/angioedema)",
"      </span>",
"      are at even lower risk for a more severe reaction (less than 5 percent). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Natural history of systemic allergic reactions to venom'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VIT is highly effective and improves the patient's quality of life beyond what is achieved with access to epinephrine and Hymenoptera avoidance. The risk of a recurrent systemic reaction with a subsequent reaction is reduced from 30 to 60 percent, to 5 percent or less. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Effectiveness of VIT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VIT results in several immunologic changes, none of which fully accounts for the therapeutic effect. The leading hypothesis is that VIT results in the production of venom-specific IgG antibodies that interfere with the IgE-mediated allergic mechanism. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A patient is a candidate for VIT if there is a history of one or more systemic reactions to past stings AND elevated levels of venom-specific IgE (either on skin testing or in vitro testing). Provided both these criteria are met (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Indications and patient selection'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend VIT for patients of any age with a moderate to severe past reaction to a sting (ie, involving respiratory or hemodynamic compromise) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest VIT for adults with mild systemic reactions (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest NOT giving VIT to children with reactions that consisted ONLY of cutaneous urticaria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angioedema (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/1\">",
"      Hunt KJ, Valentine MD, Sobotka AK, et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978; 299:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/2\">",
"      Smith PL, Kagey-Sobotka A, Bleecker ER, et al. Physiologic manifestations of human anaphylaxis. J Clin Invest 1980; 66:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/3\">",
"      Bil&ograve; BM, Bonifazi F. Epidemiology of insect-venom anaphylaxis. Curr Opin Allergy Clin Immunol 2008; 8:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/4\">",
"      Reisman RE. Natural history of insect sting allergy: relationship of severity of symptoms of initial sting anaphylaxis to re-sting reactions. J Allergy Clin Immunol 1992; 90:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/5\">",
"      van der Linden PW, Hack CE, Struyvenberg A, van der Zwan JK. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. J Allergy Clin Immunol 1994; 94:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/6\">",
"      Golden DB, Breisch NL, Hamilton RG, et al. Clinical and entomological factors influence the outcome of sting challenge studies. J Allergy Clin Immunol 2006; 117:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/7\">",
"      Golden DB, Kagey-Sobotka A, Norman PS, et al. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 2004; 351:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/8\">",
"      Valentine MD, Schuberth KC, Kagey-Sobotka A, et al. The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med 1990; 323:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/9\">",
"      Schuberth KC, Kwiterovich KA, Hagey-Sabotka A. Starting and stopping venom immunotherapy in children with insect allergy. J Allergy Clin Immunol 1988; 81:200 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     Golden DBK. Insect allergy. In: Middleton's allergy: Principles and practice, 7th ed, Adkinson NF, Bochner BS, Busse WW, et al (Eds), Mosby, Philadelphia 2009. p.1005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/11\">",
"      Goldberg A, Confino-Cohen R. Bee venom immunotherapy - how early is it effective? Allergy 2010; 65:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/12\">",
"      Reisman RE, Dvorin DJ, Randolph CC, Georgitis JW. Stinging insect allergy: natural history and modification with venom immunotherapy. J Allergy Clin Immunol 1985; 75:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/13\">",
"      Graft DF, Schuberth KC, Kagey-Sobotka A, et al. Assessment of prolonged venom immunotherapy in children. J Allergy Clin Immunol 1987; 80:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/14\">",
"      Golden DB, Valentine MD, Kagey-Sobotka A, Lichtenstein LM. Regimens of Hymenoptera venom immunotherapy. Ann Intern Med 1980; 92:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/15\">",
"      Carballada F, Boquete M, N&uacute;&ntilde;ez R, et al. Follow-up of venom immunotherapy (VIT) based on conventional techniques and monitoring of immunoglobulin E to individual venom allergens. J Investig Allergol Clin Immunol 2010; 20:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/16\">",
"      M&uuml;ller U, Thurnheer U, Patrizzi R, et al. Immunotherapy in bee sting hypersensitivity. Bee venom versus wholebody extract. Allergy 1979; 34:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/17\">",
"      Boyle RJ, Elremeli M, Hockenhull J, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev 2012; 10:CD008838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/18\">",
"      M&uuml;ller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992; 89:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/19\">",
"      M&uuml;ller U, Berchtold E, Helbling A. Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J Allergy Clin Immunol 1991; 87:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/20\">",
"      Oude Elberink JN, de Monchy JG, Golden DB, et al. Development and validation of a health-related quality-of-life questionnaire in patients with yellow jacket allergy. J Allergy Clin Immunol 2002; 109:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/21\">",
"      Confino-Cohen R, Melamed S, Goldberg A. Debilitating beliefs and emotional distress in patients given immunotherapy for insect sting allergy: a prospective study. Allergy Asthma Proc 2009; 30:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/22\">",
"      Oude Elberink JN, De Monchy JG, Van Der Heide S, et al. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002; 110:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/23\">",
"      Golden DB, Moffitt J, Nicklas RA, et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol 2011; 127:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/24\">",
"      Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007; 120:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/25\">",
"      Bonifazi F, Jutel M, Bil&oacute; BM, et al. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/26\">",
"      Ru&euml;ff F, Bil&ograve; MB, Jutel M, et al. Sublingual immunotherapy with venom is not recommended for patients with Hymenoptera venom allergy. J Allergy Clin Immunol 2009; 123:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/27\">",
"      Patriarca G, Nucera E, Roncallo C, et al. Sublingual desensitization in patients with wasp venom allergy: preliminary results. Int J Immunopathol Pharmacol 2008; 21:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/28\">",
"      Golden DB, Marsh DG, Kagey-Sobotka A, et al. Epidemiology of insect venom sensitivity. JAMA 1989; 262:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/29\">",
"      Reisman RE. Insect stings. N Engl J Med 1994; 331:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/30\">",
"      Lockey RF, Turkeltaub PC, Baird-Warren IA, et al. The Hymenoptera venom study I, 1979-1982: demographics and history-sting data. J Allergy Clin Immunol 1988; 82:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/31\">",
"      Valentine MD. Insect-sting anaphylaxis. Ann Intern Med 1993; 118:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/32\">",
"      M&uuml;ller UR. Bee venom allergy in beekeepers and their family members. Curr Opin Allergy Clin Immunol 2005; 5:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/33\">",
"      Schwartz HJ, Golden DB, Lockey RF. Venom immunotherapy in the Hymenoptera-allergic pregnant patient. J Allergy Clin Immunol 1990; 85:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/34\">",
"      Tunon-de-Lara JM, Villanueva P, Marcos M, Taytard A. ACE inhibitors and anaphylactoid reactions during venom immunotherapy. Lancet 1992; 340:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/35\">",
"      Ober AI, MacLean JA, Hannaway PJ. Life-threatening anaphylaxis to venom immunotherapy in a patient taking an angiotensin-converting enzyme inhibitor. J Allergy Clin Immunol 2003; 112:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/36\">",
"      Ru&euml;ff F, Przybilla B, Bil&oacute; MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/37\">",
"      Rank MA, Oslie CL, Krogman JL, et al. Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors. Allergy Asthma Proc 2008; 29:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/38\">",
"      White KM, England RW. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy. Ann Allergy Asthma Immunol 2008; 101:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/39\">",
"      Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/40\">",
"      M&uuml;ller UR, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 2005; 115:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/41\">",
"      Caviglia AG, Passalacqua G, Senna G. Risk of severe anaphylaxis for patients with Hymenoptera venom allergy: Are angiotensin-receptor blockers comparable to angiotensin-converting enzyme inhibitors? J Allergy Clin Immunol 2010; 125:1171; author reply 1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/42\">",
"      Graft DF, Schuberth KC, Kagey-Sobotka A, et al. A prospective study of the natural history of large local reactions after Hymenoptera stings in children. J Pediatr 1984; 104:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/43\">",
"      Mauriello PM, Barde SH, Georgitis JW, Reisman RE. Natural history of large local reactions from stinging insects. J Allergy Clin Immunol 1984; 74:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/44\">",
"      Golden DB, Kelly D, Hamilton RG, Craig TJ. Venom immunotherapy reduces large local reactions to insect stings. J Allergy Clin Immunol 2009; 123:1371.",
"     </a>",
"    </li>",
"    <li>",
"     Mosbech H, Frew AJ. The immunologic response to Hymenoptera venoms. In: Monograph on insect allergy, 4th ed, Levine MI, Lockey RF (Eds), American Academy of Allergy Asthma and Immunology, Milwaukee 2003. p.75.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/46\">",
"      Lessof MH, Sobotka AK, Lichtenstein LM. Effects of passive antibody in bee venom anaphylaxis. Johns Hopkins Med J 1978; 142:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/47\">",
"      Golden DB, Lawrence ID, Hamilton RH, et al. Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol 1992; 90:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/48\">",
"      McHugh SM, Deighton J, Stewart AG, et al. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995; 25:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/49\">",
"      Jutel M, Pichler WJ, Skrbic D, et al. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995; 154:4187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/50\">",
"      Pereira-Santos MC, Baptista AP, Melo A, et al. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy. Clin Exp Allergy 2008; 38:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/51\">",
"      Nasser SM, Ying S, Meng Q, et al. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol 2001; 31:3704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16936/abstract/52\">",
"      Konno S, Golden DB, Schroeder J, et al. Increased expression of osteopontin is associated with long-term bee venom immunotherapy. J Allergy Clin Immunol 2005; 115:1063.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4090 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-FD0A04FE88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_34_16936=[""].join("\n");
var outline_f16_34_16936=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY OF SYSTEMIC ALLERGIC REACTIONS TO VENOM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECTIVENESS OF VIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Reduced risk of recurrent reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Honeybee versus vespid VIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INDICATIONS AND PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Patients with past systemic reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3921273\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5913870\">",
"      Patients requiring ACE inhibitors or beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Patients with large local reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/4090\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4090|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/36/21068\" title=\"table 1\">",
"      Symptoms and signs of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/25/412\" title=\"table 2\">",
"      VIT patient selection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12313?source=related_link\">",
"      Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14824?source=related_link\">",
"      Diagnosis of Hymenoptera venom allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13239?source=related_link\">",
"      Hymenoptera venom immunotherapy: Determining duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=related_link\">",
"      Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/5/42066?source=related_link\">",
"      Patient information: Allergy shots (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27062?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Therapeutic mechanisms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_34_16937="Atrial tachycardias in children";
var content_f16_34_16937=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Atrial tachycardias in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/34/16937/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/34/16937/contributors\">",
"     Ronald J Kanter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/34/16937/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/34/16937/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/34/16937/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/34/16937/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/34/16937/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5913098\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial tachycardia (AT) is a non-sinus arrhythmia that results in a heart rate greater than the 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile for age and does not require the atrioventricular (AV) junction, accessory pathways, or ventricular tissue for initiation and maintenance of the elevated heart rate. Atrial fibrillation and atrial flutter, although fulfilling this definition, are usually not included in the designation of AT and are typically identified as specific entities.",
"   </p>",
"   <p>",
"    Atrial tachyarrhythmias are most commonly seen in children with congenital heart disease (CHD) in whom cardiac surgery has been performed; they also occur in children without cardiac surgery or CHD and may result in significant morbidity.",
"   </p>",
"   <p>",
"    Atrial tachycardias, including atrial flutter and fibrillation, in children not having undergone heart surgery will be reviewed here. Atrial arrhythmias in patients with congenital heart disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17226?source=see_link\">",
"     \"Atrial arrhythmias (including AV block) in congenital heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913105\">",
"    <span class=\"h1\">",
"     NOMENCLATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial tachycardia is a subset of supraventricular tachycardia (SVT), which is a broad group of tachycardic disorders that includes any rapid rhythm that arises from structures above the bundle branches, including the atrium.",
"   </p>",
"   <p>",
"    AT can be divided into several different tachyarrhythmias based on ECG (P wave) phenotype, whether a single or multiple foci are involved in the origin of the tachycardia, and the frequency and duration of tachycardia (ie,",
"    <span class=\"nowrap\">",
"     sporadic/paroxysmal,",
"    </span>",
"    frequently recurrent, or persistent tachycardia). The tachycardia mechanism (macroreentry, microreentry, enhanced automaticity, and triggered) only loosely correlates with this schema and should be avoided as part of the classification nomenclature unless the mechanism is clearly known. For completeness sake, atrial flutter and fibrillation are also discussed in this review.",
"   </p>",
"   <p>",
"    The following classification is used in this review:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary atrial tachycardia, or simply atrial tachycardia, implies a non-sinus tachycardia, but having discrete and monotonous P waves. Beyond this general term, the nomenclature continues to evolve, and presently, some experts use the terms atrial ectopic tachycardia and focal atrial tachycardia interchangeably. We prefer to use these two terms as sub-types of primary atrial tachycardia along with sinoatrial node reentry tachycardia, with the intent of communicating different tachycardia characteristics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Atrial ectopic tachycardia (AET), sometimes referred to as ectopic atrial tachycardia (EAT), emanates from a single atrial focus, is mostly incessant, and has a variable rate over time that is influenced by the autonomic nervous system. During periods of marked vagotonia, AET may be suppressed in some individuals. The P waves are discrete and non-sinus in appearance. As with all pathologic atrial tachycardias, the PR interval may be inappropriately long relative to the atrial rate. This tachycardia usually occurs due to an area of enhanced automaticity.",
"     </li>",
"     <li>",
"      Focal atrial tachycardia (FAT), also due to a single focus, behaves in a paroxysmal manner, stopping and starting abruptly. It may be a rare sporadic event or may recur frequently, even nearly incessantly. The rate is usually relatively constant within a given paroxysm. Although the name does not imply a mechanism, microreentry or triggered activity are thought to be the most common cause. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=see_link\">",
"       \"Focal atrial tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sinoatrial node reentry tachycardia (SANRT) is a form of FAT, but one which sometimes is categorized separately. Like all reentry tachycardias, it starts and stops abruptly. Its P waves are identical to sinus P waves, as it emanates from the head of the sinoatrial node. Similar to AET and other FATs, the PR interval may be longer than expected for the tachycardia rate. It may be terminated with intravenous adenosine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34166?source=see_link\">",
"       \"Sinoatrial nodal reentrant tachycardia (SANRT)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chaotic atrial tachycardia (CAT, which is called multifocal atrial tachycardia in adults) is diagnosed when there are at least three different rapidly depolarizing, non-sinus P wave morphologies during a 10-second rhythm strip or ECG. The degree of persistence versus intermittency of the tachycardia is not implied by the name. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=see_link\">",
"       \"Multifocal atrial tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Typical atrial flutter (AFl) is a macroreentry tachycardia in which the critical part of the large electrical circuit passes between the inferior vena cava and the tricuspid valve annulus, the cavotricuspid isthmus. It manifests as a sawtooth pattern on ECG, usually with 2:1 atrioventricular block. The pattern is often better observed when an intravenous bolus of adenosine is administered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13256?source=see_link\">",
"       \"Overview of the evaluation and management of atrial flutter\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intraatrial reentry tachycardia (IART) implies a macro-reentry mechanism and usually follows surgery for congenital heart disease. Its appearance and behavior are akin to atrial flutter, although, by definition, the anatomical mechanism of IART is different than typical atrial flutter. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17226?source=see_link\">",
"       \"Atrial arrhythmias (including AV block) in congenital heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Atrial fibrillation (AF) involves multiple, simultaneous atrial reentry wavelets which appear on a rhythm strip as a low amplitude or choppy, irregular baseline with a variable R-R interval. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link\">",
"       \"Overview of atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"       \"Epidemiology of and risk factors for atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Descriptors of atrial tachycardia, such as \"sporadic\", \"frequently recurrent\", \"non-sustained incessant\", and \"persistent\", help communicate the tachycardia behavior, but may also lead to confusion. These terms represent a continuum that describes the frequency and persistence of the arrhythmia but the mechanism is not implied.",
"   </p>",
"   <p>",
"    In some conditions, the above classification implies the underlying tachycardia mechanism (AET, SANRT, IART, AFl, AF), but not in others (FAT, CAT). Although the correlation of mechanism with rhythm strip phenotype is imperfect, there are some clinical features that are associated with specific mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H436425#H436425\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Automaticity and triggered activity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H436418#H436418\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Mechanisms of reentry'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reentry always implies a sudden onset and termination of tachycardia but not the frequency of events. For single anatomic circuit reentrant mechanisms (eg, SANRT, IART, AFl), the atrial rate is fairly constant within an episode.",
"     </li>",
"     <li>",
"      Enhanced automaticity occurs when a small area of atrial muscle has depolarization properties that are faster than that of the underlying or normal atrial tissue and sinoatrial node. Such a site tends to depolarize at rates which vary over time and are influenced by changes in autonomic tone.",
"     </li>",
"     <li>",
"      Triggered activity occurs when a site suddenly depolarizes rapidly in response to catecholamine surge and secondary intracellular calcium loading. The rate is also relatively constant. This mechanism may be very difficult to detect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The other important distinction that defines the classification of pediatric atrial tachycardia is whether or not the child has undergone cardiac surgery. Atrial arrhythmias associated with congenital heart disease and cardiac surgery are discussed separately.",
"   </p>",
"   <p>",
"    Our approach is to use the above classification schema delineated by the rhythm strip, adding modifiers based upon the onset, frequency,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistence of tachycardia episodes, and if appropriate, the underlying mechanism (eg, sporadic FAT, non-sustained incessant CAT, or persistent AET).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913112\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although atrial arrhythmias occur most commonly following surgery for congenital heart disease, they can occur spontaneously in the fetus, child, and adolescent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913120\">",
"    <span class=\"h2\">",
"     Fetus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal arrhythmias occur in approximately one to two percent of pregnancies, of which five to eight percent are due to non-sinus tachycardia. Supraventricular tachycardia (SVT) is the most common non-sinus fetal tachycardia and has a heart rate that is typically between 220 and 300 bpm. By far, the most common fetal SVTs are orthodromic atrioventricular (AV) reciprocating tachycardia and atrial flutter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias\", section on 'Tachyarrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913128\">",
"    <span class=\"h2\">",
"     Infants and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children and infants without cardiac surgery, primary atrial tachycardia appears throughout infancy and childhood and accounts for 14 percent of SVT cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/1\">",
"     1",
"    </a>",
"    ]. Based on an estimated prevalence of SVT of 1 in 200 to 400 children, the prevalence of primary atrial tachycardia in children is approximately 0.03 to 0.08 percent. By comparison, the prevalence of asymptomatic ectopic atrial tachycardia in adult males applying for a pilot's license was 0.34 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link&amp;anchor=H2#H2\">",
"     \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913135\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES AND NATURAL HISTORY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913143\">",
"    <span class=\"h2\">",
"     Frequency and duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs and symptoms of atrial tachycardias depend upon the duration and persistence of the tachycardia and the rate of ventricular response. The presentation is affected by the age of onset as older verbal patients can describe palpitations, potentially leading to earlier detection, whereas infants and toddlers may present with more serious findings because of their inability to verbally describe symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913150\">",
"    <span class=\"h2\">",
"     Sustained tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a group, sustained atrial tachycardias (&ldquo;persistent&rdquo; or &ldquo;non-sustained incessant&rdquo;, using the nomenclature above) are more likely to represent atrial ectopic tachycardia (AET), or incessant or frequently recurring focal atrial (FAT), and, in infants, chaotic atrial tachycardia (CAT). They usually are associated with a slower ventricular rate than the more common types of SVT (AV reciprocating tachycardia and AV node reentry tachycardia [AVNRT]) and other types of atrial tachycardia (eg, sporadic FAT).",
"   </p>",
"   <p>",
"    Affected patients may not recognize palpitations or are unable to verbalize symptoms, and may only come to medical attention after the development of heart failure. This is called tachycardia-induced cardiomyopathy. These patients have impaired myocardial performance, including left ventricular dilatation, reduced shortening fraction, and load-independent measures of hypocontractility (stress-velocity index) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/3\">",
"     3",
"    </a>",
"    ]. The chronic increased atrial rate that is likely to lead to tachycardia-induced cardiomyopathy is not well defined. In our experience, some teenagers with average heart rates of 110 to 120 bpm may have normal cardiac function for up to eight years without any sign of myocardial impairment.",
"   </p>",
"   <p>",
"    Clinical manifestations of tachycardia-induced cardiomyopathy vary depending upon the patient's age.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the affected fetus, nonimmune hydrops fetalis is likely to develop. Ascites, pleural and pericardial effusions, and increased skin thickness can be detected on antenatal ultrasonography. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link&amp;anchor=H15#H15\">",
"       \"Nonimmune hydrops fetalis\", section on 'Arrhythmias'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infants present with nonspecific signs of heart failure including tachypnea, poor feeding, sweating, and failure to thrive. These symptoms are more common when the infants increase their exertions, such as during feeding.",
"     </li>",
"     <li>",
"      Older children and teenagers present with complaints of palpitations (feeling the heart beat or race)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      classic symptoms of heart failure including dyspnea, fatigue with an inability to keep up with peers, respiratory distress, and diaphoresis (sweating). Symptoms are more severe and common with exertion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical improvement usually occurs after ablation therapy with normalization of left ventricular contractility and later reduction in left ventricular volume within 17 weeks of the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/3\">",
"     3",
"    </a>",
"    ]. However, patients may have persistent derangement in diastolic function, and cardiac interstitial fibrosis, thought to represent permanent damage, has been reported one year after resolution of the tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913158\">",
"    <span class=\"h2\">",
"     Paroxysmal tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal atrial tachycardias may clinically simulate the more common forms of SVT, AV reciprocating tachycardia and AVNRT. Sporadic FAT and atrial flutter are the most common atrial tachycardias to fall into this clinical category. Paroxysmal tachycardias present with sudden palpitations, shortness of breath, presyncope, dizziness, and sometimes chest pain. The preverbal child may become irritable or suddenly quiet with associated pallor, diaphoresis, and feeding intolerance.",
"   </p>",
"   <p>",
"    In some patients with atrial flutter, the above symptoms may not occur because they may have such a fast atrial rate that there is 2:1 AV conduction. In these patients, atrial flutter may become persistent, and if untreated, lead to tachycardia-induced cardiomyopathy. Sporadic symptoms in such a patient may represent moments of 1:1 AV conduction, but within the context of a persistent arrhythmia.",
"   </p>",
"   <p>",
"    Syncope is a relatively uncommon sign of atrial tachycardias, but if it occurs, especially in children who have undergone cardiac surgery, it is associated with an increased risk of sudden death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12409?source=see_link&amp;anchor=H7#H7\">",
"     \"Suspected heart disease in infants and children: Criteria for referral\", section on 'Syncope'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913166\">",
"    <span class=\"h2\">",
"     Specific disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913174\">",
"    <span class=\"h3\">",
"     Focal (ectopic) atrial tachycardia and atrial ectopic tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, the presentation of these two entities can range from sporadic episodes (more likely focal atrial tachycardia [FAT]) of mild symptoms of palpitations and dizziness to sustained tachycardia with heart failure from tachycardia-induced cardiomyopathy (more likely atrial ectopic tachycardia [AET]) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/3\">",
"     3",
"    </a>",
"    ]. They can occur at any age and are most commonly of idiopathic origin, although they have been reported in association with cardiomyopathy, myocardial infarction, respiratory infection, congenital heart disease, myocarditis, and chronic pulmonary disease, such as bronchopulmonary dysplasia with pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, it is unclear whether any of these conditions are risk factors for either FAT or AET.",
"   </p>",
"   <p>",
"    Affected infants and small children are generally responsive to medical therapy, and there is a reasonable likelihood of spontaneous resolution after a few months or years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In one report of infants less than six months of age, the arrhythmia spontaneously resolved within one year in 14 of 15 patients (93 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/7\">",
"     7",
"    </a>",
"    ]. In contrast, older children (greater than three years of age) are less likely to respond to medical therapy and have a lower resolution rate. In several case series, spontaneous remission rates vary from 40 to 75 percent for patients up to 18 years of age within 10 to 28 months of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/5,8-10\">",
"     5,8-10",
"    </a>",
"    ]. In patients with chronic or frequently recurrent conditions who are not responsive to medical therapy, ablation therapy is suggested. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=see_link\">",
"     \"Focal atrial tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913182\">",
"    <span class=\"h3\">",
"     Chaotic atrial tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chaotic atrial tachycardia is also referred to as multifocal atrial tachycardia in adults. An uncommon arrhythmia in children, it usually occurs as a transient disorder during early infancy with mild ventricular dysfunction, often associated with a respiratory illness. It typically resolves completely after six months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/6,11-14\">",
"     6,11-14",
"    </a>",
"    ]. Late arrhythmias are unlikely to occur, and the prognosis for long-term outcome is excellent in children with no underlying abnormality. In some cases, chaotic atrial tachycardia is seen in patients with structural heart disease, and the outcome is dependent upon the underlying condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=see_link\">",
"     \"Multifocal atrial tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913190\">",
"    <span class=\"h3\">",
"     Atrial flutter and intraatrial reentry tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial flutter can occur in fetuses and neonates with structurally normal hearts. Comorbid conditions are not usually present; however, cases of atrial flutter associated with neonatal Coxsackie myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/15\">",
"     15",
"    </a>",
"    ] and following maternal treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/38/1639?source=see_link\">",
"     lithium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/16\">",
"     16",
"    </a>",
"    ] have been reported. The mechanism is thought to be similar to adults, involving macroreentry around the tricuspid valve, although definitive studies have not been performed. Neonatal atrial flutter rarely reoccurs following cardioversion with or without medical treatment.",
"   </p>",
"   <p>",
"    Atrial flutter is exceedingly rare in older children with structurally normal hearts, and it is primarily seen in children with a history of previous cardiac surgery, particularly following the Mustard, Senning, or Fontan procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. If this rhythm does not involve macroreentry around the tricuspid valve, it is called intraatrial reentry tachycardia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913198\">",
"    <span class=\"h3\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) is uncommon in children, and most pediatric cases are associated with congenital heart disease, cardiomyopathy, or Wolff-Parkinson-White syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. There is a growing appreciation of adolescent patients who develop AF immediately following a more common SVT, so-called &ldquo;tachycardia-induced-tachycardia&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/23\">",
"     23",
"    </a>",
"    ]. Also, paroxysmal AF may occur in biologically predisposed but otherwise completely healthy patients during a hypervagal event or after drinking a cold beverage. In rare cases, AF may be seen in a child with hyperthyroidism; however, in this setting, assessment should include an evaluation for a possible structural heart lesion.",
"   </p>",
"   <p>",
"    There have been reported rare familial cases of AF, which have been associated with sinus node dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/24\">",
"     24",
"    </a>",
"    ] or with fetal onset [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/25\">",
"     25",
"    </a>",
"    ]. In three families with autosomal dominant AF, the affected gene was mapped to 10q22-q24 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/26\">",
"     26",
"    </a>",
"    ]. AF has also been associated with mutations in several ion channel genes including potassium (KVLQT1) and sodium (SCN5A) channels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link&amp;anchor=H262710425#H262710425\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\", section on 'Monogenic inheritance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913206\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the fetus, the",
"    <strong>",
"    </strong>",
"    diagnosis of atrial tachycardia is made by ultrasonography, or, if available, magnetocardiography. After birth, the diagnosis is based on the surface electrocardiogram (ECG).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913213\">",
"    <span class=\"h2\">",
"     Fetal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the fetus, the detection of arrhythmias and the identification of the specific type are usually accomplished with m-mode ultrasound analysis of atrial and ventricular wall motion or of valve opening and closure, and Doppler flow across valves or in the aorta. Identification of the specific rhythm is made on the basis of the atrial and ventricular rates. In some tertiary centers, fetal magnetocardiography is available to detect electrophysiologic signals so that arrhythmias can be identified and their mechanisms classified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913220\">",
"    <span class=\"h2\">",
"     Electrocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;After birth, atrial tachycardias (ATs) are identified by 12-lead surface ECG. In all of these disorders, the ECG demonstrates an inappropriately rapid heart rate for age (ie, greater than the 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile) and narrow QRS complex.",
"   </p>",
"   <p>",
"    ECG characteristics are used in clarifying the underlying rhythm disturbances as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Focal atrial tachycardia (FAT) and atrial ectopic tachycardia (AET) &ndash; The QRS complexes appear normal and occur at regular intervals. The P wave has a uniform morphology but its appearance usually differs from sinus rhythm and is dependent on the location of the focus (",
"      <a class=\"graphic graphic_waveform graphicRef74611 \" href=\"UTD.htm?42/4/43079\">",
"       waveform 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=see_link&amp;anchor=H9#H9\">",
"       \"Focal atrial tachycardia\", section on 'Electrocardiographic features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sinoatrial node reentry tachycardia is a common form of FAT. It is a paroxysmal arrhythmia with P wave morphology identical to that during sinus rhythm, and a longer PR interval than would be expected for exercise-induced sinus tachycardia at the same heart rate (",
"      <a class=\"graphic graphic_waveform graphicRef76364 \" href=\"UTD.htm?17/28/17862\">",
"       waveform 2",
"      </a>",
"      ). The P waves may even be partially superimposed on the previous T wave. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34166?source=see_link\">",
"       \"Sinoatrial nodal reentrant tachycardia (SANRT)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chaotic AT (multifocal AT) &ndash; The following ECG findings are required for the diagnosis of chaotic AT [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/27,28\">",
"       27,28",
"      </a>",
"      ] (",
"      <a class=\"graphic graphic_waveform graphicRef52317 \" href=\"UTD.htm?26/38/27232\">",
"       waveform 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=see_link\">",
"       \"Multifocal atrial tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Discrete P waves with at least",
"      <strong>",
"       three",
"      </strong>",
"      different morphologies (including the normal sinus P wave) in any single lead. P wave morphology is generally best seen in leads II, III, and V1.",
"     </li>",
"     <li>",
"      The P-P intervals, the P-R duration, and the R-R intervals vary.",
"     </li>",
"     <li>",
"      Atrial rate &gt;100 bpm (usually 250 to 600 bpm).",
"     </li>",
"     <li>",
"      The P waves are separated by isoelectric intervals, which discriminates this rhythm from atrial fibrillation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial flutter and intraatrial reentry tachycardia &ndash; This arrhythmia usually has a 2:1 AV conduction relationship. The atrial flutter rate is generally 260 to 320 bpm and results in a ventricular rate usually between 100 to 150 bpm (",
"      <a class=\"graphic graphic_waveform graphicRef82303 \" href=\"UTD.htm?3/44/3785\">",
"       waveform 4",
"      </a>",
"      ). The flutter waves usually have a monotonously repeating saw tooth pattern due to a constantly undulating or zigzag baseline. This pattern either represents continuous depolarization and repolarization of the atria, or right followed by left atrial depolarization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link\">",
"       \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In some cases in which atrioventricular block makes it difficult to recognize atrial flutter, persistent flutter waves can be demonstrated by vagal maneuvers or the use of intravenous adenosine (",
"      <a class=\"graphic graphic_waveform graphicRef72312 \" href=\"UTD.htm?25/62/26595\">",
"       waveform 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Atrial fibrillation &ndash; Atrial fibrillation is an irregular rhythm without regular or organized atrial activity (",
"      <a class=\"graphic graphic_waveform graphicRef62698 \" href=\"UTD.htm?26/9/26774\">",
"       waveform 6",
"      </a>",
"      ). Multiple reentrant circuits within the atrial myocardium generate multiple mobile wavelets, which often compete with or even extinguish each other. As a result, no uniform activation of the atrial tissue and no distinctive P waves are generated or recognized on the surface ECG. Since these multiple wavelets generate rapid and localized impulses, the sinus node is suppressed or not able to be expressed as it cannot activate the atrium. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=see_link\">",
"       \"The electrocardiogram in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 12-lead ECG can also discriminate between sinus tachycardia due to decompensated dilated cardiomyopathy and tachycardia-induced cardiomyopathy caused by atrial tachycardia emanating from a focus near the sinus node. Features that favor tachycardia-induced cardiomyopathy include episodes of second degree atrioventricular (AV) block (",
"    <a class=\"graphic graphic_waveform graphicRef59685 \" href=\"UTD.htm?36/5/36947\">",
"     waveform 7",
"    </a>",
"    ), or a negative P wave in both leads V1 and V2 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913227\">",
"    <span class=\"h2\">",
"     Other cardiac tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the diagnosis of atrial tachycardia is made, the following cardiac tests may be required:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echocardiogram &ndash; The transthoracic echocardiographic is used to assess myocardial function and identify any potential structural cardiac defects that may have precipitated the rhythm disturbance.",
"     </li>",
"     <li>",
"      Electrophysiology study &ndash; Electrophysiology study is used to confirm the underlying arrhythmia, determine its mechanism, identify site(s) of origin (focus or foci), and guide therapeutic decisions (eg, ablation or change in antiarrhythmic drug therapy). In many centers, catheter ablation is performed at the same time as the diagnostic EPS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12326?source=see_link\">",
"       \"Overview of invasive cardiac electrophysiology studies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913234\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913242\">",
"    <span class=\"h2\">",
"     Fetal atrial tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of fetal tachyarrhythmias including atrial tachycardia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias\", section on 'Tachyarrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913249\">",
"    <span class=\"h2\">",
"     Acute management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute management of an infant or child who presents with supraventricular tachycardia (SVT) including atrial tachycardia is challenging because the exact mechanism of tachycardia is generally unknown. The acute management is dependent on the patient&rsquo;s presentation and clinical status. The goal of therapy is to initially stabilize any patient with hemodynamic instability and to terminate the arrhythmia (",
"    <a class=\"graphic graphic_table graphicRef53559 \" href=\"UTD.htm?21/42/22189\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"     algorithm 1",
"    </a>",
"    ). The acute management of SVT is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of supraventricular tachycardia in children\", section on 'Acute management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913256\">",
"    <span class=\"h2\">",
"     Chronic management",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the acute episode is terminated, chronic management for AT is dependent upon the underlying arrhythmia, the likelihood of spontaneous resolution, and the severity of symptoms. In the majority of cases, options include pharmacologic therapy and catheter ablation. Management varies from institution to institution as there is a lack of data due to the small number of patients to definitely determine the optimal approach.",
"   </p>",
"   <p>",
"    The following sections outline our initial approach for more common pediatric scenarios based on the underlying specific arrhythmia, the likelihood of resolution",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    response to medical therapy, and severity of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87931592\">",
"    <span class=\"h3\">",
"     Focal atrial tachycardia (FAT) and atrial ectopic tachycardia (AET)",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the rate of spontaneous resolution of FAT and AET is age-dependent, and symptoms may vary from mild symptoms of episodic palpitations to sustained tachycardia with congestive heart failure from tachycardia-induced cardiomyopathy. Management of these arrhythmias is complicated by the fact that cardioversion is generally ineffective.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants &ndash; In infants with tachycardia-induced cardiomyopathy, pharmacologic therapy is the initial approach because of the high likelihood of eventual spontaneous resolution. However, the optimal choice of medication is uncertain for either initial treatment or for resistant arrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/7,9,30-35\">",
"       7,9,30-35",
"      </a>",
"      ]. Symptoms may improve initially with the administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"       digoxin",
"      </a>",
"      by lowering the ventricular rate and improving ventricular function, but it does not have any effect on the ectopic focus. For complete tachycardia suppression, preferred drugs include",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/9\">",
"       9",
"      </a>",
"      ] and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/30-32\">",
"       30-32",
"      </a>",
"      ], although",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/49/32534?source=see_link\">",
"       flecainide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/33\">",
"       33",
"      </a>",
"      ], moricizine [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/34\">",
"       34",
"      </a>",
"      ], and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/26/8617?source=see_link\">",
"       sotalol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/35\">",
"       35",
"      </a>",
"      ] also have reported value. [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/30-32\">",
"       30-32",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In one report, AET was suppressed in 18 of 19 infants using a stepwise approach, starting with digoxin, followed by propafenone, digoxin plus propafenone, digoxin plus amiodarone, and digoxin with both propafenone and amiodarone [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/7\">",
"       7",
"      </a>",
"      ]. If the arrhythmia is suppressed, drug therapy is tolerated, and cardiac function normalizes, the drug is usually discontinued after one year, as the arrhythmia is expected to resolve in most cases.",
"     </li>",
"     <li>",
"      Older children &ndash; In older children, if ventricular function is still preserved, medical management may be initiated with a beta-blocker to lower the ventricular rate. However, catheter ablation has become widely accepted as the treatment of choice before selecting the antiarrhythmic drugs noted above, due to their marginal safety profiles. If there is evidence of tachycardia-induced cardiomyopathy, catheter ablation is generally performed as soon as the patient is considered sufficiently stable to undergo the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87931637\">",
"    <span class=\"h3\">",
"     Chaotic atrial tachycardia (CAT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, pediatric CAT is most often seen as a transient condition in infants with resolution within six months of presentation. This arrhythmia is thought to virtually always spontaneously resolve, although published follow-up data from this patient group are lacking.",
"   </p>",
"   <p>",
"    In these patients, medical treatment is challenging because cardioversion is typically not accomplished with the administration of adenosine, overdrive pacing, or synchronized cardioversion. As a result, therapy is directed at controlling the ventricular response rate with a combination of oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    , beta blocker, and calcium channel blocker. If this strategy is unsuccessful, and especially if tachycardia-induced cardiomyopathy is present, pharmacologic cardioversion is attempted with oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/37\">",
"     37",
"    </a>",
"    ],",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/49/32534?source=see_link\">",
"     flecainide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/38\">",
"     38",
"    </a>",
"    ], or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/13,39\">",
"     13,39",
"    </a>",
"    ]. Once sinus rhythm is established and ventricular function normalizes, we usually continue therapy for an additional six months or up to one year of age in patients who required therapeutic intervention.",
"   </p>",
"   <p>",
"    Patients are followed with ambulatory rhythm monitoring and echocardiography every month until ventricular function normalizes and then less frequently. It is reasonable to follow these patients periodically until school age.",
"   </p>",
"   <p>",
"    A single case report does describe successful catheter ablation at a single anatomical atrial site in an infant [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87931664\">",
"    <span class=\"h3\">",
"     Neonatal atrial flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the newborn with atrial flutter, we initially begin therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    . Standard enteral or parenteral loading based upon weight and gestational age may be accomplished over 16 hours. If this does not result in conversion to sinus rhythm, we attempt electrical cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/41-46\">",
"     41-46",
"    </a>",
"    ]. Unlike older children and adults, calcium channel blocking agents should always be avoided in infants, due to substantial risk of potentially fatal cardiovascular collapse. This same caveat should also apply to intravenous beta-blocking agents other than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/48/5895?source=see_link\">",
"     esmolol",
"    </a>",
"    . Direct current cardioversion as primary therapy is also reasonable, as the efficacy of digoxin has never been shown in a controlled manner. Once there is resolution of the arrhythmia, we continue treatment with digoxin for an additional six months. Following discontinuation of therapy, patients are followed for an additional year with ECG and ambulatory rhythm monitoring. Parents are taught how to measure their infant&rsquo;s heart rate and how to recognize signs of early congestive heart failure. Recurrence is rare, and an evaluation for intrinsic structural, functional, or channelopathic conditions should be performed if there is a repeat event.",
"   </p>",
"   <p>",
"    This approach is best illustrated by a case series of 25 newborns with atrial flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/43\">",
"     43",
"    </a>",
"    ]. Seven of 21 converted to sinus rhythm with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    therapy and electrical conversion resulted in sustained sinus rhythm in 9 of 16 patients (13 after failure of digoxin and three as the first treatment). Sinus rhythm was eventually achieved in 23 patients; and two died of complications of prematurity without resolution of atrial flutter.",
"   </p>",
"   <p>",
"    An alternative to electrical cardioversion for termination of neonatal atrial flutter is the use of esophageal pacing at a cycle length 50 to 100 msec less than that of the atrial rate, which is also used in children with atrial flutter or IART after cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913271\">",
"    <span class=\"h2\">",
"     Radiofrequency catheter ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiofrequency catheter ablation of atrial tachycardia foci has been used to treat patients with AT who are symptomatic, have tachycardia-induced cardiomyopathy, in whom antiarrhythmic drugs are ineffective, or if tachycardia recurs after drug discontinuation. In most cases, it is the primary therapy for an older child with tachycardia-induced cardiomyopathy.",
"   </p>",
"   <p>",
"    In a report of 376 foci of AET from the Pediatric Radiofrequency Catheter Ablation Registry, ablation was thought to be initially successful in 88 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/48\">",
"     48",
"    </a>",
"    ]. However, the recurrence rate of this arrhythmia following ablation is probably higher than other forms of SVT. This is because sedation for the procedure may suppress automatic foci so that tachycardias may be quiescent and thus not treatable. In the report from the Registry, complications occurred in approximately three percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16937/abstract/48\">",
"     48",
"    </a>",
"    ]. These are more likely to occur in small atria, and include stenosis of the superior cavoatrial junction, pulmonary vein ostial stenosis, phrenic nerve damage, and sinus node damage.",
"   </p>",
"   <p>",
"    The overview and technical aspects of catheter ablation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=see_link\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913278\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial tachycardia (AT) is a non-sinus arrhythmia that results in a heart rate greater than the 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile for age and does not require the atrioventricular (AV) junction, accessory pathways, or ventricular tissue for initiation and maintenance of the elevated heart rate. Atrial fibrillation and atrial flutter although fulfilling this definition, are usually not included in the definition of AT and are typically identified as specific entities.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial arrhythmias are most commonly seen in children with congenital heart disease (CHD) in whom cardiac surgery is performed; however, they also occur in children without cardiac surgery or CHD and result in significant morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H5913112\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17226?source=see_link\">",
"       \"Atrial arrhythmias (including AV block) in congenital heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      AT can be divided in several classification schema based on ECG (P wave) phenotype, whether a single or multiple foci are involved in the origin of the tachycardia, and the frequency and duration of tachycardia (ie,",
"      <span class=\"nowrap\">",
"       sporadic/paroxysmal,",
"      </span>",
"      frequently recurrent, or persistent tachycardia). The tachycardia mechanism (macroreentry, microreentry, enhanced automaticity, and triggered) only loosely correlates with this schema and should be avoided as part of the tachycardia &ldquo;label&rdquo; unless the mechanism is clearly known. (See",
"      <a class=\"local\" href=\"#H5913105\">",
"       'Nomenclature'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the signs and symptoms of AT depend upon the duration and persistence of the tachycardia, the rate of ventricular response, and the age of the patient. Older verbal patients often complain of palpitations, potentially leading to earlier detection, whereas infants and toddlers may present with more serious findings because of their inability to verbally describe symptoms.",
"     </li>",
"     <li>",
"      Patients with sustained tachycardia are at risk of developing tachycardia-induced cardiomyopathy, which may lead to heart failure. Symptoms of heart failure vary with age: nonimmune hydrops fetalis in the affected fetus; nonspecific findings of poor feeding, sweating, failure to thrive, and tachypnea in infants; and classic symptoms of dyspnea, fatigue on exertions, and diaphoresis in older children. (See",
"      <a class=\"local\" href=\"#H5913150\">",
"       'Sustained tachycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Paroxysmal tachycardia often present with acute symptoms of palpitations, shortness of breath, presyncope, dizziness, and sometime chest pain. In the nonverbal child, findings include irritability, pallor, diaphoresis, and feeding intolerance. (See",
"      <a class=\"local\" href=\"#H5913158\">",
"       'Paroxysmal tachycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children, clinical manifestations regarding age of onset, spontaneous resolution and response to therapy, risk of underlying congenital heart disease, and incidence vary for specific atrial arrhythmias (eg, focal AT, atrial ectopic tachycardia, chaotic AT, atrial flutter, and atrial fibrillation). (See",
"      <a class=\"local\" href=\"#H5913166\">",
"       'Specific disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After birth, the diagnosis of AT is based on a 12-lead surface electrocardiogram (ECG). ECG characteristics are used in clarifying the underlying rhythm disturbances. In some patients, further cardiac testing is performed, including echocardiography to assess myocardial function and potential structural cardiac defects, and electrophysiology study to confirm the underlying arrhythmia and determine its mechanism and site of origin, and to guide therapeutic decisions. (See",
"      <a class=\"local\" href=\"#H5913220\">",
"       'Electrocardiography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5913227\">",
"       'Other cardiac tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management is divided into acute and chronic interventions.",
"     </li>",
"     <li>",
"      The acute management is dependent on the patient&rsquo;s presentation and clinical status. The goal of therapy is to initially stabilize any patient with hemodynamic instability, and to terminate the arrhythmia (",
"      <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef53559 \" href=\"UTD.htm?21/42/22189\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=see_link&amp;anchor=H2#H2\">",
"       \"Management of supraventricular tachycardia in children\", section on 'Acute management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      After the acute episode is terminated, chronic intervention is dependent upon the underlying arrhythmia, the likelihood of resolution, and the severity of symptoms. In the majority of cases, options include pharmacologic therapy and catheter ablation. Management varies from institution to institution as there is a lack of data due to the small number of patients to definitely determine the optimal approach. (See",
"      <a class=\"local\" href=\"#H5913256\">",
"       'Chronic management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/1\">",
"      Ko JK, Deal BJ, Strasburger JF, Benson DW Jr. Supraventricular tachycardia mechanisms and their age distribution in pediatric patients. Am J Cardiol 1992; 69:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/2\">",
"      Poutiainen AM, Koistinen MJ, Airaksinen KE, et al. Prevalence and natural course of ectopic atrial tachycardia. Eur Heart J 1999; 20:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/3\">",
"      Fishberger SB, Colan SD, Saul JP, et al. Myocardial mechanics before and after ablation of chronic tachycardia. Pacing Clin Electrophysiol 1996; 19:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/4\">",
"      Tomita M, Ikeguchi S, Kagawa K, et al. Serial histopathologic myocardial findings in a patient with ectopic atrial tachycardia-induced cardiomyopathy. J Cardiol 1997; 29:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/5\">",
"      Wang JN, Wu JM, Tsai YC, Lin CS. Ectopic atrial tachycardia in children. J Formos Med Assoc 2000; 99:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/6\">",
"      Donnerstein RL, Berg RA, Shehab Z, Ovadia M. Complex atrial tachycardias and respiratory syncytial virus infections in infants. J Pediatr 1994; 125:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/7\">",
"      Bauersfeld U, Gow RM, Hamilton RM, Izukawa T. Treatment of atrial ectopic tachycardia in infants &lt; 6 months old. Am Heart J 1995; 129:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/8\">",
"      Salerno JC, Kertesz NJ, Friedman RA, Fenrich AL Jr. Clinical course of atrial ectopic tachycardia is age-dependent: results and treatment in children &lt; 3 or &gt; or =3 years of age. J Am Coll Cardiol 2004; 43:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/9\">",
"      Mehta AV, Sanchez GR, Sacks EJ, et al. Ectopic automatic atrial tachycardia in children: clinical characteristics, management and follow-up. J Am Coll Cardiol 1988; 11:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/10\">",
"      Naheed ZJ, Strasburger JF, Benson DW Jr, Deal BJ. Natural history and management strategies of automatic atrial tachycardia in children. Am J Cardiol 1995; 75:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/11\">",
"      Farooki ZQ, Green EW. Multifocal atrial tachycardia in two neonates. Br Heart J 1977; 39:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/12\">",
"      Salim MA, Case CL, Gillette PC. Chaotic atrial tachycardia in children. Am Heart J 1995; 129:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/13\">",
"      Fish FA, Mehta AV, Johns JA. Characteristics and management of chaotic atrial tachycardia of infancy. Am J Cardiol 1996; 78:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/14\">",
"      Bradley DJ, Fischbach PS, Law IH, et al. The clinical course of multifocal atrial tachycardia in infants and children. J Am Coll Cardiol 2001; 38:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/15\">",
"      Shah SS, Hellenbrand WE, Gallagher PG. Atrial flutter complicating neonatal Coxsackie B2 myocarditis. Pediatr Cardiol 1998; 19:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/16\">",
"      Till J, Wren C. Atrial flutter in the fetus and young infant: an association with accessory connections. Br Heart J 1992; 67:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/17\">",
"      Hayes CJ, Gersony WM. Arrhythmias after the Mustard operation for transposition of the great arteries: a long-term study. J Am Coll Cardiol 1986; 7:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/18\">",
"      Gewillig M, Cullen S, Mertens B, et al. Risk factors for arrhythmia and death after Mustard operation for simple transposition of the great arteries. Circulation 1991; 84:III187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/19\">",
"      Garson A Jr, Bink-Boelkens M, Hesslein PS, et al. Atrial flutter in the young: a collaborative study of 380 cases. J Am Coll Cardiol 1985; 6:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/20\">",
"      Flinn, CJ, Wolff, GS, Campbell, RM, et, al. Natural history of supraventricular rhythms in 182 children following the Mustard operation. J Am Coll Cardiol 1983; 1:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/21\">",
"      Radford DJ, Izukawa T. Atrial fibrillation in children. Pediatrics 1977; 59:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/22\">",
"      Kirsh JA, Walsh EP, Triedman JK. Prevalence of and risk factors for atrial fibrillation and intra-atrial reentrant tachycardia among patients with congenital heart disease. Am J Cardiol 2002; 90:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/23\">",
"      Kuo JY, Tai CT, Chiang CE, et al. Mechanisms of transition between double paroxysmal supraventricular tachycardias. J Cardiovasc Electrophysiol 2001; 12:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/24\">",
"      Bertram H, Paul T, Beyer F, Kallfelz HC. Familial idiopathic atrial fibrillation with bradyarrhythmia. Eur J Pediatr 1996; 155:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/25\">",
"      Tikanoja T, Kirkinen P, Nikolajev K, et al. Familial atrial fibrillation with fetal onset. Heart 1998; 79:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/26\">",
"      Brugada R, Tapscott T, Czernuszewicz GZ, et al. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med 1997; 336:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/27\">",
"      Bisset GS 3rd, Seigel SF, Gaum WE, Kaplan S. Chaotic atrial tachycardia in childhood. Am Heart J 1981; 101:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/28\">",
"      Liberthson RR, Colan SD. Multifocal or chaotic atrial rhythm: report of nine infants, delineation of clinical course and management, and review of the literature. Pediatr Cardiol 1982; 2:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/29\">",
"      Gelb BD, Garson A Jr. Noninvasive discrimination of right atrial ectopic tachycardia from sinus tachycardia in \"dilated cardiomyopathy\". Am Heart J 1990; 120:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/30\">",
"      Heusch A, Kramer HH, Krogmann ON, et al. Clinical experience with propafenone for cardiac arrhythmias in the young. Eur Heart J 1994; 15:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/31\">",
"      Janousek J, Paul T. Safety of oral propafenone in the treatment of arrhythmias in infants and children (European retrospective multicenter study). Working Group on Pediatric Arrhythmias and Electrophysiology of the Association of European Pediatric Cardiologists. Am J Cardiol 1998; 81:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/32\">",
"      Celiker A, Ozer S, Ozme S, et al. Experience with propafenone for the treatment of cardiac arrhythmias in children. Turk J Pediatr 1990; 32:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/33\">",
"      Perry JC, McQuinn RL, Smith RT Jr, et al. Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics. J Am Coll Cardiol 1989; 14:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/34\">",
"      Evans VL, Garson A Jr, Smith RT, et al. Ethmozine (moricizine HCl): a promising drug for \"automatic\" atrial ectopic tachycardia. Am J Cardiol 1987; 60:83F.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/35\">",
"      Maragn&egrave;s P, Tipple M, Fournier A. Effectiveness of oral sotalol for treatment of pediatric arrhythmias. Am J Cardiol 1992; 69:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/36\">",
"      Walsh EP, Saul JP, Hulse JE, et al. Transcatheter ablation of ectopic atrial tachycardia in young patients using radiofrequency current. Circulation 1992; 86:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/37\">",
"      Celiker A, Ko&ccedil;ak G, Lenk MK, et al. Short- and intermediate-term efficacy of amiodarone in infants and children with cardiac arrhythmia. Turk J Pediatr 1997; 39:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/38\">",
"      Houyel L, Fournier A, Davignon A. Successful treatment of chaotic atrial tachycardia with oral flecainide. Int J Cardiol 1990; 27:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/39\">",
"      Reimer A, Paul T, Kallfelz HC. Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias. Am J Cardiol 1991; 68:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/40\">",
"      Bevilacqua LM, Rhee EK, Epstein MR, Triedman JK. Focal ablation of chaotic atrial rhythm in an infant with cardiomyopathy. J Cardiovasc Electrophysiol 2000; 11:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/41\">",
"      Lisowski LA, Verheijen PM, Benatar AA, et al. Atrial flutter in the perinatal age group: diagnosis, management and outcome. J Am Coll Cardiol 2000; 35:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/42\">",
"      Jaeggi E, Fouron JC, Drblik SP. Fetal atrial flutter: diagnosis, clinical features, treatment, and outcome. J Pediatr 1998; 132:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/43\">",
"      Casey FA, McCrindle BW, Hamilton RM, Gow RM. Neonatal atrial flutter: significant early morbidity and excellent long-term prognosis. Am Heart J 1997; 133:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/44\">",
"      Peng CC, Chen MR, Hou CJ, et al. Atrial flutter in the neonate and early infancy. Jpn Heart J 1998; 39:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/45\">",
"      Drago F, Mazza A, Garibaldi S, et al. Isolated neonatal atrial flutter: clinical features, prognosis and therapy. G Ital Cardiol 1998; 28:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/46\">",
"      Uerpairojkit B, Tanawattanacharoen S, Manotaya S, et al. Intrauterine therapy of fetal atrial flutter. J Obstet Gynaecol Res 1998; 24:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/47\">",
"      Butto F, Dunnigan A, Overholt ED, et al. Transesophageal study of recurrent atrial tachycardia after atrial baffle procedures for complete transposition of the great arteries. Am J Cardiol 1986; 57:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16937/abstract/48\">",
"      Kugler JD, Danford DA, Houston KA, et al. Pediatric radiofrequency catheter ablation registry success, fluoroscopy time, and complication rate for supraventricular tachycardia: comparison of early and recent eras. J Cardiovasc Electrophysiol 2002; 13:336.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14407 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-1201EFFE29-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_34_16937=[""].join("\n");
var outline_f16_34_16937=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5913278\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5913098\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5913105\">",
"      NOMENCLATURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5913112\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5913120\">",
"      Fetus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5913128\">",
"      Infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5913135\">",
"      CLINICAL FEATURES AND NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5913143\">",
"      Frequency and duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5913150\">",
"      Sustained tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5913158\">",
"      Paroxysmal tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5913166\">",
"      Specific disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5913174\">",
"      - Focal (ectopic) atrial tachycardia and atrial ectopic tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5913182\">",
"      - Chaotic atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5913190\">",
"      - Atrial flutter and intraatrial reentry tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5913198\">",
"      - Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5913206\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5913213\">",
"      Fetal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5913220\">",
"      Electrocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5913227\">",
"      Other cardiac tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5913234\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5913242\">",
"      Fetal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5913249\">",
"      Acute management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5913256\">",
"      Chronic management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87931592\">",
"      - Focal atrial tachycardia (FAT) and atrial ectopic tachycardia (AET)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87931637\">",
"      - Chaotic atrial tachycardia (CAT)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87931664\">",
"      - Neonatal atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5913271\">",
"      Radiofrequency catheter ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5913278\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/14407\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14407|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/37/11860\" title=\"algorithm 1\">",
"      Pediatric tachycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14407|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/42/22189\" title=\"table 1\">",
"      Pediatric supraventricular tachycardia rapid overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14407|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/4/43079\" title=\"waveform 1\">",
"      Atrial tachycardia ECG 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?17/28/17862\" title=\"waveform 2\">",
"      ECG SA nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?26/38/27232\" title=\"waveform 3\">",
"      Multifocal atrial tachycardia - two month old infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?3/44/3785\" title=\"waveform 4\">",
"      ECG atrial flutter tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?25/62/26595\" title=\"waveform 5\">",
"      Atrial flutter and AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?26/9/26774\" title=\"waveform 6\">",
"      Atrial fibrillation tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?36/5/36947\" title=\"waveform 7\">",
"      Atrial tachycardia with AV block",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17226?source=related_link\">",
"      Atrial arrhythmias (including AV block) in congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=related_link\">",
"      Catheter ablation of cardiac arrhythmias: Overview and technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type I atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=related_link\">",
"      Focal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=related_link\">",
"      Management of supraventricular tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=related_link\">",
"      Multifocal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=related_link\">",
"      Nonimmune hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12326?source=related_link\">",
"      Overview of invasive cardiac electrophysiology studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13256?source=related_link\">",
"      Overview of the evaluation and management of atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=related_link\">",
"      Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34166?source=related_link\">",
"      Sinoatrial nodal reentrant tachycardia (SANRT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=related_link\">",
"      Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12409?source=related_link\">",
"      Suspected heart disease in infants and children: Criteria for referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=related_link\">",
"      The electrocardiogram in atrial fibrillation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_34_16938="Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease";
var content_f16_34_16938=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/34/16938/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/34/16938/contributors\">",
"     Lauren B Elman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/34/16938/contributors\">",
"     Leo McCluskey, MD, MBE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/34/16938/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/34/16938/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/34/16938/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/34/16938/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/34/16938/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive, presently incurable, neurodegenerative disorder that causes muscle weakness, disability, and eventually death.",
"   </p>",
"   <p>",
"    This topic will review the clinical evaluation and laboratory testing needed to support the diagnosis of ALS and other forms of motor neuron disease, as well as the differential diagnosis of ALS. Other aspects of ALS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23450?source=see_link\">",
"     \"Epidemiology and pathogenesis of amyotrophic lateral sclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16138?source=see_link\">",
"     \"Familial amyotrophic lateral sclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33193?source=see_link\">",
"     \"Symptom-based management of amyotrophic lateral sclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23240?source=see_link\">",
"     \"Disease modifying treatment of amyotrophic lateral sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyotrophic lateral sclerosis (ALS) is one of multiple degenerative motor neuron diseases that are clinically defined, based on the involvement of upper",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower motor neurons. ALS is the most common form of motor neuron disease. The diagnosis of ALS is based upon clinical criteria that include the presence of upper motor neuron and lower motor neuron signs, progression of disease, and the absence of an alternative explanation. There is no single diagnostic test that can confirm or entirely exclude the diagnosis of motor neuron disease.",
"   </p>",
"   <p>",
"    Practically speaking, clinicians make the diagnosis of ALS when it is suggested by the history and physical examination, supported by electrodiagnostic studies, and not excluded by neuroimaging and laboratory studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ALS is suggested when there are progressive symptoms consistent with upper and lower motor neuron dysfunction that present in one of four body segments",
"    <span class=\"nowrap\">",
"     (cranial/bulbar,",
"    </span>",
"    cervical, thoracic, and lumbosacral) followed by spread to other segments over a period of months to years. The course is not relapsing and remitting, but rather is insidiously progressive. Involuntary weight loss and muscle wasting unrelated to nutrition may also occur.",
"   </p>",
"   <p>",
"    The signs and symptoms associated with ALS are described in the tables for limb (",
"    <a class=\"graphic graphic_table graphicRef72454 \" href=\"UTD.htm?24/58/25517\">",
"     table 1",
"    </a>",
"    ), bulbar (",
"    <a class=\"graphic graphic_table graphicRef75146 \" href=\"UTD.htm?33/2/33837\">",
"     table 2",
"    </a>",
"    ), axial (",
"    <a class=\"graphic graphic_table graphicRef67913 \" href=\"UTD.htm?9/60/10188\">",
"     table 3",
"    </a>",
"    ) and respiratory (",
"    <a class=\"graphic graphic_table graphicRef58537 \" href=\"UTD.htm?36/37/37467\">",
"     table 4",
"    </a>",
"    ) locations.",
"   </p>",
"   <p>",
"    In this setting, the diagnosis of ALS is further suggested by an absence of associated neuropathic or radiculopathic pain, sensory loss, sphincter dysfunction, ptosis, or extraocular nerve or muscle dysfunction. While sensory symptoms may occur in 20 to 30 percent of patients with ALS, the sensory examination is usually normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\", section on 'Sensory symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Phenomena considered to exclude the diagnosis of ALS are supranuclear gaze paresis, tremor or other involuntary movements, cerebellar ataxia, extrapyramidal symptoms, and autonomic dysfunction. However, one or more of these features are considered to be part of an ALS-PLUS syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\", section on 'ALS-plus syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cognitive dysfunction does not exclude the diagnosis of ALS. Frontotemporal executive dysfunction can precede or follow the onset of motor symptoms in up to 40 percent of patients with ALS. In most cases, the symptoms are mild and possibly only detectable with formal cognitive testing. However, overt frontotemporal lobar dementia occurs in approximately 10 percent of patients with ALS, and may be more common in patients with bulbar onset ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since 5 to 10 percent of ALS cases are related to a genetic mutation (ie, familial ALS or FALS), a thorough family history should be obtained. The family history should emphasize relatives with the diagnosis of ALS but also explore those who may have suffered from a progressive motor disorder not necessarily labeled as ALS. Mutations that cause FALS have been identified in multiple genes, and some of these mutations also cause frontotemporal dementia. Thus, the family history should seek to identify any relatives with the diagnosis of dementia, cognitive decline, a language disorder, personality change, or late onset (eg, age 40s to 60s) psychiatric disease, particularly if labeled as schizophrenia. Because FALS may be also be accompanied by neurologic dysfunction in other systems as part of an &lsquo;ALS-plus&rsquo; syndrome, a family history of parkinsonism or other neurodegenerative disorders may also be informative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16138?source=see_link\">",
"     \"Familial amyotrophic lateral sclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\", section on 'ALS-plus syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is also essential to determine if one or more family members underwent brain and spinal cord autopsy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obtained genetic testing, since this information may be invaluable in supporting the diagnosis of familial ALS and may even allow identification of a specific genetic mutation. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Genetic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of both upper and lower motor neuron signs in multiple segments is required for the diagnosis of ALS. These are described in the tables for limb (",
"    <a class=\"graphic graphic_table graphicRef72454 \" href=\"UTD.htm?24/58/25517\">",
"     table 1",
"    </a>",
"    ), bulbar (",
"    <a class=\"graphic graphic_table graphicRef75146 \" href=\"UTD.htm?33/2/33837\">",
"     table 2",
"    </a>",
"    ), axial (",
"    <a class=\"graphic graphic_table graphicRef67913 \" href=\"UTD.htm?9/60/10188\">",
"     table 3",
"    </a>",
"    ) and respiratory (",
"    <a class=\"graphic graphic_table graphicRef58537 \" href=\"UTD.htm?36/37/37467\">",
"     table 4",
"    </a>",
"    ) signs and symptoms associated with ALS.",
"   </p>",
"   <p>",
"    Lower motor neuron signs include weakness, atrophy and fasciculations. While patients may notice muscular weakness, they often do not notice fasciculations (",
"    <a class=\"graphic graphic_movie graphicRef66062 \" href=\"UTD.htm?6/10/6318\">",
"     movie 1",
"    </a>",
"    ) or muscular atrophy (",
"    <a class=\"graphic graphic_movie graphicRef53274 \" href=\"UTD.htm?6/36/6735\">",
"     movie 2",
"    </a>",
"    ) until these signs are pointed out during an examination.",
"   </p>",
"   <p>",
"    Upper motor neuron signs include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased tone and increased extremity deep tendon reflexes (",
"      <a class=\"graphic graphic_movie graphicRef50755 \" href=\"UTD.htm?9/37/9823\">",
"       movie 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The presence of any reflexes in muscles that are profoundly weak and wasted",
"     </li>",
"     <li>",
"      Pathologic reflexes such as crossed adductors, a jaw jerk, or Hoffman sign [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The syndrome of pseudobulbar affect, which consists of inappropriate laughing, crying,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      forced yawning",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Babinski sign (reflex great toe extension, often with fanning of the small toes, with lateral plantar stimulation) is present in about one-half of patients with ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/6\">",
"     6",
"    </a>",
"    ], but is a definitive indicator of upper motor neuron pathology when present (",
"    <a class=\"graphic graphic_movie graphicRef74817 \" href=\"UTD.htm?13/29/13791\">",
"     movie 4",
"    </a>",
"    ). Lateral plantar stimulation normally produces reflex toe flexion without other leg or foot movement. Triple flexion occurs when plantar stimulation produces reflex great toe extension, flexion of the knee, and flexion of the hip.",
"   </p>",
"   <p>",
"    A lack of toe movement with plantar stimulation, the silent toe, may be considered an upper motor neuron sign when the contralateral side demonstrates normal flexor toe movement. Additional manifestations of triple flexion, such as contraction of the tensor fascia lata and other hip flexors, may occur in response to plantar stimulation even if the toe is not upgoing. Absence of an upgoing toe with plantar stimulation when there are multiple other upper motor neuron signs may at times be explained by lower motor neuron weakness of the great toe extensor (extensor hallucis longus) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical standard for the diagnosis of ALS is the revised El Escorial World Federation of Neurology criteria, also known as the Airlie House criteria (",
"    <a class=\"graphic graphic_algorithm graphicRef62831 \" href=\"UTD.htm?18/10/18593\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. These criteria allow assignment of diagnostic certainty and were designed for research purposes to ensure appropriate inclusion of patients into clinical trials. The El Escorial criteria have been validated pathologically [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/9\">",
"     9",
"    </a>",
"    ] and interobserver agreement is acceptable [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By the revised El Escorial criteria, diagnosis of ALS requires the presence of [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Evidence of lower motor neuron degeneration by clinical, electrophysiological, or neuropathological examination",
"     </li>",
"     <li>",
"      Evidence of upper motor neuron degeneration by clinical examination",
"     </li>",
"     <li>",
"      Progressive spread of symptoms or signs within a region or to other regions, as determined by history or examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The revised El Escorial criteria require the absence of electrophysiologic and pathologic evidence of other disease processes that might explain the signs of lower",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    upper motor neuron degeneration, and the absence of neuroimaging evidence of other disease processes that might explain the observed clinical and electrophysiologic signs.",
"   </p>",
"   <p>",
"    In 2008, the Awaji ALS criteria were proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/11\">",
"     11",
"    </a>",
"    ], given that approximately 21 percent of patients die from ALS without having ever met the El Escorial criteria for disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Although similar to the revised El Escorial criteria, the newer Awaji criteria differ by allowing electrodiagnostic and clinical criteria for lower motor neuron signs to be combined to determine if a single limb is abnormal, and by permitting fasciculation potentials by needle electromyography to be used as evidence of ongoing denervation in a muscle with evidence of neurogenic change [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/11\">",
"     11",
"    </a>",
"    ]. These changes were expected to improve the sensitivity of the criteria for the diagnosis of ALS without reducing the specificity when compared with the revised El Escorial (Airlie House) criteria. This expectation is supported by a 2012 systematic review and meta-analysis of eight studies evaluating the accuracy of the Awaji criteria for the diagnosis of ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/14\">",
"     14",
"    </a>",
"    ]. The pooled sensitivity was higher with the Awaji criteria compared with the revised El Escorial criteria (81 versus 62 percent), while the specificities for both sets of criteria were 98 percent.",
"   </p>",
"   <p>",
"    There are other forms of motor neuron disease that are considered variants of ALS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressive muscular atrophy is a progressive disorder that is limited to lower motor neurons. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\", section on 'Progressive muscular atrophy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      At times, upper motor neuron signs develop during the clinical course and the designation is changed to lower motor neuron-onset ALS. The revised El Escorial criteria consider progressive muscular atrophy as &lsquo;suspected ALS&rsquo;. Patients with progressive muscular atrophy are currently excluded from participation in clinical trials.",
"     </li>",
"     <li>",
"      Primary lateral sclerosis is a progressive disorder that is clinically limited to the upper motor neurons. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\", section on 'Primary lateral sclerosis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Consensus criteria consider it appropriate to consider this diagnosis when at least four years of clinical progression has occurred without clinical evidence of lower motor neuron disease [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/15\">",
"       15",
"      </a>",
"      ]. The revised El Escorial criteria do not consider this disorder as part of the schema of ALS. It is notable, however, that patients with clinically isolated upper motor neuron presentation may eventually develop clinical or electromyographic evidence of lower motor neuron abnormalities. This disorder is then referred to as upper motor neuron-onset ALS and may then meet criteria for the diagnosis of ALS.",
"     </li>",
"     <li>",
"      Progressive bulbar palsy is a progressive upper and lower motor neuron disorder of cranial muscles. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\", section on 'Progressive bulbar palsy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      When both upper and lower motor neuron findings are present, the disorder meets criteria for the diagnosis of &lsquo;clinically possible ALS&rsquo;. In nearly all cases, upper",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lower motor neuron abnormalities will eventually spread to limb, axial,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      respiratory motor neurons and these patients may meet criteria for ALS. In this circumstance, the designation is changed to bulbar-onset ALS.",
"     </li>",
"     <li>",
"      Flail arm syndrome presents with progressive lower motor neuron weakness of the arms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\", section on 'Flail arm syndrome'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In the absence of upper motor neuron signs, the most appropriate diagnostic category for patients with flail arm syndrome is progressive muscular atrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/16\">",
"       16",
"      </a>",
"      ]. Criteria for the diagnosis of ALS are met if upper motor neuron signs develop in the arms or in other segments.",
"     </li>",
"     <li>",
"      Flail leg syndrome presents with slowly progressive, distal lower motor neuron weakness of the legs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link&amp;anchor=H28382562#H28382562\">",
"       \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\", section on 'Flail leg syndrome'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In the absence of upper motor neuron signs, the most appropriate diagnostic category for patients with flail leg syndrome is progressive muscular atrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/16\">",
"       16",
"      </a>",
"      ]. Criteria for the diagnosis of ALS are met if upper motor neuron signs develop in the legs or in other segments.",
"     </li>",
"     <li>",
"      ALS-plus syndrome is the designation for patients who meet the clinical criteria for ALS and also have features of other disorders that exclude the diagnosis of ALS, such as autonomic insufficiency, parkinsonism, supranuclear gaze paresis, and cerebellar ataxia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\", section on 'ALS-plus syndrome'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      While cognitive dysfunction was once thought to exclude the diagnosis of ALS, this is no longer the case.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ELECTRODIAGNOSTIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;While ALS is primarily a clinical diagnosis, sensory and motor nerve conduction studies and electromyography are a standard part of the evaluation of motor neuron disease. Electrodiagnostic studies are most helpful when clinical evidence supporting the diagnosis of ALS is limited or conflicting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Electromyography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electromyographic findings in ALS combine features of acute and chronic denervation and reinnervation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute denervation findings include fibrillations and positive sharp waves. Using the Awaji Island criteria, fasciculations in muscles with neurogenic change are considered equivalent to fibrillations and positive sharp waves.",
"     </li>",
"     <li>",
"      Chronic denervation and reinnervation findings include large amplitude, long duration, complex motor unit action potentials (MUAPs) with neurogenic recruitment and a reduced interference pattern. Instability of motor unit action potentials indicative of recent reinnervation is considered an important indication of ongoing denervation and reinnervation by the Awaji criteria.",
"     </li>",
"     <li>",
"      Fasciculation potentials may also appear in denervated muscle and represent spontaneous firing of motor units that are not voluntarily recruited. Fasciculations may be visible to the naked eye when they occur on the surface of muscles (",
"      <a class=\"graphic graphic_movie graphicRef66062 \" href=\"UTD.htm?6/10/6318\">",
"       movie 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef63510 \" href=\"UTD.htm?17/24/17806\">",
"       movie 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The electromyographic abnormalities noted in muscles of patients with ALS are not pathognomonic for the disease, but can be seen in any disease causing chronic and ongoing denervation. However, the diagnosis of ALS should be suggested by the observation of similar abnormalities in many muscles of proximal and distal limbs, in the absence of radiological demonstration of corresponding nerve root compression considered significant enough to cause the abnormality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nerve conduction studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensory and motor nerve conduction studies are most often normal in ALS, though compound motor action potential (CMAP) amplitudes may be reduced in severely atrophic and denervated muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Motor unit number estimation is a nerve conduction-based method that assesses the number of viable motor axons innervating small hand or foot muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/20\">",
"     20",
"    </a>",
"    ]. Although this technique has applications to many diseases, it has been applied most successfully to ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Motor unit numbers drop prior to the onset of clinical weakness, and changes in this measure can be used as an outcome measure in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Electrodiagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following principles have been emphasized regarding electrodiagnostic evidence of lower motor neuron disease in patients with suspected ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general the electrodiagnostic evaluation includes multiple motor and sensory conduction studies in two or more limbs and needle examination of multiple muscles in three limbs, mid-thoracic paraspinal region and bulbar region.",
"     </li>",
"     <li>",
"      Motor conduction block should be absent.",
"     </li>",
"     <li>",
"      Motor conduction velocities should be normal in the arm and leg. However, loss of motor axons with resulting reduction of the compound muscle action potential amplitude may be associated with mild slowing of conduction velocity.",
"     </li>",
"     <li>",
"      Sensory amplitudes and velocities in the arm and leg should be normal or preserved in relationship to motor amplitudes.",
"     </li>",
"     <li>",
"      Evidence of acute or ongoing muscle denervation, as indicated by the presence of fibrillation potentials and positive sharp waves, should be present in multiple muscles of the regions examined. Per the Awaji Island consensus criteria, fasciculations are considered indicative of an acute or ongoing denervation in muscles demonstrating evidence of chronic denervation.",
"     </li>",
"     <li>",
"      Evidence of chronic denervation and reinnervation should be present in multiple muscles in one or more limbs and may also be present in bulbar and thoracic muscles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of lower motor neuron disease can be confirmed if these conditions are fulfilled, but the presence of upper motor neuron disease must also be clinically evident in order to make the diagnosis of ALS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Repetitive nerve stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive nerve stimulation is a nerve conduction technique that assess the integrity of the neuromuscular junction and is useful for the diagnosis of disorders such as myasthenia gravis and the Lambert-Eaton myasthenic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Thus, repetitive nerve stimulation may be useful if these conditions are a consideration in the differential diagnosis during the evaluation of suspected motor neuron disease.",
"   </p>",
"   <p>",
"    Repetitive nerve stimulation may be normal or abnormal in patients with ALS, since the physiology of ongoing denervation with reinnervation can cause an abnormal finding of a decrement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/27-33\">",
"     27-33",
"    </a>",
"    ]. In the setting of active collateral sprouting with reinnervation, transmission at newly formed, unstable neuromuscular junctions may be intermittent, leading to a decremental response on RNS and diagnostic confusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Single fiber EMG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single fiber electromyography is used to measure jitter (an evaluation of neuromuscular junction function) and fiber density (an electrophysiologic assessment of reinnervation following denervation). Jitter measurement may be affected by the presence of ongoing reinnervation and newly formed, unstable neuromuscular junctions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/17,34\">",
"     17,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased fiber density is a nonspecific finding that may be present in any muscle that has undergone denervation and reinnervation. Collateral sprouting increases the number of muscle fibers within the territory of reinnervated motor units. As a result, adjacent muscle fibers within any region of a",
"    <span class=\"nowrap\">",
"     denervated/reinnervated",
"    </span>",
"    muscle are more likely to be part of the same motor unit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Transcranial magnetic stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;External stimulation with a magnet over the motor cortex, cervical spine and lumbosacral spine produces a compound muscle action potential that can be recorded from the surface. The difference between the latency of the response elicited by cranial versus cervical or cranial versus lumbosacral stimulation is called the central motor conduction time and is a reflection of the integrity of central motor pathways. Slowing of central motor conduction time has been reported in patients with ALS.",
"   </p>",
"   <p>",
"    Transcranial magnetic stimulation remains a largely experimental technique and is not used routinely for clinical diagnosis. However, correlation with clinical upper motor neuron signs has been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/11,35-41\">",
"     11,35-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OTHER DIAGNOSTIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As already noted, there is no single diagnostic test that can confirm or entirely exclude the diagnosis of motor neuron disease. However, neuroimaging and laboratory studies are often important to exclude alternative diagnoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging has traditionally been used to exclude other possible diagnoses in the evaluation of suspected ALS. Magnetic resonance imaging (MRI) is the preferred modality, unless there is a contraindication. Brain MRI should be performed whenever bulbar disease is present. Cervical and lumbosacral spine MRI can be used to evaluate lower motor neuron disease in the arms and legs.",
"   </p>",
"   <p>",
"    When evaluating upper motor neuron disease, MRI should be performed in all segments rostral to the clinical findings; this includes the brain, cervical spine, and thoracic spine when upper motor neuron findings are in the legs. Conventional MRI is usually normal in ALS, although increased signal in the corticospinal tracts on T2-weighted and FLAIR images and hypointensity of the motor cortex on T2-weighted images has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental imaging techniques to detect upper motor neuron disease in ALS include magnetic resonance spectroscopy and diffusion-tensor imaging. Magnetic resonance spectroscopy provides biochemical and metabolic information in the form of a spectrum obtained at a region of interest. The three major peaks observed on an in vivo proton magnetic resonance spectrum are from N-acetyl aspartate (NAA), choline (Cho), and creatine (Cr). NAA is thought to correlate with neuronal integrity. The data are presented either quantitatively or as ratios.",
"   </p>",
"   <p>",
"    The balance of evidence has shown reduced NAA:Cr [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/38,42,44-46\">",
"     38,42,44-46",
"    </a>",
"    ] or NAA:Cho [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/35,44,47\">",
"     35,44,47",
"    </a>",
"    ] or NAA:Cr+Cho [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/48\">",
"     48",
"    </a>",
"    ] in the motor cortex in patients with ALS. Quantitative magnetic resonance spectroscopy studies have shown total NAA levels to be reduced by 5 percent to 19 percent in the motor cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/35,46,47,49-52\">",
"     35,46,47,49-52",
"    </a>",
"    ]. The findings, however, have been mixed, with some studies not showing significant differences between patients and controls [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Correlation with clinical parameters has not been consistently achieved.",
"   </p>",
"   <p>",
"    Diffusion-tensor imaging is a structural neuroimaging technique that measures the extent and direction of water diffusion. Diffusion of brain water has been shown to have strong directionality (anisotropy) in white matter [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Diffusion anisotropy is the result of restricted diffusion of water molecules across myelinated white matter fibers compared with diffusion along the fibers. Patients with ALS have been shown to have decreased fractional anisotropy and increased mean diffusivity in the corticospinal tracts at multiple levels [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/57-59\">",
"     57-59",
"    </a>",
"    ] and in the corpus callosum [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing of blood, urine, and sometimes cerebrospinal fluid is performed routinely during the evaluation of motor neuron disease.",
"   </p>",
"   <p>",
"    Routine lab work usually includes complete blood count with differential, electrolytes including calcium and phosphate, liver function tests, thyroid studies, creatine kinase, erythrocyte sedimentation rate, antinuclear antibody, rheumatoid factor, vitamin B12, anti-GM1 antibody, serum protein electrophoresis with immunofixation, and urine protein electrophoresis with immunofixation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In ALS, creatine kinase may be elevated up to approximately 1000",
"      <span class=\"nowrap\">",
"       U/L",
"      </span>",
"      on the basis of denervation.",
"     </li>",
"     <li>",
"      In patients with an elevated serum calcium level, the serum parathyroid hormone level should be checked. ALS is rarely associated with primary hyperparathyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Identification of a serum paraprotein should prompt further work-up with a 24-hour urine protein electrophoresis, a skeletal survey, and CT of the chest, abdomen and pelvis to look for myeloma and lymphoma. In such cases, referral to a",
"      <span class=\"nowrap\">",
"       hematologist/oncologist",
"      </span>",
"      for bone marrow biopsy may be appropriate.",
"     </li>",
"     <li>",
"      In some cases, testing for Lyme disease may be appropriate in regions where it is endemic. This is particularly important in the following situations:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When the clinical manifestations include radicular or neuropathic pain and or unilateral peripheral facial palsy",
"     </li>",
"     <li>",
"      When sensory signs and symptoms are present",
"     </li>",
"     <li>",
"      When MRI of the brain demonstrates multiple white matter signal hyperintensities",
"     </li>",
"     <li>",
"      When MRI of the brain and spine demonstrate meningeal signal change and or enhancement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Lyme antibody screen will typically suffice if it is clearly negative. However, a confirmatory Western blot should be obtained if the antibody screen is equivocal or positive. Furthermore, cerebrospinal fluid (CSF) analysis for cells, protein, oligoclonal bands, Lyme antibody, Lyme antibody synthesis ratio (ratio of serum Lyme antibody titer and serum albumin compared to CSF Lyme antibody titer and CSF albumen) and Lyme polymerase chain reaction should be obtained if the antibody screen is positive.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testing for HIV may be appropriate particularly in younger patients, at-risk individuals, and those with atypical features. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36553?source=see_link\">",
"       \"Polio and infectious diseases of the anterior horn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Screening for heavy metals in the blood and urine is not required if there is no known occupational exposure. Only lead intoxication has been reported to cause a condition resembling lower motor neuron predominant ALS. This condition has been largely eliminated through monitoring of occupational exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Testing for the antibodies found in myasthenia gravis (acetylcholine receptor antibodies and MuSK antibodies) and Lambert-Eaton myasthenic syndrome (voltage-gated calcium channel antibodies) is appropriate in the right clinical setting, and is particularly appropriate in patients with bulbar dysfunction or any ocular motility disturbance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link\">",
"       \"Diagnosis of myasthenia gravis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\", section on 'VGCC antibody testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lumbar puncture and CSF analysis should be performed if there is clinical suspicion for Lyme disease, HIV infection, or chronic inflammatory demyelinating polyneuropathy (CIDP).",
"     </li>",
"     <li>",
"      Lumbar puncture for CSF analysis that includes cytology and a search for systemic malignancy should be considered in lower motor neuron disorders with symptoms that have progressed over a period of less than two years. This recommendation is based on our clinical experience and the knowledge that multiple types of cancer can produce a subacutely progressive lower motor disorder by direct infiltration of the meninges, motor roots, and cranial nerves. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=see_link\">",
"       \"Clinical features and diagnosis of leptomeningeal metastases from solid tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, lymphoma and breast cancer can produce an indirect paraneoplastic degeneration of the motor neurons that is most commonly subacute to chronic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6583?source=see_link&amp;anchor=H3#H3\">",
"     \"Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia\", section on 'Motor neuron syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing is not a routine part of the diagnostic evaluation in ALS. However, familial ALS or FALS accounts for 5 to 10 percent of all ALS cases. Clinical genetic testing for FALS is available to look for causative mutations in a number of genes. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16138?source=see_link&amp;anchor=H29079495#H29079495\">",
"     \"Familial amyotrophic lateral sclerosis\", section on 'Genes to test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genetic testing for specific ALS-causing mutations is most useful for establishing the diagnosis (particularly for juvenile or early-stage disease) and for assessing risk among family members of an affected relative with an established genetic cause. To properly interpret genetic test results for ALS genes, it is necessary to know whether the person being tested has ALS and whether a mutation in the family has already been identified. The recurrence risk of ALS in a given family (ie, whether or not another family member will develop ALS) is estimated primarily by determining the inheritance pattern. Autosomal dominant inheritance is the most common pattern in hereditary ALS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16138?source=see_link&amp;anchor=H19#H19\">",
"     \"Familial amyotrophic lateral sclerosis\", section on 'Genetic testing and counseling'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1104160884\">",
"    <span class=\"h2\">",
"     Neuromuscular ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited evidence suggests that the use of muscle ultrasound to detect fasciculations can aid in the diagnosis of ALS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30232?source=see_link&amp;anchor=H28971343#H28971343\">",
"     \"Diagnostic ultrasound in neuromuscular disease\", section on 'Dynamic changes in diseased muscle'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one prospective unblinded report of 81 patients with sporadic ALS, fasciculations were detected at a significantly higher rate by ultrasound compared with needle EMG in a variety of muscles including the tongue (60 versus 0 percent), biceps brachii (88 versus 66 percent), and tibialis anterior (83 versus 45 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/63\">",
"     63",
"    </a>",
"    ]. Consequently, the proportion of patients who fulfilled Awaji diagnostic criteria for definite or probable ALS using information from both EMG and ultrasound was modestly higher compared with EMG alone (79 versus 74 percent).",
"   </p>",
"   <p>",
"    Another small study found that ultrasound can identify nerve and muscle atrophy in patients with ALS compared with controls, but these findings are recognized as nonspecific because they occur in a variety of neuropathic and myopathic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, additional research is needed to determine the true utility of neuromuscular ultrasound in the diagnosis of ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle biopsy is not a routine part of the diagnostic evaluation of ALS but may be performed if myopathy is suspected on clinical, electrodiagnostic, or serological grounds.",
"   </p>",
"   <p>",
"    Findings on muscle biopsy in ALS are the nonspecific findings of chronic denervation with reinnervation. Denervated fibers may appear shrunken, angular, and darkly staining. Fiber type grouping is a prominent finding that reflects reinnervation. Muscle cell type (fast, slow, or intermediate twitch) is determined by the innervating motor neuron and leads to characteristic staining intensities. Normally, different fiber types are distributed randomly within the muscle, leading to a variegated appearance. With reinnervation, the likelihood that adjacent fibers will be innervated by the same motor neuron increases, leading to groups of adjacent fibers having the same staining characteristics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete evaluation should be aimed at eliminating the possibility that signs or symptoms may be accounted for by an alternative diagnosis (",
"    <a class=\"graphic graphic_table graphicRef64932 \" href=\"UTD.htm?14/17/14621\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Multifocal motor neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multifocal motor neuropathy, also known as multifocal motor neuropathy with conduction block, is characterized by lower motor neuron signs that often present in a bibrachial pattern. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link&amp;anchor=H47#H47\">",
"     \"Overview of upper extremity peripheral nerve syndromes\", section on 'Multifocal motor neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Motor nerve conduction studies in multifocal motor neuropathy often show evidence of conduction block, representing focal demyelination. Sensory conduction through the same segment of nerve is normal. Elevated titers of GM1 antibodies may be seen in 30 to 80 percent of patients.",
"   </p>",
"   <p>",
"    Multifocal motor neuropathy is a particularly important diagnosis to consider, as the condition is treatable with intravenous immune globulin and other forms of immunosuppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cervical radiculomyelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical spondylosis with nerve root compression can cause the combination of lower motor neuron signs at the level of abnormality with upper motor neuron signs below it. This condition often includes radicular or distal sensory abnormalities and sphincter dysfunction, but these features may be absent. Cervical MRI establishes the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27944?source=see_link\">",
"     \"Cervical spondylotic myelopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Benign fasciculations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous fasciculations may occur in up to 70 percent of people [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/66\">",
"     66",
"    </a>",
"    ]. A smaller proportion of this group will experience relatively frequent fasciculations that may be widespread or relatively focal and may be accompanied by cramps. Long-term follow-up of patients with excess fasciculations who have a normal examination and normal electromyography suggests that this is a truly benign condition and does not confer an increased risk for the development of motor neuron disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/67-69\">",
"     67-69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Inflammatory myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymyositis, dermatomyositis, and inclusion body myopathy comprise the inflammatory myopathies. Weakness of voluntary muscles as well as dysphagia may occur in all of these conditions. Polymyositis and dermatomyositis usually present with proximal weakness including neck extensor weakness. Inclusion body myopathy often presents with weakness in the quadriceps and weakness in the finger flexors that is out of proportion to intrinsic hand muscle weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=see_link\">",
"     \"Clinical manifestations and diagnosis of inclusion body myositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Muscle biopsy is usually required for diagnosis of these disorders. Electrophysiologic findings consistent with myopathy are often seen, but motor unit morphology and recruitment in end-stage myopathy can appear similar to findings characteristic of chronic denervation. Polymyositis and dermatomyositis usually cause a markedly elevated creatine kinase, but occasionally this is not seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Post-polio syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-polio syndrome is a condition that occurs many years after partial or full clinical recovery from viral poliomyelitis. It is characterized by neurologic and musculoskeletal complaints. Progressive weakness with or without atrophy may occur in segments that were affected at the time of initial infection. Upper motor neuron signs do not occur. The condition may also include pain in muscles or joints and generalized fatigue. The diagnosis of post-polio syndrome is clinical and is based on slow progression of the above clinical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/45/5849?source=see_link\">",
"     \"Post-polio syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Monomelic amyotrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monomelic amyotrophy, also known as focal amyotrophy, is a condition that presents clinically with juvenile onset of focal atrophy and weakness, most commonly of a single hand and arm and rarely of a leg.",
"   </p>",
"   <p>",
"    One form of monomelic amyotrophy known as Hirayama disease progresses over one to five years (less commonly over eight years) and then plateaus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/62,72-77\">",
"     62,72-77",
"    </a>",
"    ]. Another form, known as the O'Sullivan-McLeod syndrome, progresses over a longer period of 25 to 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/78\">",
"     78",
"    </a>",
"    ]. Both are male predominant disorders that affect one or occasionally both upper extremities with weakness that is distal (90 percent) more commonly than proximal (10 percent). Recovery does not occur, but both conditions are considered to be benign since they do not progress to systemic motor neuron disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/62,79-81\">",
"     62,79-81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While usually sporadic, familial cases of upper extremity monomelic amyotrophy have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/73,77,82-84\">",
"     73,77,82-84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lower extremity monomelic amyotrophy is much less common. It is male predominant with weakness that is most often present asymmetrically in the gastrocnemius, peronei, and hamstrings more commonly than the quadriceps. Progression occurs over a few years and is followed by a clinical plateau [",
"    <a class=\"abstract\" href=\"UTD.htm?16/34/16938/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Hereditary spastic paraplegia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary spastic paraplegia is a large group of inherited neurologic disorders, in which the prominent feature is a progressive upper motor neuron spastic weakness of the legs that is similar to that seen in ALS and primary lateral sclerosis. However, unlike those conditions, patients with hereditary spastic paraplegia may have urinary urgency and high arched feet. Some forms of hereditary spastic paraplegia may be associated with cerebellar dysfunction, optic atrophy, and peripheral neuropathy (SPG7), or with cognitive decline, upper extremity weakness, dysarthria, nystagmus, and thinning of the corpus callosum on MRI (SPG11). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link&amp;anchor=H29#H29\">",
"     \"Disorders affecting the spinal cord\", section on 'Hereditary spastic paraplegias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Myasthenia gravis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenia gravis occasionally can present as a bulbar syndrome with dysphagia and dysarthria but without the ptosis or ocular motility disturbance that commonly accompany myasthenia. This presentation can mimic bulbar onset ALS. The absence of upper or lower motor neuron bulbar signs, presence of ocular findings, and a history of diurnal variation of symptoms weigh in favor of myasthenia gravis. In addition, it is more common for myasthenia to present with ptosis and ocular dysmotility, in which case it is unlikely to be confused with bulbar ALS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testing for acetylcholine receptor-binding antibodies should be performed on all patients if myasthenia gravis is suspected. Testing for MuSK antibodies should be pursued if acetylcholine receptor antibodies are negative. The diagnosis of myasthenia gravis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link\">",
"     \"Diagnosis of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Repetitive nerve stimulation and single fiber electromyography of facial muscles may be abnormal in both myasthenia gravis and bulbar onset ALS with lower motor neuron facial weakness. Cranial muscles such as the tongue, masseter, or sternocleidomastoid will demonstrate electrophysiologic evidence of denervation and reinnervation in bulbar onset ALS. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Repetitive nerve stimulation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'Single fiber EMG'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence of an association between hyperthyroidism and motor neuron disease. However, clinical features in patients with thyrotoxicosis may include upper motor neuron signs related to pyramidal tract dysfunction and lower motor neuron signs related to a peripheral neuropathy; these may overlap with those of ALS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30057?source=see_link&amp;anchor=H21#H21\">",
"     \"Neurologic manifestations of hyperthyroidism and Graves' disease\", section on 'Motor neuron disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topic(s) (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/35/21041?source=see_link\">",
"       \"Patient information: Amyotrophic lateral sclerosis (ALS) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of amyotrophic lateral sclerosis (ALS) is based upon clinical criteria that include the presence of upper motor neuron and lower motor neuron signs, progression of disease, and the absence of an alternative explanation. The upper motor neuron and lower motor neuron involvement may impair limb (",
"    <a class=\"graphic graphic_table graphicRef72454 \" href=\"UTD.htm?24/58/25517\">",
"     table 1",
"    </a>",
"    ), bulbar (",
"    <a class=\"graphic graphic_table graphicRef75146 \" href=\"UTD.htm?33/2/33837\">",
"     table 2",
"    </a>",
"    ), axial (",
"    <a class=\"graphic graphic_table graphicRef67913 \" href=\"UTD.htm?9/60/10188\">",
"     table 3",
"    </a>",
"    ) and respiratory (",
"    <a class=\"graphic graphic_table graphicRef58537 \" href=\"UTD.htm?36/37/37467\">",
"     table 4",
"    </a>",
"    ) function. Cognitive change related to frontotemporal dysfunction may be the presenting symptom in a small subset of patients. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical evaluation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In practical terms, the diagnosis is made when it is suggested by the history and physical examination, supported by electrodiagnostic studies, and not excluded by neuroimaging and laboratory studies. The revised El Escorial criteria for ALS (",
"      <a class=\"graphic graphic_algorithm graphicRef62831 \" href=\"UTD.htm?18/10/18593\">",
"       algorithm 1",
"      </a>",
"      ) allow assignment of diagnostic certainty but were designed for research purposes. The newer Awaji criteria increase sensitivity without sacrificing specificity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend electrodiagnostic testing with nerve conduction studies and electromyography in all patients with suspected ALS. Sensory and motor nerve conduction studies are most often normal in ALS, although compound motor action potential amplitudes may be reduced in severely atrophic and denervated muscles. Electromyography typically reveals combined features of acute and chronic denervation in ALS. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Electrodiagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuroimaging is used to exclude other possible diagnoses in the evaluation of suspected ALS. In the absence of a contraindication, we recommend MRI evaluation in all segments rostral to the clinical findings; this includes the brain, cervical spine, and thoracic spine when upper motor neuron findings are in the legs. Conventional MRI is usually normal in ALS. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend laboratory testing of blood and urine to exclude alternative diagnoses in patients with suspected motor neuron disease and ALS. We recommend lumbar puncture for cerebrospinal fluid analysis if there is clinical suspicion for the diagnosis of chronic inflammatory demyelinating polyneuropathy, Lyme disease, HIV infection, or lymphoma, or if there is a rapidly progressive isolated lower motor neuron syndrome. Additional laboratory testing may be required in certain clinical settings. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic testing is not a routine part of the diagnostic evaluation in ALS but can be helpful in making the diagnosis in familial ALS, which accounts for 5 to 10 percent of all ALS cases. Genetic testing for specific ALS-causing mutations is most useful for establishing the diagnosis (particularly for juvenile or early-stage disease) and for assessing risk among family members of an affected relative with an established genetic cause. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Muscle biopsy is not a routine part of the diagnostic evaluation of ALS but should be performed if there is clinical suspicion of inflammatory myopathy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Muscle biopsy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of ALS is extensive (",
"      <a class=\"graphic graphic_table graphicRef64932 \" href=\"UTD.htm?14/17/14621\">",
"       table 5",
"      </a>",
"      ). It is of particular importance to exclude multifocal motor neuropathy, cervical radiculomyelopathy, benign fasciculations, inflammatory myopathy, post-polio syndrome, monomelic amyotrophy, myasthenia gravis and other forms of motor neuron disease in patients with suspected ALS. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/1\">",
"      Lomen-Hoerth C. Characterization of amyotrophic lateral sclerosis and frontotemporal dementia. Dement Geriatr Cogn Disord 2004; 17:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/2\">",
"      Strong MJ, Lomen-Hoerth C, Caselli RJ, et al. Cognitive impairment, frontotemporal dementia, and the motor neuron diseases. Ann Neurol 2003; 54 Suppl 5:S20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/3\">",
"      Lomen-Hoerth C, Murphy J, Langmore S, et al. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003; 60:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/4\">",
"      Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002; 59:1077.",
"     </a>",
"    </li>",
"    <li>",
"     Mitsumoto H, Chad DA, Pioro EP. Amyotrophic lateral sclerosis. In: Contemporary Neurology Series, 49, F.A. Davis Company, Philadelphia 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/6\">",
"      LANDAU WM, CLARE MH. The plantar reflex in man, with special reference to some conditions where the extensor response is unexpectedly absent. Brain 1959; 82:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/7\">",
"      Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial \"Clinical limits of amyotrophic lateral sclerosis\" workshop contributors. J Neurol Sci 1994; 124 Suppl:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/8\">",
"      Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/9\">",
"      Chaudhuri KR, Crump S, al-Sarraj S, et al. The validation of El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis: a clinicopathological study. J Neurol Sci 1995; 129 Suppl:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/10\">",
"      Forbes RB, Colville S, Swingler RJ. Are the El Escorial and Revised El Escorial criteria for ALS reproducible? A study of inter-observer agreement. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/11\">",
"      de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008; 119:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/12\">",
"      Ross MA, Miller RG, Berchert L, et al. Toward earlier diagnosis of amyotrophic lateral sclerosis: revised criteria. rhCNTF ALS Study Group. Neurology 1998; 50:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/13\">",
"      Traynor BJ, Codd MB, Corr B, et al. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch Neurol 2000; 57:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/14\">",
"      Costa J, Swash M, de Carvalho M. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis:a systematic review. Arch Neurol 2012; 69:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/15\">",
"      Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology 2006; 66:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/16\">",
"      Wijesekera LC, Mathers S, Talman P, et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology 2009; 72:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/17\">",
"      Daube JR. Electrodiagnostic studies in amyotrophic lateral sclerosis and other motor neuron disorders. Muscle Nerve 2000; 23:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/18\">",
"      Krivickas LS. Amyotrophic lateral sclerosis and other motor neuron diseases. Phys Med Rehabil Clin N Am 2003; 14:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/19\">",
"      de Carvalho M, Swash M. Nerve conduction studies in amyotrophic lateral sclerosis. Muscle Nerve 2000; 23:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/20\">",
"      Olney RK, Lomen-Hoerth C. Motor unit number estimation (MUNE): how may it contribute to the diagnosis of ALS? Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1 Suppl 2:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/21\">",
"      Shefner JM, Gooch CL. Motor unit number estimation in neurologic disease. Adv Neurol 2002; 88:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/22\">",
"      Gooch CL, Shefner JM. ALS surrogate markers. MUNE. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5 Suppl 1:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/23\">",
"      de Carvalho M, Scotto M, Lopes A, Swash M. Quantitating progression in ALS. Neurology 2005; 64:1783.",
"     </a>",
"    </li>",
"    <li>",
"     Shefner, JM. Amyotrophic lateral sclerosis. In: Office practice of neurology, Samuels, MA, Feske, SK (Eds), 2nd ed, Churchill Livingstone, Philadelphia 2003. p.548.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/25\">",
"      LAMBERT EH, MULDER DW. Electromyographic studies in amyotrophic lateral sclerosis. Proc Staff Meet Mayo Clin 1957; 32:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/26\">",
"      MULDER DW, LAMBERT EH, EATON LM. Myasthenic syndrome in patients with amyotrophic lateral sclerosis. Neurology 1959; 9:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/27\">",
"      Henderson RD, Daube JR. Decrement in surface-recorded motor unit potentials in amyotrophic lateral sclerosis. Neurology 2004; 63:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/28\">",
"      Jillapalli D, Shefner JM. Single motor unit variability with threshold stimulation in patients with amyotrophic lateral sclerosis and normal subjects. Muscle Nerve 2004; 30:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/29\">",
"      Wang FC, De Pasqua V, G&eacute;rard P, Delwaide PJ. Prognostic value of decremental responses to repetitive nerve stimulation in ALS patients. Neurology 2001; 57:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/30\">",
"      Killian JM, Wilfong AA, Burnett L, et al. Decremental motor responses to repetitive nerve stimulation in ALS. Muscle Nerve 1994; 17:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/31\">",
"      Denys EH, Norris FH Jr. Amyotrophic lateral sclerosis. Impairment of neuromuscular transmission. Arch Neurol 1979; 36:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/32\">",
"      Brown WF, Jaatoul N. Amyotrophic lateral sclerosis. Electrophysiologic study (number of motor units and rate of decay of motor units). Arch Neurol 1974; 30:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/33\">",
"      Carleton SA, Brown WF. Changes in motor unit populations in motor neurone disease. J Neurol Neurosurg Psychiatry 1979; 42:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/34\">",
"      Cui LY, Liu MS, Tang XF. Single fiber electromyography in 78 patients with amyotrophic lateral sclerosis. Chin Med J (Engl) 2004; 117:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/35\">",
"      Pohl C, Block W, Tr&auml;ber F, et al. Proton magnetic resonance spectroscopy and transcranial magnetic stimulation for the detection of upper motor neuron degeneration in ALS patients. J Neurol Sci 2001; 190:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/36\">",
"      Schulte-Mattler WJ, M&uuml;ller T, Zierz S. Transcranial magnetic stimulation compared with upper motor neuron signs in patients with amyotrophic lateral sclerosis. J Neurol Sci 1999; 170:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/37\">",
"      Kaufmann P, Mitsumoto H. Amyotrophic lateral sclerosis: objective upper motor neuron markers. Curr Neurol Neurosci Rep 2002; 2:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/38\">",
"      Kaufmann P, Pullman SL, Shungu DC, et al. Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Neurology 2004; 62:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/39\">",
"      Pouget J, Trefouret S, Attarian S. Transcranial magnetic stimulation (TMS): compared sensitivity of different motor response parameters in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1 Suppl 2:S45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/40\">",
"      Miscio G, Pisano F, Mora G, Mazzini L. Motor neuron disease: usefulness of transcranial magnetic stimulation in improving the diagnosis. Clin Neurophysiol 1999; 110:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/41\">",
"      Floyd AG, Yu QP, Piboolnurak P, et al. Transcranial magnetic stimulation in ALS: utility of central motor conduction tests. Neurology 2009; 72:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/42\">",
"      Chan S, Shungu DC, Douglas-Akinwande A, et al. Motor neuron diseases: comparison of single-voxel proton MR spectroscopy of the motor cortex with MR imaging of the brain. Radiology 1999; 212:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/43\">",
"      Oba H, Araki T, Ohtomo K, et al. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology 1993; 189:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/44\">",
"      Jones AP, Gunawardena WJ, Coutinho CM, et al. Preliminary results of proton magnetic resonance spectroscopy in motor neurone disease (amytrophic lateral sclerosis). J Neurol Sci 1995; 129 Suppl:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/45\">",
"      Abe K, Takanashi M, Watanabe Y, et al. Decrease in N-acetylaspartate/creatine ratio in the motor area and the frontal lobe in amyotrophic lateral sclerosis. Neuroradiology 2001; 43:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/46\">",
"      Mitsumoto H, Ulug AM, Pullman SL, et al. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology 2007; 68:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/47\">",
"      Pohl C, Block W, Karitzky J, et al. Proton magnetic resonance spectroscopy of the motor cortex in 70 patients with amyotrophic lateral sclerosis. Arch Neurol 2001; 58:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/48\">",
"      Rooney WD, Miller RG, Gelinas D, et al. Decreased N-acetylaspartate in motor cortex and corticospinal tract in ALS. Neurology 1998; 50:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/49\">",
"      Bowen BC, Bradley WG. Amyotrophic lateral sclerosis: the search for a spectroscopic marker of upper motoneuron involvement. Arch Neurol 2001; 58:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/50\">",
"      Bowen BC, Pattany PM, Bradley WG, et al. MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol 2000; 21:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/51\">",
"      Gredal O, Rosenbaum S, Topp S, et al. Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy. Neurology 1997; 48:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/52\">",
"      Sarchielli P, Pelliccioli GP, Tarducci R, et al. Magnetic resonance imaging and 1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis. Neuroradiology 2001; 43:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/53\">",
"      Ellis CM, Simmons A, Andrews C, et al. A proton magnetic resonance spectroscopic study in ALS: correlation with clinical findings. Neurology 1998; 51:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/54\">",
"      Kenn W, Ochs G, Pabst TA, Hahn D. 1H spectroscopy in patients with amyotrophic lateral sclerosis. J Neuroimaging 2001; 11:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/55\">",
"      Pierpaoli C, Basser PJ. Toward a quantitative assessment of diffusion anisotropy. Magn Reson Med 1996; 36:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/56\">",
"      Basser PJ, Pajevic S, Pierpaoli C, et al. In vivo fiber tractography using DT-MRI data. Magn Reson Med 2000; 44:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/57\">",
"      Iwata NK, Aoki S, Okabe S, et al. Evaluation of corticospinal tracts in ALS with diffusion tensor MRI and brainstem stimulation. Neurology 2008; 70:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/58\">",
"      Toosy AT, Werring DJ, Orrell RW, et al. Diffusion tensor imaging detects corticospinal tract involvement at multiple levels in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2003; 74:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/59\">",
"      Menke RA, Abraham I, Thiel CS, et al. Fractional Anisotropy in the Posterior Limb of the Internal Capsule and Prognosis in Amyotrophic Lateral Sclerosis. Arch Neurol 2012; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/60\">",
"      Filippini N, Douaud G, Mackay CE, et al. Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology 2010; 75:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/61\">",
"      Jackson CE, Amato AA, Bryan WW, et al. Primary hyperparathyroidism and ALS: is there a relation? Neurology 1998; 50:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/62\">",
"      Rowland LP. Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1998; 160 Suppl 1:S6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/63\">",
"      Misawa S, Noto Y, Shibuya K, et al. Ultrasonographic detection of fasciculations markedly increases diagnostic sensitivity of ALS. Neurology 2011; 77:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/64\">",
"      Cartwright MS, Walker FO, Griffin LP, Caress JB. Peripheral nerve and muscle ultrasound in amyotrophic lateral sclerosis. Muscle Nerve 2011; 44:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/65\">",
"      Swash M, Carvalho Md. Muscle ultrasound detects fasciculations and facilitates diagnosis in ALS. Neurology 2011; 77:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/66\">",
"      REED DM, KURLAND LT. MUSCLE FASCICULATIONS IN A HEALTHY POPULATION. Arch Neurol 1963; 9:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/67\">",
"      Mitsikostas DD, Karandreas N, Coutsopetras P, et al. Fasciculation potentials in healthy people. Muscle Nerve 1998; 21:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/68\">",
"      de Carvalho M, Swash M. Fasciculation potentials: a study of amyotrophic lateral sclerosis and other neurogenic disorders. Muscle Nerve 1998; 21:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/69\">",
"      Blexrud MD, Windebank AJ, Daube JR. Long-term follow-up of 121 patients with benign fasciculations. Ann Neurol 1993; 34:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/70\">",
"      Sunnerhagen KS, Grimby G. Muscular effects in late polio. Acta Physiol Scand 2001; 171:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/71\">",
"      Chasens ER, Umlauf MG. Post-polio syndrome. Am J Nurs 2000; 100:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/72\">",
"      Rowland LP. Progressive muscular atrophy and other lower motor neuron syndromes of adults. Muscle Nerve 2010; 41:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/73\">",
"      HIRAYAMA K, TSUBAKI T, TOYOKURA Y, OKINAKA S. Juvenile muscular atrophy of unilateral upper extremity. Neurology 1963; 13:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/74\">",
"      Hirayama K. [Juvenile non-progressive muscular atrophy localized in the hand and forearm--observations in 38 cases]. Rinsho Shinkeigaku 1972; 12:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/75\">",
"      Pradhan S. Bilaterally symmetric form of Hirayama disease. Neurology 2009; 72:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/76\">",
"      Hosokawa T, Fujieda M, Wakiguchi H, Oosaki Y. Pediatric Hirayama disease. Pediatr Neurol 2010; 43:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/77\">",
"      Hirayama K, Tomonaga M, Kitano K, et al. Focal cervical poliopathy causing juvenile muscular atrophy of distal upper extremity: a pathological study. J Neurol Neurosurg Psychiatry 1987; 50:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/78\">",
"      O'Sullivan DJ, McLeod JG. Distal chronic spinal muscular atrophy involving the hands. Clin Exp Neurol 1977; 14:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/79\">",
"      Di Muzio A, Delli Pizzi C, Lugaresi A, et al. Benign monomelic amyotrophy of lower limb: a rare entity with a characteristic muscular CT. J Neurol Sci 1994; 126:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/80\">",
"      Gourie-Devi M, Nalini A. Long-term follow-up of 44 patients with brachial monomelic amyotrophy. Acta Neurol Scand 2003; 107:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/81\">",
"      Verma A, Bradley WG. Atypical motor neuron disease and related motor syndromes. Semin Neurol 2001; 21:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/82\">",
"      Sobue I, Saito N, Iida M, Ando K. Juvenile type of distal and segmental muscular atrophy of upper extremities. Ann Neurol 1978; 3:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/83\">",
"      Tandan R, Sharma KR, Bradley WG, et al. Chronic segmental spinal muscular atrophy of upper extremities in identical twins. Neurology 1990; 40:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/34/16938/abstract/84\">",
"      Nalini A, Lokesh L, Ratnavalli E. Familial monomelic amyotrophy: a case report from India. J Neurol Sci 2004; 220:95.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5138 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-4E1BBEB838-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_34_16938=[""].join("\n");
var outline_f16_34_16938=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ELECTRODIAGNOSTIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Electromyography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nerve conduction studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Electrodiagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Repetitive nerve stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Single fiber EMG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Transcranial magnetic stimulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OTHER DIAGNOSTIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1104160884\">",
"      Neuromuscular ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Multifocal motor neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cervical radiculomyelopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Benign fasciculations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Inflammatory myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Post-polio syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Monomelic amyotrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Hereditary spastic paraplegia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5138\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5138|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?18/10/18593\" title=\"algorithm 1\">",
"      Revised El Escorial schema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5138|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?6/10/6318\" title=\"movie 1\">",
"      Fasciculations deltoid and triceps ALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?6/36/6735\" title=\"movie 2\">",
"      Arm and hand atrophy in ALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?9/37/9823\" title=\"movie 3\">",
"      Knee jerk hyperreflexia in ALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?13/29/13791\" title=\"movie 4\">",
"      Bilateral Babinski signs in ALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?17/24/17806\" title=\"movie 5\">",
"      Tongue atrophy and fasciculations in ALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5138|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/58/25517\" title=\"table 1\">",
"      Limb signs symptoms ALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/2/33837\" title=\"table 2\">",
"      Bulbar signs symptoms ALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/60/10188\" title=\"table 3\">",
"      Axial signs symptoms ALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/37/37467\" title=\"table 4\">",
"      Respiratory signs symptoms ALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/17/14621\" title=\"table 5\">",
"      Differential diagnosis of ALS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27944?source=related_link\">",
"      Cervical spondylotic myelopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=related_link\">",
"      Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=related_link\">",
"      Clinical features and diagnosis of leptomeningeal metastases from solid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=related_link\">",
"      Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=related_link\">",
"      Clinical manifestations and diagnosis of inclusion body myositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=related_link\">",
"      Diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30232?source=related_link\">",
"      Diagnostic ultrasound in neuromuscular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23240?source=related_link\">",
"      Disease modifying treatment of amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23450?source=related_link\">",
"      Epidemiology and pathogenesis of amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16138?source=related_link\">",
"      Familial amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=related_link\">",
"      Frontotemporal dementia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30057?source=related_link\">",
"      Neurologic manifestations of hyperthyroidism and Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=related_link\">",
"      Overview of upper extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6583?source=related_link\">",
"      Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/35/21041?source=related_link\">",
"      Patient information: Amyotrophic lateral sclerosis (ALS) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36553?source=related_link\">",
"      Polio and infectious diseases of the anterior horn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/45/5849?source=related_link\">",
"      Post-polio syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33193?source=related_link\">",
"      Symptom-based management of amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_34_16939="Causes of noncompressive radiculopathy";
var content_f16_34_16939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F63137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F63137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of noncompressive radiculopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Diabetes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Vasculitis with nerve root infarction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Infectious or granulomatous",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Herpes zoster",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lyme disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tuberculosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Syphilis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Brucellosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cytomegalovirus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Histiocytosis X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sarcoid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Infiltration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lymphoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Carcinomatous meningitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Acute demyelination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Early Guillain-Barr&eacute; syndrome",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_34_16939=[""].join("\n");
var outline_f16_34_16939=null;
var title_f16_34_16940="Neonatal pain assess tools";
var content_f16_34_16940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly used measures of pain in neonates",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Measure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Variables included",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type of pain",
"       </td>",
"       <td class=\"subtitle1\">",
"        Psychometric testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PIPP (Premature Infant Pain Profile)",
"       </td>",
"       <td>",
"        Heart rate, oxygen saturation, facial actions; takes state and gestational age into account",
"       </td>",
"       <td>",
"        Procedural, postoperative (minor)",
"       </td>",
"       <td>",
"        Reliability, validity, clinical utility well established",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NIPS (Neonatal Infant Pain Score)",
"       </td>",
"       <td>",
"        Facial expression, crying, breathing patterns, arm and leg movements, arousal",
"       </td>",
"       <td>",
"        Procedural",
"       </td>",
"       <td>",
"        Reliability, validity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NFCS (Neonatal Facial Coding System)",
"       </td>",
"       <td>",
"        Facial actions",
"       </td>",
"       <td>",
"        Procedural",
"       </td>",
"       <td>",
"        Reliability, validity, clinical utility, high degree of sensitivity to analgesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N-PASS (Neonatal Pain, Agitation, and Sedation Scale)",
"       </td>",
"       <td>",
"        Crying, irritability, behavioral state, facial expression, extremity tone, vital signs",
"       </td>",
"       <td>",
"        Postoperative, procedural, ventilated",
"       </td>",
"       <td>",
"        Reliability, validity, includes sedation end of scale, does not distinguish pain from agitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CRIES (Cry, Requires oxygen, Increased vital signs, Expression, Sleeplessness)",
"       </td>",
"       <td>",
"        Crying, facial expression, sleeplessness, requires oxygen to stay at &gt;95 percent saturation, increased vital signs",
"       </td>",
"       <td>",
"        Postoperative",
"       </td>",
"       <td>",
"        Reliability, validity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        COMFORT Scale",
"       </td>",
"       <td>",
"        Movement, calmness, facial tension, alertness, respiration rate, muscle tone, heart rate, blood pressure",
"       </td>",
"       <td>",
"        Postoperative, critical care, developed for sedation, recently validated for postoperative pain in 0- to 3-year-old infants",
"       </td>",
"       <td>",
"        Reliability, validity, clinical utility",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anand KJ, Aranda JV, Berde CB, et al. Summary proceedings from the neonatal pain-control group. Pediatrics 2006; 117:S9. Copyright &copy; 2006 American Academy of Pediatrics.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_34_16940=[""].join("\n");
var outline_f16_34_16940=null;
var title_f16_34_16941="Charateristics of precordial motion";
var content_f16_34_16941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of precordial motion with various cardiac abnormalities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Aortic regurgitation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Apex impulse hyperdynamic in mild to moderate AR",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Severe AR: LV dilatation results in sustained impulse that is displaced laterally and downward (especially in chronic AR)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Systolic retraction medial to PMI",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Palpable a wave may be present",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Mitral regurgitation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Apical systolic thrill in severe MR",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Apex impluse hyperdynamic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Severe and/or chronic MR; impulse is sustained and laterally displaced",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Can have late parasternal impulse with severe MR without pulmonary hypertension",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Parasternal (RV) heave if significant pulmonary hypertension",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          S3 visible and palpable if severe MR",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          S4 palpable with acute onset MR",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Congestive cardiomyopathy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sustained and displaced LV impulse, usually felt over 2 interspaces",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Palpable a wave (S4) and S3 common",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Parasternal lift, midsystolic bulge common",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Coronary artery disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Usually normal at rest unless prior MI",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Palpable S4 in left decubitus position",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ectopic LV thrust if dyssynergy or LV aneurysm. May have transient abnormalities (eg, bulge, heave) during acute infarction or attack of angina",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Hypertrophic cardiomyopathy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Systolic thrill superior, medial to apex impulse",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Vigorous LV apical impulse, often sustained",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Occasional mid- or late systolic bulge - \"tripple ripple\"",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Atrial septal defect",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hyperdynamic parasternal impulse",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          PA impulse may be present",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          RV impulse may be sustained if pulmonary hypertension is present and occasionally with large left to right shunt without elevated PA pressure",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Mitral stenosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Small or impalpable apex impulse but S1 typically palpable",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Opening snap palpable medial to apex",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Apical diastolic thrill in left decubitus position",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Parasternal lift is common; suggests pulmonary hypertension at rest or with effort",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Valvular aortic stenosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Systolic thrill - aortic area, 2 LICS. Or occasionally at apex",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sustained and forceful LV apical impulse",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Little lateral (leftward) displacement of apex unless LV dilatation has occurred",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Palpable a wave (S4) is common and indicates severe aortic obstruction",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AR: aortic regurgitation; LV: left ventricular;PA: pulmonary artery; RV: right ventricular; MI: myocardial infarction;MR: mitral regurgitation; LICS: left intercostal space.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Abrams, J. Examination of theprecordium. Primary Cardiol 1982; 8:156.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_34_16941=[""].join("\n");
var outline_f16_34_16941=null;
var title_f16_34_16942="RR breast cancer";
var content_f16_34_16942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multivariate relative risk of breast cancer by total folate intake and alcohol consumption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 259px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The reference group for all comparisons was women who consumed 150 to 299 &micro;g/d of total folate and less than 15 g/d of alcohol.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Zhang S, Hunter D, Hankinson S,&nbsp;et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999; 281:1632. Copyright &copy; 1999 American Medical Association. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_34_16942=[""].join("\n");
var outline_f16_34_16942=null;
var title_f16_34_16943="Hypospadias catheter";
var content_f16_34_16943=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postoperative urinary catheter following hypospadias repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic diagram of urinary drainage tube or stent used after hypospadias surgery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baskin LS. Hypospadias. In: Handbook of Pediatric Urology, 2nd ed, Baskin LS, Kogan BA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_34_16943=[""].join("\n");
var outline_f16_34_16943=null;
